
<html lang="en"     class="pb-page"  data-request-id="d4ff3db9-cced-4dc7-8024-23ddcfa44b01"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2018.61.issue-24;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.8b01098;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design" /></meta><meta name="dc.Creator" content="Adrian D.  Hobson" /></meta><meta name="dc.Creator" content="Russell A.  Judge" /></meta><meta name="dc.Creator" content="Ana L.  Aguirre" /></meta><meta name="dc.Creator" content="Brian S.  Brown" /></meta><meta name="dc.Creator" content="Yifang  Cui" /></meta><meta name="dc.Creator" content="Ping  Ding" /></meta><meta name="dc.Creator" content="Eric  Dominguez" /></meta><meta name="dc.Creator" content="Enrico  DiGiammarino" /></meta><meta name="dc.Creator" content="David A.  Egan" /></meta><meta name="dc.Creator" content="Gail M.  Freiberg" /></meta><meta name="dc.Creator" content="Sujatha M.  Gopalakrishnan" /></meta><meta name="dc.Creator" content="Christopher M.  Harris" /></meta><meta name="dc.Creator" content="Marie P.  Honore" /></meta><meta name="dc.Creator" content="Karen L.  Kage" /></meta><meta name="dc.Creator" content="Nicolas J.  Kapecki" /></meta><meta name="dc.Creator" content="Christopher  Ling" /></meta><meta name="dc.Creator" content="Junli  Ma" /></meta><meta name="dc.Creator" content="Helmut  Mack" /></meta><meta name="dc.Creator" content="Mulugeta  Mamo" /></meta><meta name="dc.Creator" content="Stefan  Maurus" /></meta><meta name="dc.Creator" content="Bradford  McRae" /></meta><meta name="dc.Creator" content="Nigel S.  Moore" /></meta><meta name="dc.Creator" content="Bernhard K.  Mueller" /></meta><meta name="dc.Creator" content="Reinhold  Mueller" /></meta><meta name="dc.Creator" content="Marian T.  Namovic" /></meta><meta name="dc.Creator" content="Kaushal  Patel" /></meta><meta name="dc.Creator" content="Steve D.  Pratt" /></meta><meta name="dc.Creator" content="C. Brent  Putman" /></meta><meta name="dc.Creator" content="Kara L.  Queeney" /></meta><meta name="dc.Creator" content="Kathy K.  Sarris" /></meta><meta name="dc.Creator" content="Lisa M.  Schaffter" /></meta><meta name="dc.Creator" content="Vincent  Stoll" /></meta><meta name="dc.Creator" content="Anil  Vasudevan" /></meta><meta name="dc.Creator" content="Lei  Wang" /></meta><meta name="dc.Creator" content="Lu  Wang" /></meta><meta name="dc.Creator" content="William  Wirthl" /></meta><meta name="dc.Creator" content="Kimberly  Yach" /></meta><meta name="dc.Description" content="A HTS campaign identified compound 1, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor. Substitution (2-Cl, 2-NH2, 2-F, 3-F) of th..." /></meta><meta name="Description" content="A HTS campaign identified compound 1, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor. Substitution (2-Cl, 2-NH2, 2-F, 3-F) of th..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 1, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01098" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01098" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01098" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01098" /></link>
        
    
    

<title>Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01098" /></meta><meta property="og:title" content="Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0025.jpeg" /></meta><meta property="og:description" content="A HTS campaign identified compound 1, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor. Substitution (2-Cl, 2-NH2, 2-F, 3-F) of the pyridine hinge binding motif or replacement with pyrimidine afforded compounds with a clean CYP inhibition profile. Cocrystal structures of an early lead compound were obtained in PKA, ROCK1, and ROCK2. This provided critical structural information for medicinal chemistry to drive compound design. The structural data indicated the preferred configuration at the central benzylic carbon would be (R), and application of this information to compound design resulted in compound 16. This compound was shown to be a potent and selective dual ROCK inhibitor in both enzyme and cell assays and efficacious in the retinal nerve fiber layer model after oral dosing. This tool compound has been made available through the AbbVie Compound Toolbox. Finally, the cocrystal structures also identified that aspartic acid residues 176 and 218 in ROCK2, which are glutamic acids in PKA, could be targeted as residues to drive both potency and kinome selectivity. Introduction of a piperidin-3-ylmethanamine group to the compound series resulted in compound 58, a potent and selective dual ROCK inhibitor with excellent predicted drug-like properties." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01098"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01098">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01098&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01098&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01098&amp;href=/doi/10.1021/acs.jmedchem.8b01098" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11074-11100</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01556" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01135" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Adrian D. Hobson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adrian D. Hobson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (508)688-8017. E-mail: <a href="/cdn-cgi/l/email-protection#5d3c392f343c337335323f2e32331d3c3f3f2b3438733e3230"><span class="__cf_email__" data-cfemail="c3a2a7b1aaa2adedabaca1b0acad83a2a1a1b5aaa6eda0acae">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adrian+D.++Hobson">Adrian D. Hobson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3948-0577" title="Orcid link">http://orcid.org/0000-0003-3948-0577</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Russell A. Judge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Russell A. Judge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Russell+A.++Judge">Russell A. Judge</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ana L. Aguirre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana L. Aguirre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana+L.++Aguirre">Ana L. Aguirre</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Brian S. Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian S. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+S.++Brown">Brian S. Brown</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yifang Cui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yifang Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yifang++Cui">Yifang Cui</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ping Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ping Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ping++Ding">Ping Ding</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Eric Dominguez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Dominguez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Dominguez">Eric Dominguez</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Enrico DiGiammarino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Enrico DiGiammarino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Enrico++DiGiammarino">Enrico DiGiammarino</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">David A. Egan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David A. Egan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Egan">David A. Egan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Gail M. Freiberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gail M. Freiberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gail+M.++Freiberg">Gail M. Freiberg</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Sujatha M. Gopalakrishnan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sujatha M. Gopalakrishnan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sujatha+M.++Gopalakrishnan">Sujatha M. Gopalakrishnan</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Christopher M. Harris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher M. Harris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+M.++Harris">Christopher M. Harris</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Marie P. Honore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marie P. Honore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marie+P.++Honore">Marie P. Honore</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Karen L. Kage</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen L. Kage</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen+L.++Kage">Karen L. Kage</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Nicolas J. Kapecki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicolas J. Kapecki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicolas+J.++Kapecki">Nicolas J. Kapecki</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Christopher Ling</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Ling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Ling">Christopher Ling</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Junli Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junli Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junli++Ma">Junli Ma</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Helmut Mack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Helmut Mack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Helmut++Mack">Helmut Mack</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Mulugeta Mamo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mulugeta Mamo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mulugeta++Mamo">Mulugeta Mamo</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Stefan Maurus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Maurus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Maurus">Stefan Maurus</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Bradford McRae</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bradford McRae</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bradford++McRae">Bradford McRae</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Nigel S. Moore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nigel S. Moore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nigel+S.++Moore">Nigel S. Moore</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Bernhard K. Mueller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernhard K. Mueller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernhard+K.++Mueller">Bernhard K. Mueller</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Reinhold Mueller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Reinhold Mueller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Reinhold++Mueller">Reinhold Mueller</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Marian T. Namovic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marian T. Namovic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marian+T.++Namovic">Marian T. Namovic</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kaushal Patel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kaushal Patel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kaushal++Patel">Kaushal Patel</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Steve D. Pratt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve D. Pratt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve+D.++Pratt">Steve D. Pratt</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">C. Brent Putman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">C. Brent Putman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=C.+Brent++Putman">C. Brent Putman</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kara L. Queeney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kara L. Queeney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kara+L.++Queeney">Kara L. Queeney</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kathy K. Sarris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathy K. Sarris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathy+K.++Sarris">Kathy K. Sarris</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lisa M. Schaffter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa M. Schaffter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa+M.++Schaffter">Lisa M. Schaffter</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Vincent Stoll</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincent Stoll</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincent++Stoll">Vincent Stoll</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Anil Vasudevan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anil Vasudevan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anil++Vasudevan">Anil Vasudevan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0004-0497" title="Orcid link">http://orcid.org/0000-0002-0004-0497</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Wang">Lei Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lu Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lu Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lu++Wang">Lu Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">William Wirthl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William Wirthl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William++Wirthl">William Wirthl</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Kimberly Yach</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kimberly Yach</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kimberly++Yach">Kimberly Yach</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01098&amp;href=/doi/10.1021%2Facs.jmedchem.8b01098" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11074â11100</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 1, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 July 2018</li><li><span class="item_label"><b>Published</b> online</span>1 November 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 December 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01098" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01098</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11074%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAdrian%2BD.%2BHobson%252C%2BRussell%2BA.%2BJudge%252C%2BAna%2BL.%2BAguirre%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D24%26contentID%3Dacs.jmedchem.8b01098%26title%3DIdentification%2Bof%2BSelective%2BDual%2BROCK1%2Band%2BROCK2%2BInhibitors%2BUsing%2BStructure-Based%2BDrug%2BDesign%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11100%26publicationDate%3DDecember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01098"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3026</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01098" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;D. Hobson&quot;},{&quot;first_name&quot;:&quot;Russell&quot;,&quot;last_name&quot;:&quot;A. Judge&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;L. Aguirre&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;S. Brown&quot;},{&quot;first_name&quot;:&quot;Yifang&quot;,&quot;last_name&quot;:&quot;Cui&quot;},{&quot;first_name&quot;:&quot;Ping&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Dominguez&quot;},{&quot;first_name&quot;:&quot;Enrico&quot;,&quot;last_name&quot;:&quot;DiGiammarino&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Egan&quot;},{&quot;first_name&quot;:&quot;Gail&quot;,&quot;last_name&quot;:&quot;M. Freiberg&quot;},{&quot;first_name&quot;:&quot;Sujatha&quot;,&quot;last_name&quot;:&quot;M. Gopalakrishnan&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;M. Harris&quot;},{&quot;first_name&quot;:&quot;Marie&quot;,&quot;last_name&quot;:&quot;P. Honore&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;L. Kage&quot;},{&quot;first_name&quot;:&quot;Nicolas&quot;,&quot;last_name&quot;:&quot;J. Kapecki&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Ling&quot;},{&quot;first_name&quot;:&quot;Junli&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Helmut&quot;,&quot;last_name&quot;:&quot;Mack&quot;},{&quot;first_name&quot;:&quot;Mulugeta&quot;,&quot;last_name&quot;:&quot;Mamo&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Maurus&quot;},{&quot;first_name&quot;:&quot;Bradford&quot;,&quot;last_name&quot;:&quot;McRae&quot;},{&quot;first_name&quot;:&quot;Nigel&quot;,&quot;last_name&quot;:&quot;S. Moore&quot;},{&quot;first_name&quot;:&quot;Bernhard&quot;,&quot;last_name&quot;:&quot;K. Mueller&quot;},{&quot;first_name&quot;:&quot;Reinhold&quot;,&quot;last_name&quot;:&quot;Mueller&quot;},{&quot;first_name&quot;:&quot;Marian&quot;,&quot;last_name&quot;:&quot;T. Namovic&quot;},{&quot;first_name&quot;:&quot;Kaushal&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;D. Pratt&quot;},{&quot;first_name&quot;:&quot;C.&quot;,&quot;last_name&quot;:&quot;Brent Putman&quot;},{&quot;first_name&quot;:&quot;Kara&quot;,&quot;last_name&quot;:&quot;L. Queeney&quot;},{&quot;first_name&quot;:&quot;Kathy&quot;,&quot;last_name&quot;:&quot;K. Sarris&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;M. Schaffter&quot;},{&quot;first_name&quot;:&quot;Vincent&quot;,&quot;last_name&quot;:&quot;Stoll&quot;},{&quot;first_name&quot;:&quot;Anil&quot;,&quot;last_name&quot;:&quot;Vasudevan&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Wirthl&quot;},{&quot;first_name&quot;:&quot;Kimberly&quot;,&quot;last_name&quot;:&quot;Yach&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;11074-11100&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01098&quot;},&quot;abstract&quot;:&quot;A HTS campaign identified compound 1, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor. Substitution (2-Cl, 2-NH2, 2-F, 3-F) of the pyridine hinge binding motif or replacement with pyrimidine afforded compounds with a clean CYP inhibition profile. Cocrystal structures of an early lead compound were obtained in PKA, ROCK1, and ROCK2. This provided critical structural information for medicinal chemistry to drive compound design. The structural data indicated the preferred configuration at the central benzylic carbon would be (R), and application of this information to compound design resulted in compound 16. This compound was shown to be a potent and selective dual ROCK inhibitor in both enzyme and cell assays and efficacious in the retinal nerve fiber layer model after oral dosing. This tool compound has been made available through the AbbVie Compound Toolbox. Finally, the cocrystal structures also identified that aspartic acid residues 176 and&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01098&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01098" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01098&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01098" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01098&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01098" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01098&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01098&amp;href=/doi/10.1021/acs.jmedchem.8b01098" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01098" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01098" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01098%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DHobson%26date%3D2018%26atitle%3DIdentification%2Bof%2BSelective%2BDual%2BROCK1%2Band%2BROCK2%2BInhibitors%2BUsing%2BStructure-Based%2BDrug%2BDesign%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D24%26spage%3D11074%26epage%3D11100%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290753" title="Equilibrium constant">Equilibrium constant</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292200" title="Layers">Layers</a>,</li><li><a href="/action/doSearch?ConceptID=291594" title="Silica">Silica</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/jmcmar.2018.61.issue-24/20181227/jmcmar.2018.61.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A HTS campaign identified compound <b>1</b>, an excellent hit-like molecule to initiate medicinal chemistry efforts to optimize a dual ROCK1 and ROCK2 inhibitor. Substitution (2-Cl, 2-NH<sub>2</sub>, 2-F, 3-F) of the pyridine hinge binding motif or replacement with pyrimidine afforded compounds with a clean CYP inhibition profile. Cocrystal structures of an early lead compound were obtained in PKA, ROCK1, and ROCK2. This provided critical structural information for medicinal chemistry to drive compound design. The structural data indicated the preferred configuration at the central benzylic carbon would be (<i>R</i>), and application of this information to compound design resulted in compound <b>16</b>. This compound was shown to be a potent and selective dual ROCK inhibitor in both enzyme and cell assays and efficacious in the retinal nerve fiber layer model after oral dosing. This tool compound has been made available through the AbbVie Compound Toolbox. Finally, the cocrystal structures also identified that aspartic acid residues 176 and 218 in ROCK2, which are glutamic acids in PKA, could be targeted as residues to drive both potency and kinome selectivity. Introduction of a piperidin-3-ylmethanamine group to the compound series resulted in compound <b>58</b>, a potent and selective dual ROCK inhibitor with excellent predicted drug-like properties.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Rho-associated coiled-coil-containing protein kinase<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> is a serine/threonine protein kinase that is more commonly referred to simply as ROCK kinase. ROCK exists as two isoforms, ROCK1<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> (also known as ROKÎ²<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a>) and ROCK2<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> (also known as ROKÎ±<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a>). In its activated form, ROCK participates in numerous signaling mechanisms including the phosphorylation of myosin light chain,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> the serine/threonine kinases Lim kinase 1 and 2,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> adducin,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and ezrin/radixin/moesin protein complex.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This has resulted in ROCK inhibition being pursued as a possible therapeutic for multiple diseases,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> most notably cerebral vasospasm,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> glaucoma,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> neurodegenerative diseases,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and hypertension.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> This interest has resulted in the discovery of multiple ATP-competitive ROCK inhibitors. For an excellent review of Rho kinases and their therapeutic potential, see Feng,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> which highlights the physiological and biological functions of rho kinases and the different chemical series that have been developed as ROCK inhibitors. These inhibitors deploy various groups for the critical interaction with the hinge region that joins the N- and C-terminal portions of the conserved protein kinase domain, including indazole,<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16â18)</a> aminofurazan,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> pyridine,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> pyrazole,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and isoquinoline.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23â25)</a></div><div class="NLM_p">Our interest was heightened by several publications demonstrating the effects of ROCK inhibitors in areas of immunology including, effects on histamine-induced airflow obstruction,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> inhibition of pulmonary eosinophilia, bronchoconstriction and airway hyperresponsiveness,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and anti-inflammatory activities.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Encouraged by this, we conducted a high-throughput screening (HTS) campaign to identify novel ROCK inhibitors. The HTS assay used ROCK2 enzyme (amino acids 11â552), with peptide substrate phosphorylation monitored via <sup>33</sup>P-labeled ATP. Approximately 700000 compounds were screened, and >3100 of these produced inhibition of ROCK2 in concentration response testing. Herein we report the discovery of an attractive hit series exemplified by compound 1 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and the subsequent structureâactivity relationship studies guided by critical structural information. This ultimately resulted in the discovery of compound <b>58</b>, a highly potent inhibitor of both ROCK1 and ROCK2 with broad selectivity across the kinome.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of HTS hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over 3000 active hits were identified from a HTS campaign and prioritized using hit-like criteria<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29â31)</a> and an affinity prediction plot.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> After structure and purity confirmation by liquid chromatography mass spectrometry (LCMS) of the prioritized hits, compound <b>1</b> was selected for further investigation. In addition to the hit-like properties exhibited by compound <b>1</b>, its synthetic tractability was also very appealing as it was afforded in just one step from 4-pyrid-4-ylbenzoic acid <b>2</b>, which was offered in gram quantity from Maybridge Chemical Co. Ltd.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and available through Ryan Scientific.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This made it an ideal candidate for follow up with focused libraries in the centralized high-throughput chemistry group (HTC) at AbbVie. In addition, there have been multiple reports on the successful development of ROCK inhibitors with pyridine as the hinge binding motif.<a onclick="showRef(event, 'ref15 ref21 ref24 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref15 ref21 ref24 ref35 ref36 ref37">(15,21,24,35â37)</a></div><div class="NLM_p">To expand the SAR for <b>1</b>, several libraries were produced by HTC. Using standard amide bond forming conditions, commercially available 4-pyrid-4-ylbenzoic acid <b>2</b> was reacted with various benzylamines <b>3</b> to afford the desired compounds with the general formula <b>4</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) (specific compounds <b>5</b>â<b>15</b> shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Scheme for HTC Library Follow up on Compound <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) PS-DCC, DIEA, DMA, microwave, 100 Â°C, 10 min.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR for Compounds <b>5</b>â<b>15</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0012.gif" alt="" id="GRAPHIC-d7e691-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0013.gif" alt="" id="gr12" /></img><div></div></div><div class="NLM_p">The compounds were evaluated in enzyme activity assays for both ROCK1 and ROCK2, with PKA used as a surrogate kinase to provide an early read on general kinome selectivity. Encouragingly, these libraries afforded immediate SAR and identified many potent ROCK1 and ROCK2 inhibitors. Compound <b>5</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) with the unsubstituted aryl ring resulted in a slight increase in the binding efficiency index (BEI) relative to the HTS hit while having no selectivity versus PKA. Introduction of the 3-methoxy in compound <b>6</b> maintained the high BEI and increased the selectivity window over PKA from 8- to almost 40-fold. Homologues <b>7</b> and <b>8</b> caused a slight drop in BEI while improving the selectivity against PKA to 65- and 85-fold, respectively. The 3-hydroxy analogue <b>9</b> produced the highest BEI of nearly 28 while having a similar selectivity to the 3-methoxy compound. The larger 3-OCF<sub>3</sub> analogue <b>10</b> and the 2,3-dimethoxy compound <b>11</b> resulted in a loss of potency, with both compounds being >1 Î¼M at all three kinases. Benzodioxolane compound <b>12</b>, the ring constrained version of <b>11</b>, had a similar potency and selectivity profile to compound <b>6</b>. Ring expansion to benzodioxepine <b>13</b> maintained the potency and BEI of the benzodioxolane at ROCK2 while affording a much larger window of selectivity over PKA of 130. The final two analogues were designed to investigate the tolerance for the introduction of solubilizing basic nitrogen groups to enable moderation of compound properties, should this be necessary later in the project. Unfortunately, while dimethylamine <b>14</b> and morpholine <b>15</b> maintained the potency and selectivity profile of <b>6</b>, this was with the penalty of a much reduced BEI of 18.1 and 15.8, respectively.</div><div class="NLM_p">In addition, these compound libraries enabled profiling in our HT-ADME panel of assays (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). This data showed that this series had good solubility, free fraction in plasma, and cellular permeability as assessed using PAMPA.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As predicted, compound <b>14</b>, in which the dimethylamine was introduced, displayed the highest solubility and free fraction. However, it was evident that the major liability was their pan-inhibition of CYP enzymes, especially 3A4, predicting unwanted drugâdrug interactions. It is well-known that 2,6-unsubstituted pyridines act as potent CYP inhibitors,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and so modification of this motif would need to be addressed during the medicinal chemistry project.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. HT-ADME Data for Compounds <b>6</b>, <b>7</b>, <b>8</b>, <b>12</b>, and <b>14</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">CYP inhibition IC<sub>50</sub>Â (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd solubility (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">Solubility (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (%Â free)</th><th class="colsep0 rowsep0" align="center" char=".">PAMPA (10<sup>â6</sup>Â cms<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">2C9</th><th class="colsep0 rowsep0" align="center" char=".">2D6</th><th class="colsep0 rowsep0" align="center" char=".">3A4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">98.0</td><td class="colsep0 rowsep0" align="char" char=".">20.2</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">9.9</td><td class="colsep0 rowsep0" align="char" char=".">99.6</td><td class="colsep0 rowsep0" align="char" char=".">18.1</td><td class="colsep0 rowsep0" align="char" char=".">0.48</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">99.7</td><td class="colsep0 rowsep0" align="char" char=".">16.2</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">33.9</td><td class="colsep0 rowsep0" align="char" char=".">97.2</td><td class="colsep0 rowsep0" align="char" char=".">14.9</td><td class="colsep0 rowsep0" align="char" char=".">2.04</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">63.3</td><td class="colsep0 rowsep0" align="char" char=".">76.8</td><td class="colsep0 rowsep0" align="char" char=".">2.47</td><td class="colsep0 rowsep0" align="char" char=".">16.0</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">2.00</td></tr></tbody></table></div></div><div class="NLM_p">While the pragmatic amide bond-forming libraries afforded useful SAR, this was a one-dimensional strategy, and a more rational design approach was desired as the project progressed. To this end, several crystallography campaigns were initiated using compounds from the HTC libraries. At the time, there were no public crystal structures of ROCK2 and limited structures of ROCK1.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In previous studies, we had successfully used PKA as a structure surrogate for ROCK kinases.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Initial structures in this study were therefore obtained in PKA. We and others (Akama<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and Boland<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>) later succeeded in obtaining some structures in ROCK kinases. The structure of the early lead compound <b>12</b> was therefore obtained in PKA, ROCK1, and ROCK2, affording a great opportunity to compare and contrast the three active sites.</div><div class="NLM_p">In PKA (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a), the hinge interaction is with the backbone nitrogen of valine 124. The hydrophobic core of the compound is sandwiched between alanine 71 and valine 58 above and leucine 174 below. The carbonyl of the amide makes a hydrogen bond with lysine 73, while the benzodioxine group forms a large van der Waals surface interaction with the glycine rich loop which is situated above it. The backbone nitrogen for phenylalanine 55 is within 3.5 Ã of an oxygen of the dioxine which is accommodated but not likely to be a productive hydrogen bond. Phenylalanine 55 also stacks against the benzodioxine group. For ROCK1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b), the binding is very similar. Here binding to the hinge is with the backbone nitrogen of methionine 156. Again, the residues of alanine 103 and valine 90 above and leucine 205 below sandwich the compound core. The amide carbonyl forms a hydrogen bond to lysine 105, and the benzodioxine ring system is forming an extensive van der Waals interaction with the glycine rich loop. Here, however, phenylalanine 87 is extended out from the glycine rich loop and does not stack against the benzodioxine group. Differences in the region of PKA Lys79 to Thr89 (ROCK1 residues Glu111 to Phe121, ROCK2 Glu127 to Phe137) likely allows for differential dynamics of the glycine rich loop between PKA and ROCK1, in particular, PKA Phe55 versus ROCK1 Phe87. The glycine rich loop and PKA Phe55 are more constrained than the glycine rich loop of either ROCK1 or ROCK2 and perhaps a driver of the observed selectivity of these compounds. For ROCK2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c), the binding mode is very similar to ROCK1. The hinge interaction is with the nitrogen backbone of methionine 172. Again, the amide carbonyl makes a hydrogen bond to lysine 121. Once again, the benzodioxine ring system is forming an extensive van der Waals interaction with the glycine rich loop. However, in the case of ROCK2, the glycine rich loop is even less constrained than that of ROCK1 with additional flexibility observed in the neighboring region of E127 to F137, which can further contribute to potency differences observed between ROCK1 and ROCK2, allowing for more optimal van der Waals contacts between the glycine rich loop substituents (benzodioxine in this case) in ROCK2 than ROCK1 or PKA.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structures of compound <b>12</b> in (a) PKA (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9L">6E9L</a>), (b) Rock1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9W">6E9W</a>), and (c) Rock2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ED6">6ED6</a>). All structures were obtained by cocrystallization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further, in these structures, there are acid residues nearby which could be reached by extension off the compound core. In ROCK1 and ROCK2, these are both aspartic acids (160 and 202 in ROCK1 and 176 and 218 in ROCK2). In PKA, these residues are both glutamic acids (128 and 171), and so targeting these residues could provide some selectivity against PKA and AKT.</div><div class="NLM_p">The structural data also suggested that the preferred configuration at the benzylic carbon would be (<i>R</i>). To test this hypothesis compounds with both (<i>R</i>)-1-(3-methoxyphenyl)ethan-1-amine and (<i>S</i>)-1-(3-methoxyphenyl)ethan-1-amine were synthesized. Gratifyingly, the two methyl isomers <b>16</b> and <b>17</b> confirmed the structural hypothesis of the preferred configuration (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). While compound <b>16</b> with the (<i>R</i>) configuration at the benzylic carbon was 10-fold more potent than the corresponding <i>des</i>-methyl analogue <b>6</b>, compound <b>17</b> with the (<i>S</i>)-configuration at the benzylic carbon was more than 3 logs less potent.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR for Compounds <b>16</b> and <b>17</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0014.gif" alt="" id="GRAPHIC-d7e1007-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char="Â±">IC<sub>50</sub> (Î¼M) at 100 Î¼M ATP</th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="colsep0 rowsep0" align="center" char=".">Â </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">CYP inhibition IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">configuration</th><th class="colsep0 rowsep0" align="center" char="Â±">ROCK1</th><th class="colsep0 rowsep0" align="center" char="Â±">ROCK2</th><th class="colsep0 rowsep0" align="center">PKA</th><th class="colsep0 rowsep0" align="center" char=".">solubility (Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (% free)</th><th class="colsep0 rowsep0" align="center" char=".">PAMPA (10<sup>â6</sup>Â cms<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">2C9</th><th class="colsep0 rowsep0" align="center" char=".">2D6</th><th class="colsep0 rowsep0" align="center" char=".">3A4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">(<i>R</i>)</td><td class="colsep0 rowsep0" align="char" char="Â±">0.017Â Â±Â 0.005</td><td class="colsep0 rowsep0" align="char" char="Â±">0.002Â Â±Â 0.001</td><td class="colsep0 rowsep0" align="center">0.24Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="char" char=".">74.3</td><td class="colsep0 rowsep0" align="char" char=".">83.1</td><td class="colsep0 rowsep0" align="char" char=".">19.6</td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char=".">3.62</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">(<i>S</i>)</td><td class="colsep0 rowsep0" align="char" char="Â±">5.1Â Â±Â 0.1</td><td class="colsep0 rowsep0" align="char" char="Â±">2.4Â Â±Â 0.9</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div></div><div class="NLM_p">To address CYP inhibition, analogues incorporating substituted pyridine or heterocyclic replacements of pyridine were designed. To secure these, a straightforward two-step synthetic route was followed. The desired pyridyl replacement was purchased as the 4-halogen analogue and reacted with 4-bromobenzoic acid under palladium catalyzed conditions. The resultant carboxylic acid was then coupled with the benzylamine component using standard conditions (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><div class="NLM_p">Introduction of 2-amino and 2-fluoro in compounds <b>18</b> and <b>19</b> resulted in a slight loss in potency at ROCK2 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). However, these compounds now had a clean profile in the CYP inhibition assays. Introduction of 2-chloro and 2-methyl in compounds <b>20</b> and <b>21</b> caused a much larger reduction in potency, while the 2,6-dimethyl analogue <b>22</b> was inactive. As a result, none of these compounds were advanced to HT-ADME for screening. The most surprising result was 3-fluoro compound <b>23</b>. Despite the lack of groups ortho to the pyridine nitrogen to afford steric hindrance, this compound had much reduced inhibition of both CYP2C9 and CYP3A4 while being the most potent ROCK2 inhibitor yet identified. There was a concern over the lability and possible reactivity of the halopyridine analogues <b>19</b> and <b>20</b>. To address this, both compounds were tested in our ALARM NMR assay<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and shown to be nonreactive. The final two compounds were heterocyclic replacements of the pyridine. As expected pyrimidine <b>24</b> displayed an improved CYP inhibition profile which was accompanied by a moderate loss in potency at ROCK2. Disappointingly, introduction of the pyridazine in compound <b>25</b> was not tolerated and resulted in essentially complete loss of potency at ROCK2.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR for Compounds <b>18</b>â<b>25</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0015.gif" alt="" id="GRAPHIC-d7e1181-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0016.gif" alt="" id="gr13" /></img><div></div></div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route towards (Benzyloxy)benzene Analogues <b>16</b>â<b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME, DIPEA, 80 Â°C, 72 h; (ii) (<i>R</i>)- or (<i>S</i>)-1-(3-methoxyphenyl)ethan-1-amine, EDAC, HOBt, 0 Â°C to RT, O/N.</p></p></figure><div class="NLM_p">Compound <b>18</b> with the 2-aminopyridine hinge binding motif had shown good potency at ROCK2 and a clean CYP inhibition profile. Data from the crystal structures suggested that substitution off the amino group would be more tolerated in ROCK1 and ROCK2 than PKA. Such an approach could be used to access the extended hinge driving selectivity versus PKA and also enabling moderation of compound properties. To interrogate this hypothesis, analogues were synthesized that introduced small alkyl and alkoxy groups off the 2-amino group. The desired compounds were obtained in one step from the chloropyridine compound <b>20</b>. Treatment of compound <b>20</b> with the chosen amine under palladium catalyzed conditions afforded the desired compounds in 34â69% yield (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_p">The most striking SAR from this series was the oblation of activity at PKA, with all the compounds having high micromolar IC<sub>50</sub>s (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Both compound <b>26</b> with an ethyl substituent and compound <b>27</b> with the methylene cyclopropyl substituent maintained respectable potency at both ROCK1 and ROCK2 while displaying good selectivity versus PKA and only a small reduction in BEI. The methylene propan-2-ol of compound <b>28</b> and the methoxy ethyl of compound <b>29</b> were less well tolerated at ROCK1 and ROCK2. Compound <b>30</b>, the homologue of <b>29</b>, with the methoxy propyl group had a similar overall profile to compounds <b>26</b> and <b>27</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR for Compounds <b>26</b>â<b>30</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0017.gif" alt="" id="GRAPHIC-d7e1281-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0018.gif" alt="" id="gr14" /></img><div></div></div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route towards (Benzyloxy)benzene Analogues <b>26</b>â<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd<sub>2</sub>(dba)<sub>3</sub>, sodium 2-methylpropan-2-olate, <sup>t</sup>BuXPhos, dioxane, N<sub>2</sub>, 80 Â°C, O/N.</p></p></figure><div class="NLM_p">Having identified suitable motifs to ameliorate the CYP inhibition, the project now turned its focus to leveraging the structural data. This suggested that compounds with improved potency at ROCK1 and ROCK2 could be obtained through targeting an interaction with the aspartic acids on the side of the pocket (ROCK1 160, 202, ROCK2 176, 218).</div><div class="NLM_p">While many enantiomerically pure Î±-substituted benzylamines are commercially available, the Î±-substituents are typically small alkyl or aryl in nature. As a result, a flexible synthetic route that provided the opportunity to introduce hydrophilic groups in a late synthetic step was investigated. To reach the aspartic acids on the side of the pocket for ROCK1 and ROCK2, the structural data suggested that a two-carbon linker from the benzylic carbon would be the optimal spacer length for incorporation of the amine. Fortunately, many enantiomerically pure 3-amino-3-phenylpropanoic acids are available. (<i>R</i>)-3-Amino-3-(3-methoxyphenyl)propanoic acid was identified as the key starting material as this incorporated both the correct configuration at the benzylic carbon and the optimal 3-methoxyphenyl that had been identified in the previous SAR studies.</div><div class="NLM_p">Treatment of boc-(<i>R</i>)-3-amino-3-(3-methoxy-phenyl)-propionic acid <b>31</b> with butyl chloroformate followed by subsequent reaction with sodium borohydride afforded alcohol <b>32</b>. Treatment with mesyl chloride efficiently afforded key intermediate <b>33</b>, which was appropriately functionalized to enable the introduction of nitrogen containing motifs that were hydrophilic in character. Finally, treatment with HCl/dioxane afforded, after aqueous workup or trituration, the desired enantiomerically pure benzylamines <b>34</b> with hydrophilic groups attached from the benzylic carbon in high chemical purity (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). This synthetic route also provided a route to alcohol <b>35</b> which enabled additional analogues to be synthesized.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route towards Key Intermediates for Compounds <b>36</b>â<b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDAC, HOBt, 0 Â°C to RT, O/N, 61%; (ii) Na<sub>2</sub>CO<sub>3</sub>, DMSO, 110 Â°C, 34%; (iii) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 Â°C, 75%; (iv) chiral separation; (v) TFA, DCM, 61%.</p></p></figure><div class="NLM_p">The first analogue compound <b>36</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) gave great encouragement being 15 times more potent than compound <b>5</b>, the corresponding compound without the ethyl pyrrolidine. Unfortunately, this increase in potency was likely due to the preferred (<i>R</i>)-configuration rather than a beneficial interaction with ASP202 (ROCK1) and ASP218 (ROCK2). Compounds <b>37</b> and <b>38</b> maintained a very respectable BEI at ROCK2, and the pyrrolidine and hydroxyl may impart benefits to drug-like properties. However, compounds <b>39</b>â<b>43</b> were all substantially less potent. The only compound of note was <b>43</b>, which both reinforced the positive view of the 3-fluoro pyridine motif identified in compound <b>23</b> and also showed good selectivity versus PKA. To confirm the importance of the benzylic carbon configuration as a potency driver, the (<i>R</i>)-methyl was incorporated with the propyloxy from compound <b>8</b> that drove selectivity versus PKA. This afforded compound <b>44</b> with an impressive BEI at ROCK2 of 21.7 in conjunction with over 600-fold selectivity versus PKA.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR for Compounds <b>36</b>â<b>44</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0019.gif" alt="" id="GRAPHIC-d7e1446-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0020.gif" alt="" id="gr15" /></img><div></div></div><div class="NLM_p">In an attempt to improve the selectivity profile, the next synthetic effort was directed at targeting an interaction with Asp160 (ROCK1) and Asp176 (ROCK2). Consideration of the structural data suggested that the central aryl ring afforded the preferred sites for attachment, optimally from the meta-position relative to the hinge binding pyridine. For compounds <b>46</b>â<b>49</b>, it was possible to effect the displacement of the 3-fluoro from the central aryl ring of <b>45</b> with the desired amine (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route towards Compounds <b>46</b>â<b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME, DIPEA, 80 Â°C, 72 h; (ii) EDAC, HOBt, 0 Â°C to RT, O/N; (iii) <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine, diamine, DMSO, 110 Â°C, O/N.</p></p></figure><div class="NLM_p">Inspection of the crystal structure suggested that introduction of a 3â5 atom linker from the meta-position (with respect to the hinge binding pyridine) of the central aryl ring should be suitable to position a nitrogen in the vicinity of the ASP160 in ROCK1 and ASP176 in ROCK2 and present the opportunity to make an interaction. The first analogue <b>46</b> introduced piperidin-4-ylmethanamine, which unfortunately resulted in the most potent compound across ROCK1, ROCK2, and PKA (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). To furnish compounds with more flexibility to secure an interaction with the aspartic acid 160 ROCK1 and 176 ROCK2, the next analogues investigated varying lengths of acyclic diamines. Increasing the linker length with compounds <b>47</b> (ethane-1,2-diamine), <b>48</b> (propane-1,3-diamine), and <b>49</b> (butane-1,4-diamine) gave the desired increased selectivity over PKA, which can be explained by looking at the structure of compound <b>47</b> in PKA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Here the shorter linker of compound <b>47</b> allows a hydrogen bond to be made in PKA with glutamic acid 128. As the linker length increases to 4 atoms in <b>49</b>, binding here would seem to be reduced. For ROCK1 and ROCK2, the linker length of compound <b>48</b> would seem to interface the shorter aspartic acid residues in these proteins.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR for Compounds <b>46</b>â<b>49</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0021.gif" alt="" id="GRAPHIC-d7e1547-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0022.gif" alt="" id="gr16" /></img><div></div></div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of compound <b>47</b> in the active site of PKA (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E99">6E99</a>). Structure was obtained by cocrystallization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having established that a 5-atom linker afforded compounds with the best selectivity, ring constrained variants of butane-1,4-diamine were considered. For the design of these compounds, emphasis was placed on the calculated physicochemical properties of the resulting compounds based on medicinal chemistry guidelines like drug-like properties,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> fraction sp<sup>3</sup> carbon,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and 3/75.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Cognizant of the CYP inhibition liability of compound <b>49</b> due to the unsubstituted pyridine, an alternative hinge binding motif was selected for these analogues. Piperidine was selected ahead of 2-aminopyridine, 2-fluoropyridine, and 3-fluoropyrdine because it increases both the PSA and Fsp3 to values associated with a safer predicted toxicity profile.</div><div class="NLM_p">From the radar plot visualization (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), it is evident that only compound <b>58</b> has excellent predicted drug-like properties including Fsp<sup>3</sup>. The radar plot data is also shown in tabular form below (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In addition compound <b>1</b>, the initial hit, and compound <b>58</b>, have calculated PSA and cLogP that suggest a reduced risk of toxicity based on the 3/75 rule. These clearly show that compound <b>58</b> has excellent calculated drug-like properties.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Radar plot of calculated physicochemical properties and (b) predicted reduced risk of toxicity, for compounds <b>1</b>, <b>5</b>, <b>6</b>, <b>16</b>, <b>44</b>, and <b>58</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Calculated Physicochemical Properties for Compounds <b>1</b>, <b>5</b>, <b>6</b>, <b>16</b>, <b>44</b>, and <b>58</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">CLogP</th><th class="colsep0 rowsep0" align="center" char=".">PSA</th><th class="colsep0 rowsep0" align="center" char=".">HBA</th><th class="colsep0 rowsep0" align="center" char=".">logÂ <i>D</i>Â 7.4</th><th class="colsep0 rowsep0" align="center" char=".">HBD</th><th class="colsep0 rowsep0" align="center" char=".">molÂ wt</th><th class="colsep0 rowsep0" align="center" char=".">NAR</th><th class="colsep0 rowsep0" align="center" char=".">NRB</th><th class="colsep0 rowsep0" align="center" char=".">Fsp<sup>3</sup></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">2.72</td><td class="colsep0 rowsep0" align="char" char=".">62.2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2.86</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">332.4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">3.37</td><td class="colsep0 rowsep0" align="char" char=".">42.0</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">3.20</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">288.3</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">3.29</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">3.04</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">318.4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">3.60</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">3.46</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">332.4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char=".">4.65</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4.34</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">360.4</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">2.60</td><td class="colsep0 rowsep0" align="char" char=".">93.4</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">0.63</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">445.6</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td></tr></tbody></table></div></div><div class="NLM_p">To facilitate these analogues an alternative synthetic route was required. The (<i>R</i>)-(+)-1-(3-substituted-phenyl)ethylamine <b>51</b> was reacted with 4-bromo-2-fluorobenzoic acid <b>50</b> to afford intermediate <b>52</b>. Nucleophilic displacement of the fluorine of <b>52</b> with mono boc-protected diamines was efficiently mediated using standard conditions and afforded the target compounds without the hinge binding motif <b>53</b>. These diastereomeric mixtures were subjected to chiral chromatography to afford stereochemically pure material. Palladium catalyzed coupling with 4-chloropyrimidine afforded the boc-protected analogues, which upon treatment with TFA furnished the desired compound <b>58</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route towards Compounds <b>54</b>â<b>58</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDAC, HOBt, 0 Â°C to RT, O/N; (ii) <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine, diamine, DMSO 110 Â°C, O/N; (iii) CH<sub>3</sub>CO<sub>2</sub>K, 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane), 4-chloropyrimidine hydrochloride, PdCl<sub>2</sub>(dppf)-DCM, Cs<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, 65 Â°C, 3 h; (iv) TFA.</p></p></figure><div class="NLM_p">Compound <b>54</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) was prepared as the pyrimidine analogue of compound <b>49</b> to establish the concept of replacing the pyridine hinge binding motif. This was confirmed with both compounds having very similar profiles for both potency and selectivity. Replacement of the butane-1,4-diamine with pyrrolidin-3-ylmethanamine that also incorporated the propyloxy group on the terminal aryl ring was not promising. Both compounds <b>55</b> and <b>56</b> were not only less potent at ROCK2 but were also far less selective versus PKA. Incorporation of piperidin-3-ylmethanamine in compounds <b>57</b> and <b>58</b> was far more beneficial. (<i>R</i>)-Isomer <b>57</b> was found to be a potent inhibitor of ROCK2 with modest selectivity over PKA. However, the (<i>S</i>)-isomer <b>58</b> retained this potency against ROCK1 and ROCK2 and introduced more than a 200-fold selectivity versus PKA. The absolute configuration of compounds <b>55</b>, <b>56</b>, <b>57</b>, and <b>58</b> was not determined. The configuration was assigned arbitrarily using the crystal structures to predict which the most selective compound was. Further studies are ongoing to assign the absolute stereochemistries of these four compounds. Additional profiling of compounds <b>57</b> and <b>58</b> showed they have good solubility and free fraction, with not surprisingly moderate permeability as assessed by PAMPA due to the primary amine.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. SAR for Compounds <b>54</b>â<b>58</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0023.gif" alt="" id="GRAPHIC-d7e1970-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0024.gif" alt="" id="gr17" /></img><div></div></div><div class="NLM_p">To identify the optimal compound for in vivo studies, 44 of the above-described ROCK inhibitors were screened in the AbbVie kinome panel that includes 80 kinases (<a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). This highlighted compound <b>16</b> as the best candidate. It provides IC<sub>50</sub> values >10 Î¼M for 63 of the kinases and over 1 Î¼M for a further 10 kinases. Consistent with the project screening data, it was highly potent at both ROCK1 (IC<sub>50</sub> 1 nM) and ROCK2 (IC<sub>50</sub> 1 nM). It only inhibited two other kinases at the low nanomolar level PKG1A (IC<sub>50</sub> 1 nM) and PKA (IC<sub>50</sub> 47 nM), showing this to be a highly selective dual ROCK1 and ROCK2 inhibitor suitable for in vivo studies. The broad kinome profiling showed that compounds <b>55</b>, <b>56</b>, <b>57</b>, and <b>58</b> were the most selective against PKG1A, while compound <b>22</b>, the hindered 2,6-dimethylpyridine, was shown to be inactive at all 80 kinases.</div><div class="NLM_p">A subset of these molecules were then progressed into a pMYPT1 ELISA, which is a ROCK dependent cell-based assay (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). Compound <b>6</b>, the 3-methoxy analogue showed good potency while compounds <b>8</b>, <b>12</b>, and <b>14</b>, with the larger aryl substituents, were less potent. Compound <b>16</b> was the most potent compound (IC<sub>50</sub> 0.012 Î¼M) and confirmed this as an excellent dual ROCK1 and ROCK2 tool compound. This compound has been made available through the AbbVie Compound Toolbox.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Compound <b>17</b>, the isomer of <b>16</b>, was 3 logs less potent, consistent with the enzyme assay result. Compounds <b>18</b>, <b>19</b>, <b>24</b>, <b>27</b>, and <b>30</b>, in which the hinge binding motif was modified to reduce CYP inhibition, demonstrated an 8â15-fold shift in the cell assay. Cell data for pyridazine <b>25</b> was almost 10 Î¼M, which agreed with the observed enzyme data and confirmed that this functional group was not tolerated. Compounds <b>44</b> and <b>58</b> were shown to be excellent dual ROCK1 and ROCK2 inhibitors with IC<sub>50</sub>s of 0.056 and 0.094 Î¼M, respectively.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Lead Compounds in pMYPT1 ELISA Cell Assay</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd</th><th class="colsep0 rowsep0" align="center">pMYPT1 IC<sub>50</sub> (Î¼M<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a>)</th><th class="colsep0 rowsep0" align="center" char=".">PAMPA (10<sup>â6</sup>Â cms<sup>â1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">PSA (Ã)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center">0.075</td><td class="colsep0 rowsep0" align="char" char=".">20.2</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="center">0.961</td><td class="colsep0 rowsep0" align="char" char=".">16.2</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="center">0.45</td><td class="colsep0 rowsep0" align="char" char=".">14.9</td><td class="colsep0 rowsep0" align="char" char=".">60.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">2.23Â Â±Â 1.3</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">54.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">0.012Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char=".">19.6</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">49.8</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">51.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">0.173Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">77.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center">0.116Â Â±Â 0.09</td><td class="colsep0 rowsep0" align="char" char=".">14.7</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center">0.415Â Â±Â 0.24</td><td class="colsep0 rowsep0" align="char" char=".">19.7</td><td class="colsep0 rowsep0" align="char" char=".">64.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="center">7.83</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">64.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="center">0.963</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">63.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="center">0.802</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">72.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="center">0.056Â Â±Â 0.01</td><td class="colsep0 rowsep0" align="char" char=".">18.8</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="center">0.094</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">93.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Errors shown for compounds tested multiple times.</p></div></div></div><div class="NLM_p">Pharmacokinetic analyses (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>) of compound <b>16</b> in both C57BL6 mice and SpragueâDawley rats all 10 Î¼mol/kg with group size <i>n</i> = 3, were performed using iv, ip, and po administration. The compound has a reasonable half-life and good exposure in both plasma and brain. While the oral bioavailability was moderately low, it was sufficient to advance the compound for in vivo testing</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Pharmacokinetics of Compound <b>16</b> in C57BL6 Mouse and SpragueâDawley Rat<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">iv</th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">ip</th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">po</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Species</th><th class="colsep0 rowsep0" align="center">Sample analyzed</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (Î¼gÂ·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vss (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (Î¼g/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (Î¼gÂ·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (Î¼g/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (Î¼gÂ·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD rat</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">2.19</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">1.03</td><td class="colsep0 rowsep0" align="char" char=".">1.80</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.67</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD rat</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">2.36</td><td class="colsep0 rowsep0" align="char" char=".">2.30</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">1.92</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C57BL6 mouse</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">1.66</td><td class="colsep0 rowsep0" align="char" char=".">2.08</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">0.84</td><td class="colsep0 rowsep0" align="char" char=".">1.42</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">brain</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="char" char=".">1.78</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">All groups <i>n</i> = 3, dose of 10 Î¼mol/kg.</p></div></div></div><div class="NLM_p">Beneficial effects of ROCK inhibitors, like Fasudil and Y-27632, have been reported in a variety of animal models of different neurodegenerative diseases.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> To confirm such potential in this hit series, compound <b>16</b> was investigated in an optic nerve crush model<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> in rats. In this model, compression of the optic nerve leads to axon dissection followed by degeneration of the retinal nerve fiber layer (RNFL) in the eye over time. Compound <b>16</b> was orally administered once daily at a dose of 10 mg/kg for 5 weeks and compared to a vehicle control. Subsequent immunohistochemical staining of the retina revealed a significant increase in the number of Î²III tubulin positive fibers in compound <b>16</b> treated animals indicative of a protection of the axons in the retinal nerve fiber layer by ROCK inhibition (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Further studies are ongoing to identify clear positive controls for this assay.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Protection of the retinal nerve fiber layer with compound <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Following a high-throughput screen compound <b>1</b>, a 4-(pyridin-4-yl)benzamide, was identified as the starting point for a medicinal chemistry project to identify a potent and kinome-selective dual ROCK1 and ROCK2 inhibitor. This compound was selected due to its excellent physicochemical properties and synthetic accessibility. Parallel synthesis was employed to generate focused compound libraries that furnished immediate SAR and most notably compound <b>12</b>. Crystal structures were obtained for this compound in PKA, ROCK1, and ROCK2. This provided critical structural information to the medicinal chemistry team to drive compound design and enabled a unique comparison of the three binding sites with the same bound inhibitor. Interrogation of the cocrystal structures indicated the preferred configuration at the central benzylic carbon would be (<i>R</i>). This information was used to select monomers for focused library design resulting in compound <b>16</b> with the (<i>R</i>)-configuration and compound <b>17</b> with the (<i>S</i>)-configuration. Comparison of the potency of these two compounds clearly supported the structural hypothesis that the (<i>R</i>)-configuration was preferred. Profiling of these early leads in a HT-ADME assay panel showed the compounds were pan-inhibitors of CYP enzymes, especially 3A4, predicting unwanted drugâdrug interactions. Substitution (2-Cl, 2-NH<sub>2</sub>, 2-F, 3-F) of the pyridine or replacement with pyrimidine afforded compounds with a clean CYP inhibition profile. Piperidine was selected ahead of 2-aminopyridine, 2-fluoropyridine, and 3-fluoropyrdine because it increases both the PSA and Fsp3 to values associated with a safer predicted toxicity profile. Additional profiling of compound <b>16</b> showed it was a potent and selective dual ROCK1 and ROCK2 inhibitor in both enzyme and cell assays and efficacious in the retinal nerve fiber layer model after oral dosing. This tool compound has been made available through the AbbVie Compound Toolbox. Finally, the cocrystal structures also identified that aspartic acid residues 176 and 218 in ROCK2, which are glutamic acids in PKA, could be targeted as residues to drive both potency and kinome selectivity. Introduction of a piperidin-3-ylmethanamine group to the compound series resulted in compound <b>58</b>, a potent and selective dual ROCK1 and ROCK2 inhibitor with excellent predicted drug-like properties including a significantly reduced Cyp inhibition profile.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise stated, reagents were purchased from Sigma-Aldrich, Acros, Alfa Aesar, or the Sigma-Aldrich Custom Packaged Reagent service. Reagent/reactant names given are as named on the commercial bottle or as generated by IUPAC conventions or CambridgeSoft ChemDraw Ultra 9.0.7. Compound names are generated by IUPAC conventions or CambridgeSoft ChemDraw Ultra 9.0.7. For all final compounds, purity was established by HPLC and purity confirmed to be â¥95%.</div><div class="NLM_p">Analytical data is included within the procedures below, in the illustrations of the general procedures, or in the tables of examples. Unless otherwise stated, all <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR data were collected on a Varian Mercury Plus 400 MHz or a Bruker AVIII 300 MHz or a Bruker 500 MHz instrument; chemical shifts are quoted in parts per million (ppm). HPLC analytical data are either detailed within the experimental or referenced to the table of LCMS and HPLC conditions (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>), using the lower case letter in high resolution mass spectra (HRMS) were obtained using an Agilent 6550 Q-TOF spectrometer with an ESI source.</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. List of HPLC Methods</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">HPLC conditions</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">a</td><td class="colsep0 rowsep0" align="left">HPLC: A gradient of 10â100% MeCN (A) and 0.1% trifluoroacetic acid in water (B) was used at a flow rate of 2.0 mL/min (0â0.1 min 10% A, 0.1â2.6 min 10â100% A, 2.6â2.9 min 100% A, 2.9â3.0 min 100â10% A, 0.5 min postrun delay).</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">b</td><td class="colsep0 rowsep0">HPLC: The gradient was 5â60% B in 0.75 min then 60â95% B to 1.15 min with a hold at 95% B for 0.75 min (1.3 mL/min flow rate). Mobile phase A was 10 mM ammonium acetate, mobile phase B was HPLC grade MeCN. The column used for the chromatography is a 4.6 mm Ã 50 mm MAC-MOD Halo C8 column (2.7 Î¼m particles). Detection methods are diode array (DAD) and evaporative light scattering (ELSD) detection as well as positive/negative electrospray ionization.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">c</td><td class="colsep0 rowsep0">HPLC: The gradient was 5â60% B in 1.5 min then 60â95% B to 2.5 min with a hold at 95% B for 1.2 min (1.3 mL/min flow rate). Mobile phase A was 10 mM ammonium acetate, mobile phase B was HPLC grade acetonitrile. The column used for the chromatography is a 4.6 mm Ã 50 mm MAC-MOD Halo C8 column (2.7 Î¼m particles). Detection methods are diode array (DAD) and evaporative light scattering (ELSD) detection as well as positive/negative electrospray ionization.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">d</td><td class="colsep0 rowsep0">HPLC: The gradient was 5â60% B in 1.5 min then 60â95% B to 2.5 min with a hold at 95% B for 1.2 min (1.3 mL/min flow rate). Mobile phase A was 10 mM ammonium acetate, mobile phase B was HPLC grade acetonitrile. The column used for the chromatography is a 4.6 mm Ã 50 mm MAC-MOD Halo C8 column (2.7 Î¼m particles). Detection methods are diode array (DAD) and evaporative light scattering (ELSD) detection as well as positive/negative electrospray ionization.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">e</td><td class="colsep0 rowsep0">HPLC: A gradient of 10â100% acetonitrile (A) and 10 mM ammonium acetate in water (B) was used, at a flow rate of 2 mL/min (0â0.1 min 10% A, 0.1â2.6 min 10â100% A, 2.6â2.9 min 100% A, 2.9â3.0 min 100â10% A. 0.5 min postrun delay).</td></tr></tbody></table></div></div><div class="NLM_p">Chiral LC analysis was performed using Varian 218 LC pumps, a Varian CVM 500 with switching valves and heaters for automatic solvent, column, and temperature control. Detection methods included a variable wavelength UV detector (Varian Prostar 320), an in-line polarimeter (PDR-chiral advanced laser polarimeter, model ALP2002) used to measure qualitative optical rotation (Â±) and an evaporative light scattering detector (ELSD) (a PS-ELS 2100 (Polymer Laboratories)). ELSD settings were as follows: evaporator, 46 Â°C; nebulizer, 24 Â°C; gas flow, 1.1 SLM.</div><div class="NLM_p">Chiral SFC analyses were performed using a Shimadzu Nexera UC SFCMS instrument (<a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). Detection methods included a PDA detector (model SPD-M20A), ESI (Â±) MS (model LCMS-2020), and an in-line polarimeter (PDR-Separations advanced laser polarimeter, model 4G-ALP) used to measure qualitative optical rotation (Â±).</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Chiral HPLC and SFC methods</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">method</th><th class="colsep0 rowsep0" align="center">conditions</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">HPLC: The gradient was 10â50% A in 19 min with a hold at 50% A for 1.5 min (1.0 mL/min flow rate). Mobile phase A was HPLC grade 2-propanol, mobile phase B was HPLC grade heptane with 0.1% diethylamine added. The column used for the chromatography was a Daicel ADH, 4.6 mm Ã 250 mm column (5 Î¼m particles). Detection methods were UV, evaporative light scattering (ELSD) detection as well as optical rotation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">HPLC: The gradient was 15â60% A in 19 min with a hold at 60% A for 1.5 min (1.0 mL/min flow rate). Mobile phase A was a 1:1 mixture of HPLC grade methanol and 200 proof ethanol, mobile phase B was HPLC grade heptane with 0.1% diethylamine added. The column used for the chromatography was a Daicel IC, 4.6 mm Ã 250 mm column (5 Î¼m particles). Detection methods were UV, evaporative light scattering (ELSD) detection as well as optical rotation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">HPLC: The gradient was 10â70% A in 19 min with a hold at 70% A for 1.5 min (1.0 mL/min flow rate). Mobile phase A was HPLC grade 2-propanol, mobile phase B was HPLC grade heptane with 0.1% diethylamine added. The column used for the chromatography was a Daicel IA, 4.6 mm Ã 250 mm column (5 Î¼m particles). Detection methods were UV, evaporative light scattering (ELSD) detection as well as optical rotation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D</td><td class="colsep0 rowsep0" align="left">HPLC: The gradient was 10â70% A in 19 min with a hold at 70% A for 1.5 min (1.0 mL/min flow rate). Mobile phase A was 200 proof ethanol, mobile phase B was HPLC grade heptane with 0.1% diethylamine added. The column used for the chromatography was a Daicel ASH, 4.6 mm Ã 250 mm column (5 Î¼m particles). Detection methods were UV, evaporative light scattering (ELSD) detection as well as optical rotation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">E</td><td class="colsep0 rowsep0" align="left">HPLC: Isocratic 30% A for 15 min (1.0 mL/min flow rate). Mobile phase A was a 1:1 mixture of HPLC grade methanol and 200 proof ethanol, mobile phase B was HPLC grade heptane with 0.2% diethylamine added. The column used for the chromatography was a Daicel ODH, 4.6 Ã 250 mm column (5 Î¼m particles). Detection methods were UV, evaporative light scattering (ELSD) detection.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">HPLC: The gradient was 10â50% A in 19 min with a hold at 50% A for 1.5 min (20.0 mL/min flow rate). Mobile phase A was HPLC grade isopropanol, mobile phase B was HPLC grade heptane with 0.1% diethylamine added. The column used for the chromatography was a Daicel ADH, 20 mm Ã 250 mm column (5 Î¼m particles). Detection methods were UV, evaporative light scattering (ELSD) detection as well as optical rotation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="left">SFC: The gradient was 10â55% A in 3.2 min with a hold at 55% A for 0.5 min (3.5 mL/min flow rate). Mobile phase A was 200 proof ethanol with 0.2% diethylamine additive, mobile phase B was SFC grade CO<sub>2</sub>. The column used for the chromatography was a Daicel IG, 4.6 mm Ã 100 mm column (3 Î¼m particles). Detection methods were UV, ESI (Â±) MS and optical rotation.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">SFC: The gradient was 10â55% A in 3.2 min with a hold at 55% A for 0.5 min (3.5 mL/min flow rate). Mobile phase A was an 80:20 mixture of HPLC grade isopropanol and acetonitrile with 0.2% diethylamine additive, mobile phase B was SFC grade CO<sub>2</sub>. The column used for the chromatography was a YMC SA, 4.6 mm Ã 100 mm column (3 Î¼m particles). Detection methods were UV, ESI (Â±) MS and optical rotation.</td></tr></tbody></table></div></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-<i>N</i>-(1-Hydroxy-3-phenylpropan-2-yl)-4-(pyridin-4-yl)benzamide (<b>1</b>)</h3><div class="NLM_p last">Synthesis was performed using a Personal Chemistry Emryâs optimizer microwave. A microwave tube was charged with PS-DCC resin (253 mg, 3 equiv), 4-(pyridin-4-yl)benzoic acid (20 mg, 0.1 mmol), and DMA (1 mL). (<i>S</i>)-2-Amino-3-phenylpropan-1-ol (17 mg, 0.11 mmol) in DMA (0.5 mL) was added followed by HOBt (14 mg, 0.11 mmol) in DMA (0.3 mL). DIEA (40 uL, 0.2 mmol) was added and the reaction heated in the microwave for 600 s at 100 Â°C. The reaction was filtered through Si-carbonate (6 mLâ1 g) and concentrated to dryness. The residue was dissolved in methanol and subjected to purification by SFC to afford the title compound (7 mg, 21%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 0.94 min. MS <i>m</i>/<i>z</i>: 333.3 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.65 (2 H, d, <i>J</i> = <i>J</i> = 6.1), 8.25 (1 H, d, <i>J</i> = 8.4), 7.95â7.83 (4 H, m), 7.74 (2 H, d, <i>J</i> = 6.2), 7.29â7.19 (4 H, m), 7.13 (1 H, ddd, <i>J</i> = 8.4, 5.5, 2.4), 4.81 (1 H, s), 4.17 (1 H, tq, <i>J</i> = 10.9, 5.5), 3.56â3.39 (2 H, m), 2.95 (1 H, dd, <i>J</i> = 13.7, 5.2), 2.80 (1 H, dd, <i>J</i> = 13.6, 9.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.82, 150.69, 146.57, 139.88, 139.85, 135.67, 129.51, 128.52, 128.51, 127.07, 126.31, 121.77, 63.33, 53.80, 36.94.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-Benzyl-4-(pyridin-4-yl)benzamide (<b>5</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except phenylmethanamine (12 mg, 0.11 mmol) to afford the title compound (9 mg, 31%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.11 min. MS <i>m</i>/<i>z</i>: 289.13 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.13 (1 H, t, <i>J</i> = 6.0), 8.65 (2 H, d, <i>J</i> = 6.0), 8.03 (2 H, d, <i>J</i> = 8.3), 7.90 (2 H, d, <i>J</i> = 8.3), 7.75 (2 H, d, <i>J</i> = 6.0), 7.32 (4 H, d, <i>J</i> = 4.3), 7.22 (1 H, dd, <i>J</i> = 8.5, 4.3), 4.50 (2 H, d, <i>J</i> = 6.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 166.05, 150.77, 146.48, 140.16, 140.03, 135.23, 128.73, 128.55, 127.66, 127.25, 127.19, 121.78, 43.13. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>17</sub>N<sub>2</sub>O 289.12626, found 289.12655.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(3-Methoxybenzyl)-4-(pyridin-4-yl)benzamide (<b>6</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except (3-methoxyphenyl)methanamine (24 mg, 0.11 mmol) to afford the title compound (24 mg, 39%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.13 min. MS <i>m</i>/<i>z</i>: 319.14 (M + H)<sup>+</sup>. <sup>1</sup>H NMR(400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.16 (1 H, t, <i>J</i> = 6.0), 8.83 (2 H, d, <i>J</i> = 6.4), 8.12 (2 H, d, <i>J</i> = 6.5), 8.09â7.99 (4 H, m), 7.23 (1 H, t, <i>J</i> = 8.1), 6.89 (2 H, d, <i>J</i> = 7.5), 6.84â6.77 (1 H, m), 4.47 (2 H, d, <i>J</i> = 6.0), 3.72 (3 H, s). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.87, 159.77, 146.74, 141.55, 138.61, 136.27, 129.82, 128.68, 127.95, 123.25, 119.84, 113.45, 112.56, 55.44, 43.11. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub> 319.13683, found 319.1372.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(3-Ethoxybenzyl)-4-(pyridin-4-yl)benzamide (<b>7</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except (3-ethoxyphenyl)methanamine (17 mg, 0.11 mmol) to afford the title compound (27 mg, 55%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method a): <i>R</i><sub>t</sub> = 0.62 min. MS <i>m</i>/<i>z</i>: 333.3 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.14 (t, <i>J</i> = 5.90 Hz, 1H), 8.81 (d, <i>J</i> = 6.39 Hz, 2H), 8.11â7.98 (m, 6H), 7.22 (t, <i>J</i> = 7.88 Hz, 1H), 6.91â6.84 (m, 2H), 6.79 (dd, <i>J</i> = 1.98, 7.46 Hz, 1H), 4.47 (d, <i>J</i> = 5.97 Hz, 2H), 3.99 (t, <i>J</i> = 6.92 Hz, 2H), 1.35â1.25 (m, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.87, 159.02, 158.39, 150.40, 147.24, 141.53, 138.80, 136.13, 129.80, 128.66, 127.87, 123.07, 119.72, 113.94, 113.02, 109.99, 63.32, 43.10, 15.10. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> 332.15248, found 332.15293.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(3-Propoxybenzyl)-4-(pyridin-4-yl)benzamide (<b>8</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except (3-propoxyphenyl)methanamine (28 mg, 0.11 mmol) to afford the title compound (29 mg, 44%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.43 min. MS <i>m</i>/<i>z</i>: 347.17 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.14 (1 H, t, <i>J</i> = 6.0), 8.84â8.78 (2 H, m), 8.11â7.98 (6 H, m), 7.21 (1 H, t, <i>J</i> = 8.1), 6.91â6.84 (2 H, m), 6.79 (1 H, dd, <i>J</i> = 7.9, 2.1), 4.47 (2 H, d, <i>J</i> = 6.0), 3.89 (2 H, t, <i>J</i> = 6.5), 1.70 (2 H, p, <i>J</i> = 7.0), 0.94 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.87, 159.19, 150.41, 147.23, 141.52, 138.80, 136.14, 129.80, 128.66, 127.87, 123.07, 119.73, 114.00, 113.05, 69.27, 43.11, 22.48, 10.85. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub> 347.16813, found 347.16862.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(3-Hydroxybenzyl)-4-(pyridin-4-yl)benzamide (<b>9</b>)</h3><div class="NLM_p last">In a 4 mL vial, a solution of 4-(pyridin-4-yl)benzoic acid (28 mg, 0.14 mmol) dissolved in DMA (1 mL) was added, followed by a solution of HATU (65 mg, 0.17 mmol) dissolved in DMA (0.6 mL), followed by triethylamine (60 uL). Then a solution of 3-(aminomethyl)phenol (21 mg, 0.17 mmol) was added dissolved in DMA (0.5 Î¼L) and the reaction shaken at 60 Â°C overnight. The reaction was dried down and dissolved in MeOH:DMSO and purified by reverse phase HPLC to afford the title compound (19 mg, 31%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 0.87 min. MS <i>m</i>/<i>z</i>: 305.12 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.28 (1 H, s), 9.12 (1 H, t, <i>J</i> = 5.9), 8.80 (2 H, d, <i>J</i> = 6.4), 8.10â8.04 (4 H, m), 8.01 (2 H, d, <i>J</i> = 8.4), 7.10 (1 H, t, <i>J</i> = 8.0), 6.76â6.70 (2 H, m), 6.65â6.58 (1 H, m), 4.42 (2 H, d, <i>J</i> = 6.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.80, 157.84, 150.31, 147.32, 141.36, 138.80, 136.16, 129.68, 128.65, 127.84, 123.04, 118.21, 114.44, 114.16, 43.04. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub> 305.12118, found 305.12162.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-(Pyridin-4-yl)-<i>N</i>-(3-(trifluoromethoxy)benzyl)benzamide (<b>10</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except (3-(trifluoromethoxy)phenyl)methanamine (33 mg, 0.11 mmol) to afford the title compound (32 mg, 46%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.46 min. MS <i>m</i>/<i>z</i>: 373.11 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.25 (1 H, t, <i>J</i> = 5.9), 8.82 (2 H, d, <i>J</i> = 6.3), 8.13â7.99 (6 H, m), 7.47 (1 H, t, <i>J</i> = 7.9), 7.36 (1 H, d, <i>J</i> = 7.7), 7.30 (1 H, s), 7.23 (1 H, d, <i>J</i> = 8.0), 4.55 (2 H, d, <i>J</i> = 5.9). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 166.06, 150.61, 148.91, 147.04, 142.92, 138.85, 135.97, 130.73, 128.67, 127.96, 126.72, 123.16, 121.80, 119.98, 119.69, 42.67. <sup>19</sup>F NMR (376 MHz, DMSO) Î´ â56.65. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>16</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 373.10856, found 373.10911.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(2,3-Dimethoxybenzyl)-4-(pyridin-4-yl)benzamide (<b>11</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except (2,3-dimethoxyphenyl)methanamine (19 mg, 0.11 mmol) to afford the title compound (23 mg, 53%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.12 min. MS <i>m</i>/<i>z</i>: 349.15 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.03 (1 H, t, <i>J</i> = 5.8), 8.83 (2 H, d, <i>J</i> = 6.5), 8.15â7.98 (6 H, m), 7.01 (2 H, t, <i>J</i> = 7.9), 6.94 (1 H, d, <i>J</i> = 6.9), 6.86 (1 H, d, <i>J</i> = 7.6), 4.51 (2 H, d, <i>J</i> = 5.8), 3.79 (3 H, s), 3.77 (3 H, s). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.88, 152.74, 150.86, 146.83, 146.70, 138.60, 136.30, 133.04, 128.68, 127.91, 124.22, 123.21, 120.35, 112.13, 60.49, 56.16, 38.00. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> 349.14739, found 349.14792.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-((2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)methyl)-4-(pyridin-4-yl)benzamide (<b>12</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except (2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)methanamine hydrochloride (24 mg, 0.12 mmol) to afford the title compound (23 mg, 51%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.15 min. MS <i>m</i>/<i>z</i>: 347.13 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.98 (1 H, t, <i>J</i> = 5.8), 8.81 (2 H, d, <i>J</i> = 6.5), 8.12â7.98 (6 H, m), 6.80â6.71 (3 H, m), 4.45 (2 H, d, <i>J</i> = 5.8), 4.30 (2 H, dd, <i>J</i> = 5.6, 2.4), 4.24 (2 H, dd, <i>J</i> = 5.0, 2.6). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 166.00, 150.52, 147.14, 143.56, 141.39, 138.74, 136.19, 128.70, 127.86, 127.74, 123.11, 120.74, 119.96, 116.06, 64.68, 64.31, 37.67. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> 347.13174, found 347.1322.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-((3,4-Dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]dioxepin-6-yl)methyl)-4-(pyridin-4-yl)benzamide (<b>13</b>)</h3><div class="NLM_p last">A 4 mL vial was charged with a solution of 4-(pyridin-4-yl)benzoic acid in DMA (20 mg, 0.1 mmol), a solution of HATU in DMA (46 mg, 0.12 mmol), triethylamine (42 Î¼L, 0.3 mmol), and 402 Î¼L of a 0.6 mmol preweighed solution in DMA (1 mL) of (3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]dioxepin-6-yl)methanamine (22 mg, 0.12 mmol). The vial was capped and stirred at 60 Â°C overnight. Upon completion the crude mixture was dried under vacuum and dissolved in DMSO/MeOH and purified by reverse phase HPLC purification to afford the title compound (22 mg, 47%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.15 min. MS <i>m</i>/<i>z</i>: 361.15 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.99 (1 H, t, <i>J</i> = 5.7), 8.82 (2 H, d, <i>J</i> = 6.4), 8.11â7.98 (6 H, m), 6.96â6.83 (3 H, m), 4.49 (2 H, s), 4.12 (4 H, dt, <i>J</i> = 20.4, 5.4), 2.10 (2 H, p, <i>J</i> = 5.5). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.84, 151.88, 150.67, 149.63, 147.01, 138.66, 136.27, 132.23, 128.68, 127.87, 123.15, 122.82, 120.67, 70.96, 70.93, 38.54, 32.16. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> 361.14739, found 361.14777.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(3-(3-(Dimethylamino)propoxy)benzyl)-4-(pyridin-4-yl)benzamide (<b>14</b>)</h3><div class="NLM_p last">As per compound <b>9</b> except 3-(3-(aminomethyl)phenoxy)-<i>N</i>,<i>N</i>-dimethylpropan-1-amine (36 mg, 0.11 mmol) to afford the title compound (23 mg, 27%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 0.74 min. MS <i>m</i>/<i>z</i>: 390.21 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.17 (1 H, t, <i>J</i> = 5.8), 8.78 (2 H, d, <i>J</i> = 6.2), 8.09â7.95 (6 H, m), 7.25 (1 H, t, <i>J</i> = 7.9), 6.95â6.86 (2 H, m), 6.82 (1 H, d, <i>J</i> = 8.2), 4.47 (2 H, d, <i>J</i> = 5.9), 4.01 (2 H, t, <i>J</i> = 5.9), 3.28â3.13 (2 H, m), 2.79 (7 H, d, <i>J</i> = 3.2), 2.07 (2 H, dq, <i>J</i> = 12.0, 5.9). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.90, 158.74, 149.39, 148.11, 141.70, 139.19, 135.84, 129.87, 128.63, 127.73, 122.75, 120.18, 114.05, 113.00, 65.05, 54.77, 43.07, 42.78, 24.44. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> 390.21033, found 390.21085.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(3-(2-Morpholinoethoxy)benzyl)-4-(pyridin-4-yl)benzamide (<b>15</b>)</h3><div class="NLM_p last">As per compound <b>13</b> except (3-(2-morpholinoethoxy)phenyl)methanamine (41 mg, 0.11 mmol) to afford the title compound (41 mg, 54%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 0.72 min. MS <i>m</i>/<i>z</i>: 418.21 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.18 (1 H, t, <i>J</i> = 5.9), 8.77 (2 H, d, <i>J</i> = 6.4), 8.09â7.95 (6 H, m), 7.28 (1 H, t, <i>J</i> = 7.9), 7.00â6.93 (2 H, m), 6.92â6.85 (1 H, m), 4.48 (2 H, d, <i>J</i> = 5.9), 4.36â4.24 (2 H, m), 4.06â3.62 (4 H, m), 3.59â3.52 (2 H, m), 3.52â3.09 (4 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.92, 158.06, 148.30, 141.85, 139.29, 135.76, 129.95, 128.62, 127.71, 122.69, 120.72, 114.29, 113.20, 63.68, 62.27, 55.63, 52.16, 43.04. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> 418.20524, found 418.20583.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>R</i>)-<i>N</i>-(1-(3-Methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>16</b>)</h3><div class="NLM_p last">A mixture of 4-(pyridin-4-yl)benzoic acid (0.969 g, 4.87 mmol), (<i>R</i>)-1-(3-methoxyphenyl)ethanamine (0.883 g, 5.84 mmol), <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (1.7 mL, 9.8 mmol), and <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethyluronium tetrafluoroborate (1.87 g, 5.83 mmol) in DMF (10 mL) was stirred overnight at RT, diluted with EtOAc, washed with 1 M NaOH, satd NaHCO<sub>3</sub>, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and purified on silica gel (50â85% EtOAc/DCM as eluent). The residue was triturated with ether to afford the title compound (1.32 g, 82%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.22 min. MS <i>m</i>/<i>z</i>: 333.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.85 (1 H, d, <i>J</i> = 8.1, 9), 8.69â8.62 (2 H, m), 8.01 (2 H, d, <i>J</i> = 8.3), 7.90 (2 H, d, <i>J</i> = 8.3), 7.78â7.72 (2 H, m), 7.23 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.0, 2.2), 5.15 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 1.47 (3 H, d, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.38, 159.74, 150.77, 146.98, 146.51, 140.08, 135.46, 129.73, 128.67, 127.14, 121.78, 118.77, 112.46, 112.25, 55.44, 48.99, 22.73.. Elemental analysis: Calculated, C = 75.88% H = 6.06% N = 8.43%. Found, C = 75.67% H = 5.85% N = 8.38%. [Î±]<sub>D</sub><sup>20</sup> = â20.7 (<i>c</i> 1.0, MeOH). HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> 333.15248, found 333.15295.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-<i>N</i>-(1-(3-Methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>17</b>)</h3><div class="NLM_p last">A mixture of 4-(pyridin-4-yl)benzoic acid (0.970 g, 4.87 mmol), (<i>S</i>)-1-(3-methoxyphenyl)ethanamine (0.884 g, 5.84 mmol), <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (1.7 mL, 9.80 mmol), and <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethyluronium tetrafluoroborate (1.87 g, 5.82 mmol) in DMF (10 mL) was stirred at RT overnight, diluted with EtOAc, washed with 1 M NaOH, satd NaHCO<sub>3</sub>, and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and purified on silica gel (20â85% EtOAc/DCM as eluent). The residue was triturated ether to afford the title compound (1.07 g, 66%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.99 min. MS <i>m</i>/<i>z</i>: 333.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.85 (1 H, d, <i>J</i> = 8.1), 8.69â8.62 (2 H, m), 8.01 (2 H, d, <i>J</i> = 8.3), 7.90 (2 H, d, <i>J</i> = 8.3), 7.78â7.72 (2 H, m), 7.23 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.1, 2.2), 5.14 (1 H, q, <i>J</i> = 7.3), 3.73 (3 H, s), 3.28 (2 H, s), 1.47 (3 H, d, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.38, 159.74, 150.77, 146.98, 146.51, 140.08, 135.46, 129.73, 128.67, 127.14, 121.78, 118.77, 112.46, 112.25, 55.44, 48.99, 22.73. Elemental analysis: Calculated, C = 75.88% H = 6.06% N = 8.43%. Found, C = 75.89% H = 5.97% N = 8.46. [Î±]<sub>D</sub><sup>20</sup> = +22.4 (<i>c</i> 1.0, MeOH). HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> 333.15248, found 333.15288.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-(2-Aminopyridin-4-yl)benzoic Acid</h3><div class="NLM_p last">4-Bromopyridin-2-amine (1.0 g, 5.78 mmol), 4-boronobenzoic acid (0.959 g, 5.78 mmol), and cesium carbonate (4.71 g, 14.45 mmol) were loaded into a 200 mL round-bottom flask. DME (40 mL) and water (10 mL) were added to the mixture, and nitrogen was bubbled through the mixture for 10 min. Tetrakis(triphenylphosphine)palladium(0) (0.334 g, 0.29 mmol) was added and the reaction heated to 80 Â°C under nitrogen. The DME was removed in vacuo and the aqueous residue diluted with water (80 mL) and washed with DCM (25 mL). The aqueous solution was filtered and the aqueous filtrate acidified with acetic acid to a pH 4.5 to afford a precipitate. The resulting solid was collected and washed with water, then dried to constant weight to afford the title compound (720 mg, 57%) as a gray solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 0.51 min. MS <i>m</i>/<i>z</i>: 214.97 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ ppm 8.24 (s, 1H), 8.11 (d, <i>J</i> = 8.25 Hz, 2H), 8.07 (d, <i>J</i> = 6.75 Hz, 1H), 7.89 (d, <i>J</i> = 8.25 Hz, 2H), 7.27 (s, 1H), 7.25 (d, <i>J</i> = 6.77 Hz, 1H).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>R</i>)-4-(2-Aminopyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>18</b>)</h3><div class="NLM_p last">Under an atmosphere of nitrogen, at RT, a gray suspension of 4-(2-aminopyridin-4-yl)benzoic acid (100 mg, 0.47 mmol) and 1-hydroxybenzotriazole hydrate (72 mg, 0.47 mmol) in anhydrous DMF (15 mL) was stirred for 15 min before the addition of <i>N</i>-methylmorpholine (0.114 mL, 1.03 mmol) and (<i>R</i>)-(+)-1-(3-methoxyphenyl)ethylamine (78 mg, 0.52 mmol) followed by <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>â²-ethylcarbodiimide hydrochloride (99 mg, 0.52 mmol). The reaction mixture was stirred at RT for 14 day. Over that period, the gray suspension decreased and a yellow solution formed. The reaction mixture was poured into water (150 mL). The product was extracted with EtOAc (3 Ã 50 mL), and the combined extracts, washed with 1 M HCl (2 Ã 30 mL) [do not discard see below ], 0.5 M NaOH (2 Ã 60 mL), and water (3 Ã 60 mL), dried (MgSO<sub>4</sub>), filtered, and solvent removed to afford a pale-yellow gum 55 mg (A). The acid aqueous extracts were combined, washed with EtOAc (2 Ã 20 mL) before being basified with 5 M NaOH (20 mL). The product was partitioned between the basic aqueous phase and the EtOAc (3 Ã 20 mL). The combined extracts were washed with water (3 Ã 25 mL), dried (MgSO<sub>4</sub>), filtered, and solvent removed in vacuo to afford a pale-yellow powdery solid 65 mg (B). The crude isolated material (A and B) was combined and purified by mass triggered purification to afford the title compound (49 mg, 30%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.7 min. MS <i>m</i>/<i>z</i>: 348.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.1, 14), 8.00â7.93 (3 H, m), 7.71 (2 H, d, <i>J</i> = 8.2), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.84â6.70 (3 H, m), 5.97 (2 H, s), 5.14 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 1.46 (3 H, d, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.50, 160.91, 159.74, 149.04, 147.69, 147.01, 141.41, 135.00, 129.72, 128.53, 126.70, 118.77, 112.47, 112.23, 110.48, 105.59, 55.44, 48.95, 22.73. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub> 348.16338, found 348.16311.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-(2-Fluoropyridin-4-yl)benzoic Acid</h3><div class="NLM_p last">A mixture of 4-bromobenzoic acid (0.5 g, 2.49 mmol), 2-fluoropyridine-4-boronic acid (0.386 g, 2.74 mmol), and cesium carbonate (2.84 g, 8.71 mmol) in DME (20 mL) and water (10 mL) was purged under vacuum and charged with nitrogen (4Ã). To the mixture was added tetrakis(triphenylphosphine)palladium(0) (0.144 g, 0.12 mmol). The reaction mixture was heated at 80 Â°C for 24 h under nitrogen. The DME was removed in vacuo, the aqueous residue diluted with water (80 mL), and the basic aqueous was washed with DCM (3 Ã 40 mL). The basic aqueous layer was filtered through a Celite pad and washed with water (2 Ã 20 mL) and DCM (2 Ã 30 mL). The filtrate was acidified to pH 4 with 1 M HCl (20 mL) and the product suspension extracted with DCM (4 Ã 100 mL). The solid was collected and dried to afford the title compound (193 mg, 36%) as a gray powdery solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.26 min. MS <i>m</i>/<i>z</i>: 218.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>R</i>)-4-(2-Fluoropyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>19</b>)</h3><div class="NLM_p last">In a 25 mL round-bottomed flask, 4-(2-fluoropyridin-4-yl)benzoic acid (100 mg, 0.46 mmol), 1-hydroxybenzotriazole hydrate (85 mg, 0.55 mmol), and <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>â²-ethylcarbodiimide hydrochloride (106 mg, 0.55 mmol) in DMF (2 mL) were added to give a green solution. The resulting solution was stirred at 20 Â°C for 30 min. <i>N</i>-Methylmorpholine (0.15 mL, 1.38 mmol) and (<i>R</i>)-1-(3-methoxyphenyl)ethanamine (70 mg, 0.46 mmol) were each added sequentially in one portion to the solution. The resulting solution was stirred at 20 Â°C overnight. The DMF was removed and the sample purified by prep LC. The fractions containing product were dried and dissolved in DCM/MeOH and concentrated/chased with ether/heptane. The residue was dried at 65 Â°C in a vacuum oven overnight to afford the title compound (67 mg, 42%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.28 min. MS <i>m</i>/<i>z</i>: 351.12 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.88 (1 H, d, <i>J</i> = 8.2), 8.32 (1 H, d, <i>J</i> = 5.3), 8.02 (2 H, d, <i>J</i> = 8.3), 7.95 (2 H, d, <i>J</i> = 8.3), 7.75 (1 H, d, <i>J</i> = 5.2), 7.59 (1 H, s), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, d, <i>J</i> = 7.8), 5.16 (1 H, q, <i>J</i> = 7.3), 3.73 (3 H, s), 1.47 (3 H, d, <i>J</i> = 7.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.70, 165.25, 163.36, 152.65 (d, <i>J</i> = 8.4), 148.69 (d, <i>J</i> = 15.8), 146.94, 138.79 (d, <i>J</i> = 3.5), 136.01, 129.74, 128.66, 127.47, 120.22 (d, <i>J</i> = 3.8), 118.76, 112.46, 112.26, 107.31 (d, <i>J</i> = 38.8), 55.44, 49.01, 22.71. <sup>19</sup>F NMR (376 MHz, DMSO) Î´ â68.57. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> 351.14306, found 351.14289.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Ethyl 4-(2-Chloropyridin-4-yl)benzoate</h3><div class="NLM_p last">A mixture of 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.26 g, 5.24 mmol), tetrakis(triphenylphosphine)palladium(0) (0.303 g, 0.26 mmol), ethyl 4-(2-chloropyridin-4-yl)benzoate (0.887 g, 3.39 mmol), cesium carbonate (4.27 g, 13.10 mmol), DME (12 mL), and water (6 mL) was heated at 80 Â°C overnight under nitrogen. The layers were separated and the organic layer concentrated. The residue was purified on silica gel (0â25% EtOAc/heptane as eluent) to afford the title compound (0.887 g, 78%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.54 min. MS <i>m</i>/<i>z</i>: 262.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-(2-Chloropyridin-4-yl)benzoic Acid</h3><div class="NLM_p last">A mixture of ethyl 4-(2-chloropyridin-4-yl)benzoate (0.887 g, 3.39 mmol) and lithium hydroxide hydrate (0.711 g, 16.95 mmol) in THF (24 mL) and water (8.0 mL) was stirred at RT overnight. After removal of the organic solvent, the residue was diluted with water (30 mL) and adjusted to pH 5 with acetic acid. The precipitate was collected by filtration, washed with water, and dried in a vacuum oven to afford the title compound (780 mg, 98%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.29 min. MS <i>m</i>/<i>z</i>: 234.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-(2-Chloropyridin-4-yl)benzoyl Chloride</h3><div class="NLM_p last">To a suspension of 4-(2-chloropyridin-4-yl)benzoic acid (730 mg, 3.12 mmol) in DCM (70 mL) was added oxalyl chloride (2.14 mL, 4.28 mmol) followed by a drop of DMF. The mixture was stirred at RT overnight. The solvent was removed to give a light-yellow solid that was used immediately in the next step.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>R</i>)-4-(2-Chloropyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>20</b>)</h3><div class="NLM_p last">To a mixture of 4-(2-chloropyridin-4-yl)benzoyl chloride (788 mg, 3.13 mmol) in DCM (30 mL) was added (<i>R</i>)-1-(3-methoxyphenyl)ethanamine (520 mg, 3.44 mmol) followed by DIEA (1.64 mL, 9.38 mmol). The mixture was stirred at RT overnight. The reaction mixture was washed with 1 M HCl (50 mL), 0.5 M NaOH (30 mL), and saturated brine (30 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford a residue that was purified on silica gel (25â50% EtOAc/heptane as eluent). Fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (1.1 g, 96%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.34 min. MS <i>m</i>/<i>z</i>: 367.18 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.1), 8.03 (1 H, d, <i>J</i> = 5.3), 7.97 (2 H, d, <i>J</i> = 8.3), 7.72 (2 H, d, <i>J</i> = 8.3), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.92 (2 H, m), 6.82â6.74 (2 H, m), 6.70 (1 H, s), 6.51 (1 H, t, <i>J</i> = 5.5), 5.14 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 3.28 (2 H, d, <i>J</i> = 3.6), 1.46 (3 H, d, <i>J</i> = 7.1), 1.13 (3 H, t, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.51, 159.97, 159.74, 148.89, 147.30, 147.01, 141.52, 134.97, 129.72, 128.51, 126.73, 118.77, 112.46, 112.23, 109.98, 105.56, 55.43, 48.95, 35.96, 22.74, 15.24. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>2</sub> 367.11351, found 367.11444.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>R</i>)-<i>N</i>-(1-(3-Methoxyphenyl)ethyl)-4-(2-methylpyridin-4-yl)benzamide (<b>21</b>)</h3><div class="NLM_p last">To a degassed suspension of (<i>R</i>)-4-bromo-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (210 mg, 0.63 mmol), 2-methylpyridin-4-ylboronic acid (110 mg, 0.80 mmol), and cesium carbonate (620 mg, 1.90 mmol) in a dioxane/water (10 mL, 1:1) was added bis(triphenylphosphine)palladium(II) dichloride (45 mg, 0.06 mmol) and the mixture heated at 100 Â°C overnight. The mixture was partitioned between EtOAc (20 mL) and water (20 mL) and the layers separated. The organic later was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated to dryness, and then partitioned between 1 M HCl (20 mL) and EtOAc (20 mL). The aqueous phase was neutralized with saturated Na<sub>2</sub>CO<sub>3</sub> (20 mL), extracted with EtOAc (2 Ã 20 mL). The combined organic layers were concentrated and purified on silica gel (0â100% EtOAc/heptane as eluent). The fractions containing the desired product were combined, concentrated, and dried in a vacuum oven at 55â60 Â°C overnight. Water (10 mL) and MeCN (3 mL) were added and the mixture lyophilized to afford the title compound (40 mg, 18%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.2 min. MS <i>m</i>/<i>z</i>: 347.17 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.84 (1 H, d, <i>J</i> = 8.1), 8.51 (1 H, d, <i>J</i> = 5.2), 8.00 (2 H, d, <i>J</i> = 8.3), 7.87 (2 H, d, <i>J</i> = 8.3), 7.62 (1 H, s), 7.53 (1 H, d, <i>J</i> = 5.1), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.2, 2.4), 5.15 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 2.53 (3 H, s), 1.47 (3 H, d, <i>J</i> = 7.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.40, 159.74, 159.15, 150.05, 146.99, 146.76, 140.36, 135.31, 129.73, 128.61, 127.09, 121.00, 118.96, 118.77, 112.47, 112.25, 55.44, 48.97, 24.58, 22.72. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub> 347.16813, found 347.16851.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>R</i>)-4-(2,6-Dimethylpyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>22</b>)</h3><div class="NLM_p last">As per compound <b>21</b> except 2,6-dimethylpyridin-4-ylboronic acid (172 mg, 1.14 mmol). The title compound (50 mg, 16%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.05 min. MS <i>m</i>/<i>z</i>: 361.19 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.84 (1 H, d, <i>J</i> = 8.1), 7.99 (2 H, d, <i>J</i> = 8.3), 7.84 (2 H, d, <i>J</i> = 8.4), 7.40 (2 H, s), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.2, 2.4), 5.15 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 2.48 (6 H, s), 1.47 (3 H, d, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.41, 159.74, 158.38, 147.16, 146.99, 140.64, 135.17, 131.87, 129.73, 129.12, 128.55, 127.04, 118.78, 118.14, 112.48, 112.24, 55.43, 48.96, 24.51, 22.71. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub> 361.18378, found 361.18431.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>R</i>)-4-(3-Fluoropyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>23</b>)</h3><div class="NLM_p last">As per compound <b>21</b> except 3-fluoropyridin-4-ylboronic acid hydrate (114 mg, 0.72 mmol). The title compound (77 mg 37%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.20 min. MS <i>m</i>/<i>z</i>: 351.18 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.88 (1 H, d, <i>J</i> = 8.1), 8.67 (1 H, d, <i>J</i> = 2.5), 8.52 (1 H, d, <i>J</i> = 4.9), 8.02 (2 H, d, <i>J</i> = 8.3), 7.76 (2 H, d, <i>J</i> = 7.1), 7.66 (1 H, dd, <i>J</i> = 6.9, 5.0), 7.23 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.0, 2.1), 5.15 (1 H, p, <i>J</i> = 7.0), 3.73 (3 H, s), 1.47 (3 H, d, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.38, 159.75, 156.49 (d, <i>J</i> = 256.2), 146.94, 146.86 (d, <i>J</i> = 5.2), 139.21 (d, <i>J</i> = 25.2), 135.67, 135.32, 134.76 (d, <i>J</i> = 10.3), 129.74, 129.17 (d, <i>J</i> = 3.3), 128.35, 124.90, 118.75, 112.44, 112.27, 55.44, 49.02, 22.74. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ â133.28 (d, <i>J</i> = 6.7, 26). HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> 351.14306, found 351.14329.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-(Pyrimidin-4-yl)benzoic Acid</h3><div class="NLM_p last">A mixture of 4-carboxyphenylboronic acid (0.604 g, 3.64 mmol), 4-chloropyrimidine hydrochloride (0.500 g, 3.31 mmol), DME (20 mL), and water (10 mL) was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (0.859 mL, 4.97 mmol) and stirred for 5 min before the addition of cesium carbonate (0.927 mL, 11.59 mmol). Nitrogen was bubbled through the reaction mixture for 10 min before the addition of tetrakis(triphenylphosphine)palladium(0) (0.191 g, 0.17 mmol). The reaction was heated at 80 Â°C under nitrogen for 72 h. The DME was removed in vacuo and the aqueous residue diluted with water (80 mL). The basic aqueous layer was washed with DCM (3 Ã 40 mL) before being filtered through Celite. The Celite was washed with water (2 Ã 20 mL) and DCM (2 Ã 30 mL). The filtrate was acidified to pH 4 with 1 M HCl (20 mL). The resultant suspension was collected, washed with DCM (4 Ã 100 mL), and dried to afford the title compound (0.565 g, 85%) as a gray powdery solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.09 min. MS <i>m</i>/<i>z</i>: 201.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 13.29â13.04 (m, 1H), 9.34â9.29 (d, <i>J</i> = 1.18, 1H), 8.96â8.91 (m, <i>J</i> = 5.36, 1H), 8.37â8.30 (m, 2H), 8.20â8.17 (dd, <i>J</i> = 1.30, 5.37, 1H), 8.13â8.08 (m, 2H).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>R</i>)-<i>N</i>-(1-(3-Methoxyphenyl)ethyl)-4-(pyrimidin-4-yl)benzamide (<b>24</b>)</h3><div class="NLM_p last">Under an atmosphere of nitrogen, at RT, a solution of 4-(pyrimidin-4-yl)benzoic acid (100 mg, 0.50 mmol) and 1-hydroxybenzotriazole hydrate (77 mg, 0.50 mmol), <i>N</i>-methylmorpholine (0.122 mL, 1.10 mmol), and (<i>R</i>)-(+)-1-(3-methoxyphenyl)ethylamine (84 mg, 0.55 mmol) in anhydrous DMF (15 mL) was stirred for 15 min before the addition of <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>â²-ethylcarbodiimide hydrochloride (106 mg, 0.55 mmol). The solution was stirred at RT for 18 h and then poured into water (150 mL) and extracted with EtOAc (3 Ã 50 mL). The combined organic extracts were washed with 0.5 M NaOH (2 Ã 60 mL) and water (3 Ã 60 mL), dried (MgSO<sub>4</sub>), filtered, and solvent removed to afford a residue dried to constant weight in the vacuo at 60 Â°C for 24 h. This afforded the title compound (142 mg, 81%) as a pale-yellow solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.96 min. MS <i>m</i>/<i>z</i>: 334.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.27 (1 H, s), 8.93â8.86 (2 H, m), 8.29 (2 H, d, <i>J</i> = 8.3), 8.15 (1 H, d, <i>J</i> = 5.4), 8.04 (2 H, d, <i>J</i> = 8.2), 7.23 (1 H, t, <i>J</i> = 8.1), 7.00â6.94 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.2, 2.4), 5.15 (1 H, p, <i>J</i> = 7.1), 3.75â3.70 (3 H, m), 1.47 (3 H, d, <i>J</i> = 7.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.32, 162.18, 159.74, 159.27, 158.73, 146.91, 138.76, 137.18, 129.75, 128.52, 127.32, 118.78, 118.03, 115.13, 112.48, 112.28, 55.44, 49.03, 22.70. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> 334.14773, found 334.14766.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>R</i>)-<i>N</i>-(1-(3-Methoxyphenyl)ethyl)-4-(pyridazin-4-yl)benzamide (<b>25</b>)</h3><div class="NLM_p last">As per compound <b>24</b> except 4-(pyridazin-4-yl)benzoic acid (95 mg, 0.48 mmol). The title compound (32 mg 25%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.25 min. MS <i>m</i>/<i>z</i>: 334.20 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.68 (1 H, d, <i>J</i> = 1.3), 9.30 (1 H, d, <i>J</i> = 5.4), 8.89 (1 H, d, <i>J</i> = 8.1), 8.09â7.99 (5 H, m), 7.23 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.2, 2.4), 5.15 (1 H, p, <i>J</i> = 7.2), 3.73 (3 H, s), 1.47 (3 H, d, <i>J</i> = 7.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.22, 159.75, 152.15, 149.83, 146.93, 136.92, 136.74, 136.17, 129.75, 128.78, 127.58, 123.88, 118.76, 112.45, 112.28, 55.44, 49.03, 22.72. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> 334.14773, found 334.14817.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>R</i>)-4-(2-(Ethylamino)pyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>26</b>)</h3><div class="NLM_p last">A suspension of sodium 2-methylpropan-2-olate (17 mg, 0.18 mmol), (<i>R</i>)-4-(2-chloropyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (55 mg, 0.15 mmol) and ethanamine (2.0 M in THF, 0.112 mL, 0.22 mmol) in dioxane (1 mL) was degassed by bubbling nitrogen through it for 3 min. A suspension of Pd<sub>2</sub>(dba)<sub>3</sub> (14 mg, 0.02 mmol) and <sup>t</sup>BuXPhos (28 mg, 0.07 mmol) in dioxane (0.6 mL) was degassed by bubbling nitrogen through for 3 min, heated to 80 Â°C for 1 min, cooled down to RT for 10 min, then added to the reaction mixture. The resulting mixture was stirred at 80 Â°C overnight and then evaporated to dryness. The crude material was purified on silica gel (15â95% MeCN/Water as eluent) to afford the title compound (39 mg, 69%) as a white fluffy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.81 min. MS <i>m</i>/<i>z</i>: 376.24 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.1), 8.03 (1 H, d, <i>J</i> = 5.3), 7.97 (2 H, d, <i>J</i> = 8.3), 7.72 (2 H, d, <i>J</i> = 8.3), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.92 (2 H, m), 6.82â6.74 (2 H, m), 6.70 (1 H, s), 6.51 (1 H, t, <i>J</i> = 5.5), 5.14 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 3.28 (2 H, d, <i>J</i> = 3.6), 1.46 (3 H, d, <i>J</i> = 7.1), 1.13 (3 H, t, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.51, 159.97, 159.74, 148.89, 147.30, 147.01, 141.52, 134.97, 129.72, 128.51, 126.73, 118.77, 112.46, 112.23, 109.98, 105.56, 55.43, 48.95, 35.96, 22.74, 15.24. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub> 376.19468, found 376.1952.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>R</i>)-4-(2-(Cyclopropylmethylamino)pyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>27</b>)</h3><div class="NLM_p last">As per compound <b>26</b> except cyclopropylmethanamine (0.02 mL, 0.23 mmol). The title compound was afforded (32 mg, 54%) as a white fluffy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.03 min. MS <i>m</i>/<i>z</i>: 402.23 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.1), 8.02 (1 H, d, <i>J</i> = 5.2), 7.97 (2 H, d, <i>J</i> = 8.3), 7.72 (2 H, d, <i>J</i> = 8.3), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.92 (2 H, m), 6.81â6.74 (3 H, m), 6.62 (1 H, t, <i>J</i> = 5.6), 5.14 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 3.16 (2 H, t, <i>J</i> = 6.1), 1.46 (3 H, d, <i>J</i> = 7.1), 1.11â0.99 (1 H, m), 0.47â0.36 (2 H, m), 0.27â0.16 (2 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.51, 160.03, 159.74, 148.80, 147.27, 147.01, 141.50, 134.98, 129.72, 128.51, 126.72, 118.77, 112.46, 112.23, 109.98, 105.77, 55.43, 48.95, 45.75, 22.74, 11.41, 3.80. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> 402.21033, found 402.21088.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>R</i>)-4-(2-(2-Hydroxy-2-methylpropylamino)pyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>28</b>)</h3><div class="NLM_p last">As per compound <b>26</b> except 1-amino-2-methylpropan-2-ol (20 mg, 0.23 mmol). The title compound was afforded (39 mg, 62%) as a white fluffy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.78 min. MS <i>m</i>/<i>z</i>: 420.24 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.1), 8.03â7.93 (3 H, m), 7.73 (2 H, d, <i>J</i> = 8.3), 7.22 (1 H, t, <i>J</i> = 8.1), 6.99â6.93 (2 H, m), 6.89 (1 H, s), 6.82â6.74 (2 H, m), 6.41 (1 H, t, <i>J</i> = 5.8), 5.14 (1 H, p, <i>J</i> = 7.0), 4.69 (1 H, s), 3.73 (3 H, s), 3.27 (2 H, s), 1.46 (3 H, d, <i>J</i> = 7.1), 1.12 (6 H, s). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.50, 160.48, 159.74, 148.44, 147.32, 147.01, 141.41, 134.99, 129.72, 128.50, 126.72, 118.77, 112.47, 112.24, 110.06, 106.12, 70.22, 55.44, 52.49, 48.95, 28.00, 22.73. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> 420.22089, found 420.22137.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>R</i>)-4-(2-(2-Methoxyethylamino)pyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (<b>29</b>)</h3><div class="NLM_p last">As per compound <b>26</b> except 2-methoxyethanamine (0.02 mL, 0.23 mmol). The title compound was afforded (33 mg, 54%) as a white fluffy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.85 min. MS <i>m</i>/<i>z</i>: 406.22 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.0), 8.06â8.00 (1 H, m), 7.97 (2 H, d, <i>J</i> = 7.6), 7.72 (2 H, d, <i>J</i> = 7.7), 7.22 (1 H, td, <i>J</i> = 8.1, 1.0), 6.96 (2 H, d, <i>J</i> = 5.0), 6.82â6.74 (3 H, m), 6.59 (1 H, s), 5.13 (1 H, q, <i>J</i> = 7.2), 3.73 (3 H, d, <i>J</i> = 1.0), 3.46 (4 H, s), 3.26 (3 H, s), 1.46 (3 H, d, <i>J</i> = 7.0). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.51, 159.87, 159.74, 148.74, 147.33, 147.01, 141.42, 135.00, 129.72, 128.51, 126.73, 118.77, 112.46, 112.24, 110.19, 106.03, 71.39, 58.40, 55.43, 48.95, 40.83, 22.74. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub> 406.20524, found 406.20556.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>R</i>)-<i>N</i>-(1-(3-Methoxyphenyl)ethyl)-4-(2-(3-methoxypropylamino)pyridin-4-yl)benzamide (<b>30</b>)</h3><div class="NLM_p last">As per compound <b>27</b>, 3-methoxypropan-1-amine (0.02 mL, 0.23 mmol). The title compound was afforded (22 mg, 34%) as a white fluffy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.85 min. MS <i>m</i>/<i>z</i>: 420.24 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.81 (1 H, d, <i>J</i> = 8.1), 8.03 (1 H, d, <i>J</i> = 5.3), 7.97 (2 H, d, <i>J</i> = 8.2), 7.72 (2 H, d, <i>J</i> = 8.3), 7.22 (1 H, t, <i>J</i> = 8.0), 6.99â6.93 (2 H, m), 6.83â6.74 (2 H, m), 6.72 (1 H, s), 6.56 (1 H, t, <i>J</i> = 5.6), 5.14 (1 H, p, <i>J</i> = 6.9), 3.73 (3 H, s), 3.39 (2 H, t, <i>J</i> = 6.3), 3.34â3.29 (2 H, m), 3.25â3.20 (3 H, m), 1.76 (2 H, p, <i>J</i> = 6.6), 1.46 (3 H, d, <i>J</i> = 7.1). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.51, 160.05, 159.74, 148.85, 147.31, 147.01, 141.48, 134.98, 129.72, 128.51, 126.73, 118.77, 112.46, 112.23, 110.03, 105.60, 70.33, 58.35, 55.43, 48.95, 38.49, 29.63, 22.73. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub> 420.22089, found 420.22138.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>R</i>)-<i>tert</i>-Butyl 3-Hydroxy-1-phenylpropylcarbamate</h3><div class="NLM_p last">Di-<i>tert</i>-butyl dicarbonate (413 mg, 1.89 mmol) was added to a stirred mixture of (<i>R</i>)-3-amino-3-phenylpropan-1-ol hydrochloride (237 mg, 1.26 mmol), DCM (3 mL), and Et<sub>3</sub>N (0.37 mL, 2.65 mmol) and the mixture stirred at RT overnight. The mixture was concentrated and purified on silica gel (0â50% EtOAc/heptane as eluent). Fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (309 mg, 97%) as an oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.35 min. MS <i>m</i>/<i>z</i>: no ionization.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>R</i>)-3-(<i>tert</i>-Butoxycarbonylamino)-3-phenylpropyl Methanesulfonate</h3><div class="NLM_p last">A solution of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-phenylpropylcarbamate (295 mg, 1.174 mmol) in pyridine (2 mL) was cooled down to 0 Â°C. Methanesulfonyl chloride (0.10 mL, 1.29 mmol) was added dropwise. The mixture was slowly warmed up to RT and stirred overnight then diluted with DCM and washed with water. The organic layer was concentrated to afford the title compound (390 mg, 101%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.46 min. MS <i>m</i>/<i>z</i>: no ionization</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>R</i>)-<i>tert</i>-Butyl 1-Phenyl-3-(pyrrolidin-1-yl)propylcarbamate</h3><div class="NLM_p last">To a mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-phenylpropyl methanesulfonate (380 mg, 1.15 mmol) and K<sub>2</sub>CO<sub>3</sub> (319 mg, 2.31 mmol) in MeCN (3 mL) was added pyrrolidine (0.19 mL, 2.31 mmol) dropwise. The mixture was heated at 50 Â°C for 4 h, filtered, washed with MeCN, and concentrated. The residue was partitioned between DCM and 1 M HCl and the organic layer dried (MgSO<sub>4</sub>) and concentrated to afford the title compound (301 mg, 86%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.24 min. MS <i>m</i>/<i>z</i>: no ionization.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>R</i>)-1-Phenyl-3-(pyrrolidin-1-yl)propan-1-amine Dihydrochloride</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 1-phenyl-3-(pyrrolidin-1-yl)propylcarbamate (301 mg, 0.99 mmol) and 4 M HCl in dioxane (2 mL, 8.0 mmol) was stirred at RT for 1 h then concentrated. Ether was added and the solution decanted. The residue was dissolved in MeOH and concentrated dry to give an oil (276 mg, 101%) that was used in the next step.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (<i>R</i>)-<i>N</i>-(1-Phenyl-3-(pyrrolidin-1-yl)propyl)-4-(pyridin-4-yl)benzamide (<b>36</b>)</h3><div class="NLM_p last">To a vial charged with 4-(pyridin-4-yl)benzoic acid (50 mg, 0.25 mmol), HOBt (42 mg, 0.28 mmol), and EDC (53 mg, 0.28 mmol) was added a solution of (<i>R</i>)-1-phenyl-3-(pyrrolidin-1-yl)propan-1-amine dihydrochloride (76 mg, 0.28 mmol) in DMF (1 mL), followed by DIEA (88 Î¼L, 0.50 mmol). The mixture was stirred at RT for 1 h then purified by HPLC (5â65% MeCN/10 mM ammonium acetate as eluent). Fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (35 mg, 36%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.50 min. MS <i>m</i>/<i>z</i>: 386.19 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.11 (1 H, d, <i>J</i> = 8.0), 8.69â8.62 (2 H, m), 7.98 (2 H, d, <i>J</i> = 8.3), 7.90 (2 H, d, <i>J</i> = 8.3), 7.75 (2 H, dd, <i>J</i> = 4.7, 1.5), 7.38 (2 H, d, <i>J</i> = 7.2), 7.31 (2 H, t, <i>J</i> = 7.6), 7.21 (1 H, t, <i>J</i> = 7.3), 5.11 (1 H, q, <i>J</i> = 7.9), 2.48â2.41 (6 H, m), 1.99 (2 H, dq, <i>J</i> = 14.5, 7.3), 1.74â1.62 (4 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.53, 150.77, 146.49, 144.22, 140.15, 135.45, 128.68, 128.52, 127.20, 127.10, 126.89, 121.79, 54.06, 53.16, 52.50, 35.07, 23.61. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O 386.21541, found 386.21655.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>R</i>)-<i>tert</i>-Butyl 3-Hydroxy-1-(3-methoxyphenyl)propylcarbamate</h3><div class="NLM_p last">To a cold solution (0 Â°C) of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-methoxyphenyl)propanoic acid (0.5 g, 1.69 mmol) in DME (5 mL) was added <i>N</i>-methylmorpholine (0.20 mL, 1.86 mmol) followed by isobutyl carbonochloridate (0.24 mL, 1.86 mmol). The mixture was stirred at 0 Â°C for 30 min, and then the precipitate was filtered off and washed with small amount of DME. The mixture was cooled to 0 Â°C and a suspension of NaBH<sub>4</sub> (0.1 g, 2.54 mmol) in water (1 mL) added. The mixture was stirred at RT for 10 min then water (20 mL) was added. The mixture was extracted with EtOAc (3 Ã 25 mL) and the combined organic layers dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford the title compound as a colorless oil that was used in the next step without further purification. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.34 min. MS <i>m</i>/<i>z</i>: 282.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>R</i>)-3-(<i>tert</i>-Butoxycarbonylamino)-3-(3-methoxyphenyl)propyl Methanesulfonate</h3><div class="NLM_p last">A stirred solution of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-methoxyphenyl)propylcarbamate (0.48 g, 1.69 mmol), DCM (5 mL) and Et<sub>3</sub>N (0.24 mL, 1.69 mmol) was cooled to 0 Â°C. Methanesulfonyl chloride (0.16 mL, 2.03 mmol) was added dropwise and the mixture warmed RT and stirred overnight. The mixture was diluted with DCM (20 mL), washed with water (20 mL), 1 M HCl (20 mL), and brine (20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to dryness to give an colorless oil that was triturated with ether. The resulting solid was collected by filtration, washed with ether, and dried to afford the title compound (421 mg, 69%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.45 min. MS <i>m</i>/<i>z</i>: weak ionization min. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.48 (d, <i>J</i> = 8.6, 1H), 7.24 (t, <i>J</i> = 7.8, 1H), 6.84 (dd, <i>J</i> = 8.0, 24.2, 3H), 4.59 (dd, <i>J</i> = 8.1, 15.7, 1H), 4.23â4.05 (m, 2H), 3.74 (s, 3H), 3.15 (s, 3H), 2.08â1.93 (m, 2H), 1.36 (s, 9H).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (<i>R</i>)-<i>tert</i>-Butyl 1-(3-Methoxyphenyl)-3-(pyrrolidin-1-yl)propylcarbamate</h3><div class="NLM_p last">To a mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-methoxyphenyl)propyl methanesulfonate (250 mg, 0.70 mmol) and K<sub>2</sub>CO<sub>3</sub> (192 mg, 1.39 mmol) in MeCN (3 mL) was added pyrrolidine (0.12 mL, 1.39 mmol) dropwise. The mixture was heated at 50 Â°C for 6 h then filtered, washed with MeCN, and concentrated. The residue was partitioned between DCM and 1 M HCl and the organic layer dried (MgSO<sub>4</sub>), filtered, and concentrated to afford the title compound (243 mg, 104%) as a semisolid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.25 min; MS <i>m</i>/<i>z</i>: 335.20 (M + H)<sup>+</sup>.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>R</i>)-1-(3-Methoxyphenyl)-3-(pyrrolidin-1-yl)propan-1-amine Dihydrochloride</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxyphenyl)-3-(pyrrolidin-1-yl)propylcarbamate (233 mg, 0.70 mmol) and 4 M HCl in dioxane (1.5 mL, 6.00 mmol) was stirred at RT for 1 h (turned from a solution to a milky solution). Ether was added and the solution decanted. The residue was dissolved in MeOH and concentrated dry to afford the title compound as a semisolid that was used in the next step.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>R</i>)-<i>N</i>-(1-(3-Methoxyphenyl)-3-(pyrrolidin-1-yl)propyl)-4-(pyridin-4-yl)benzamide (<b>37</b>)</h3><div class="NLM_p last">To a vial charged with 4-(pyridin-4-yl)benzoic acid (60 mg, 0.301 mmol), HOBt (55 mg, 0.36 mmol), and EDC (69 mg, 0.36 mmol) was added a solution of (<i>R</i>)-1-(3-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-1-amine dihydrochloride (102 mg, 0.331 mmol) in DMF (1 mL), followed by DIEA (116 Î¼L, 0.663 mmol), and the mixture was stirred at RT for 1 h. The mixture was concentrated and purified by HPLC (5â65% MeCN/10 mM ammonium acetate over 40 min; flow rate 21 mL/min). Fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (77 mg, 62%) as a hydroscopic solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.52 min. MS <i>m</i>/<i>z</i>: 416.18 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.08 (1 H, d, <i>J</i> = 8.0), 8.69â8.62 (2 H, m), 7.98 (2 H, d, <i>J</i> = 8.3), 7.90 (2 H, d, <i>J</i> = 8.4), 7.75 (2 H, d, <i>J</i> = 6.1), 7.22 (1 H, t, <i>J</i> = 8.1), 6.98â6.91 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.3, 2.3), 5.08 (1 H, q, <i>J</i> = 8.0), 3.73 (3 H, s), 2.46â2.38 (6 H, m), 1.97 (2 H, ddt, <i>J</i> = 20.1, 13.6, 6.9), 1.68 (4 H, s). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.52, 159.72, 150.77, 146.49, 145.92, 140.14, 135.47, 129.70, 128.50, 127.22, 121.79, 119.19, 112.80, 112.30, 55.43, 54.05, 53.17, 52.50, 35.17, 23.62. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub> 416.22598, found 416.22656. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, a): 95% ee, negative (â) optical rotation.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>R</i>)-3-Amino-3-(3-methoxyphenyl)propan-1-ol Hydrochloride</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-methoxyphenyl)propylcarbamate (476 mg, 1.69 mmol) and 4 M HCl in dioxane (4 mL, 16.00 mmol) was stirred at RT for 30 min. The reaction mixture was concentrated, ether added and a sticky semisolid formed, decanted, and evaporated to dryness. This gave the title compound (368 mg, 100%) as a semisolid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.10 min. MS <i>m</i>/<i>z</i>: 182.12 (M + H)<sup>+</sup>.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>R</i>)-<i>N</i>-(3-Hydroxy-1-(3-methoxyphenyl)propyl)-4-(pyridin-4-yl)benzamide (<b>38</b>)</h3><div class="NLM_p last">To a vial charged with 4-(pyridin-4-yl)benzoic acid (50 mg, 0.25 mmol), HOBt (46 mg, 0.30 mmol) and EDC (58 mg, 0.30 mmol) was added a solution of (<i>R</i>)-3-amino-3-(3-methoxyphenyl)propan-1-ol hydrochloride (66 mg, 0.30 mmol) in DMF (1 mL), followed by DIEA (53 Î¼L, 0.30 mmol). The mixture was stirred at RT for 1 h then purified by HPLC (10â70% MeCN/10 mM ammonium acetate over 40 min; flow rate 21 mL/min). Fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (55 mg, 60%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 0.98 min. MS <i>m</i>/<i>z</i>: 363.16 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.82 (1 H, d, <i>J</i> = 8.2), 8.65 (2 H, d, <i>J</i> = 5.9), 7.99 (2 H, d, <i>J</i> = 8.3), 7.90 (2 H, d, <i>J</i> = 8.3), 7.78â7.71 (2 H, m), 7.22 (1 H, t, <i>J</i> = 8.1), 6.95 (2 H, d, <i>J</i> = 7.5), 6.81â6.74 (1 H, m), 5.19â5.09 (1 H, m), 4.54 (1 H, s), 3.73 (3 H, s), 3.28 (2 H, s), 2.02 (1 H, ddd, <i>J</i> = 14.5, 8.7, 4.6), 1.89 (1 H, dq, <i>J</i> = 13.2, 6.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.63, 159.71, 150.77, 146.51, 146.16, 140.09, 135.53, 129.68, 128.60, 127.17, 121.78, 119.25, 112.87, 112.26, 58.35, 55.42, 50.86, 39.45. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> 363.16304, found 363.16352. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, a): >99% ee, negative (â) optical rotation.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 4-(2-Fluoropyridin-4-yl)benzoate</h3><div class="NLM_p last">A stirred mixture of 2-fluoropyridin-4-ylboronic acid (2.36 g, 16.74 mmol) and methyl 4-bromobenzoate (2.95 g, 12.76 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.967 g, 0.84 mmol), cesium carbonate (13.64 g, 41.9 mmol), DME (50 mL), and water (6 mL) was heated at 80 Â°C overnight under nitrogen. The aqueous layer was removed and the organic layer concentrated and purified on silica gel (0â20% EtOAc/heptane as eluent) to afford the title compound (2.95 g, 91%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.35 min. (no ionization). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.31 (d, <i>J</i> = 5.3 Hz, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 2H), 7.70 (d, <i>J</i> = 8.3 Hz, 2H), 7.43 (d, <i>J</i> = 5.3 Hz, 1H), 7.16 (s, 1H), 3.96 (s, 3H).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 4-(2-Fluoropyridin-4-yl)benzoic Acid Hydrochloride</h3><div class="NLM_p last">To a 100 mL round-bottomed flask charged with methyl 4-(2-fluoropyridin-4-yl)benzoate (1.53 g, 6.62 mmol) and LiOH (0.317 g, 13.23 mmol) was added 1,4-dioxane (20 mL) and water (1 mL) to give a white suspension. The resulting suspension was stirred at 40 Â°C for 2 h then cooled to RT. The reaction mixture was acidified to pH 1 by addition of 6 M HCl then cooled down to about 4 Â°C in an ice bath. The precipitate was collected by filtration, washed with cold water (10 mL), and dried under to afford the title compound (1.3 g, 77%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.72 min. MS <i>m</i>/<i>z</i>: 216 (M â H)<sup>â</sup>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) Î´ 8.29 (d, <i>J</i> = 5.3 Hz, 1H), 8.16 (d, <i>J</i> = 8.2 Hz, 2H), 7.88 (d, <i>J</i> = 8.2 Hz, 2H), 7.66 (d, <i>J</i> = 5.3 Hz, 1H), 7.43 (s, 1H).</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>R</i>)-<i>tert</i>-Butyl 3-Hydroxy-1-(3-methoxyphenyl)propylcarbamate</h3><div class="NLM_p last">To a cold solution (0 Â°C) of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-methoxyphenyl)propanoic acid (4.03 g, 13.64 mmol) in DME (40 mL) was added <i>N</i>-methylmorpholine (1.65 mL, 15.01 mmol) followed by isobutyl carbonochloridate (1.96 mL, 15.01 mmol) and the mixture stirred at 0 Â°C for 30 min. The precipitate was filtered off and washed with a small amount of DME and cooled to 0 Â°C. A suspension of NaBH<sub>4</sub> (0.774 g, 20.46 mmol) in water (8 mL) was then added in one portion. The mixture was stirred at RT for 10 min then water (20 mL) was added. The mixture was extracted with EtOAc (3 Ã 25 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a colorless oil (3.82 g, 99%) that was used in the next step without further purification. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.97 min. MS <i>m</i>/<i>z</i>: 282 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.29 (d, <i>J</i> = 8.6, 1H), 7.21 (t, <i>J</i> = 8.1, 1H), 6.84 (d, <i>J</i> = 6.6, 2H), 6.80â6.73 (m, 1H), 4.57 (d, <i>J</i> = 6.7, 1H), 4.45 (t, <i>J</i> = 4.9, 1H), 3.73 (s, 3H), 3.35 (d, <i>J</i> = 5.4, 1H), 3.31â3.25 (m, 1H), 1.89â1.59 (m, 2H), 1.36 (s, 9H).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>R</i>)-3-(<i>tert</i>-Butoxycarbonylamino)-3-(3-methoxyphenyl)propyl Methanesulfonate</h3><div class="NLM_p last">To a solution of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-methoxyphenyl)propylcarbamate (3 g, 10.66 mmol) and DCM (40 mL) under nitrogen at 0 Â°C was added Et<sub>3</sub>N (1.49 mL, 10.66 mmol). Methanesulfonyl chloride (1.0 mL, 12.80 mmol) was then added dropwise. After stirring for 3 h, the solution was diluted with DCM (50 mL) and washed with water (50 mL), 0.5 M aq HCl (50 mL) and saturated aqueous NaHCO<sub>3</sub> (50 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford the title compound (3.58 g, 93%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.34 min. MS <i>m</i>/<i>z</i>: 377 (M + H<sub>2</sub>O)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.48 (d, <i>J</i> = 7.8 1H), 7.24 (t, <i>J</i> = 7.8, 1H), 6.90â6.78 (m, 3H), 4.63â4.54 (m, 1H), 4.24â4.05 (m, 2H), 3.74 (s, 3H), 3.15 (s, 3H), 2.09â1.94 (m, 2H), 1.36 (s, 9H).</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (<i>R</i>)-<i>tert</i>-Butyl 1-(3-Methoxyphenyl)-3-morpholinopropylcarbamate</h3><div class="NLM_p last">To a solution of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-methoxyphenyl)propyl methanesulfonate (3.58 g, 9.96 mmol) and acetonitrile (50 mL) under nitrogen was added morpholine (3.47 mL, 39.8 mmol). Cesium carbonate (6.49 g, 19.92 mmol) was then added in one portion. The resulting mixture was warmed to 75 Â°C for 16 h. The mixture was allowed to cool to RT and then filtered. The volatiles were removed under reduced pressure and the residue partitioned between 50% saturated aqueous NaHCO<sub>3</sub> (100 mL) and DCM (50 mL). The layers were separated and the aqueous layer extracted with DCM (50 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude material was purified on silica gel to afford the title compound (3.13 g, 90%) as a thick, clear, colorless oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method d): <i>R</i><sub>t</sub> = 1.71 min. MS <i>m</i>/<i>z</i>: 351 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.38 (d, <i>J</i> = 8.7, 1H), 7.21 (t, <i>J</i> = 7.9, 1H), 6.88â6.82 (m, 2H), 6.79â6.73 (m, 1H), 4.60â4.43 (m, 1H), 3.73 (s, 3H), 3.62â3.50 (m, 4H), 2.33â2.26 (m, 4H), 2.19 (t, <i>J</i> = 7.1, 2H), 1.86â1.60 (m, 2H), 1.35 (s, 9H).</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>R</i>)-1-(3-Methoxyphenyl)-3-morpholinopropan-1-amine, 2 Hydrochloric Acid</h3><div class="NLM_p last">To (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxyphenyl)-3-morpholinopropylcarbamate (1.57 g, 4.48 mmol) was added 4 M HCl in dioxane (24.64 mL, 99 mmol). The solution was stirred at RT for 2.5 h. The volatiles were removed under reduced pressure and the residue triturated with Et<sub>2</sub>O (2 Ã 10 mL) to afford the title compound (1.66 g, 115%) as a yellow-white solid, which was used without further purification. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method d): <i>R</i><sub>t</sub> = 0.56 min. MS <i>m</i>/<i>z</i>: 251 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 11.69â11.43 (m, 1H), 8.80 (s, 3H), 7.34 (t, <i>J</i> = 6.8, 1H), 7.25 (s, 1H), 7.12 (d, <i>J</i> = 7.2, 1H), 6.99â6.90 (d, <i>J</i> = 7.6, 1H), 4.50â4.35 (m, 1H), 3.95â3.80 (m, 4H), 3.77 (s, 3H), 3.73â3.60 (m, 1H), 3.50â3.40 (m, 1H), 3.17â2.77 (m, 5H), 2.38â2.22 (m, 1H).</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>R</i>)-4-(2-Fluoropyridin-4-yl)-<i>N</i>-(1-(3-methoxyphenyl)-3-morpholinopropyl)benzamide (<b>39</b>)</h3><div class="NLM_p last">To a flask containing 4-(2-fluoropyridin-4-yl)benzoic acid hydrochloride (85 mg, 0.33 mmol), EDC (96 mg, 0.50 mmol), (<i>R</i>)-1-(3-methoxyphenyl)-3-morpholinopropan-1-amine dihydrochloride (140 mg, 0.37 mmol), and HOBt (56 mg, 0.37 mmol) was added DIEA (0.29 mL, 1.67 mmol) followed by DMF (2 mL). The mixture was stirred at RT for 1 h, evaporated to dryness, and purified on silica gel (0â3% MeOH/DCM as eluent) to afford the title compound (122 mg, 81%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 0.98 min. MS <i>m</i>/<i>z</i>: 450.21 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.93 (1 H, d, <i>J</i> = 8.2), 8.32 (1 H, d, <i>J</i> = 5.3), 8.04â7.93 (4 H, m), 7.75 (1 H, d, <i>J</i> = 5.3), 7.59 (1 H, s), 7.22 (1 H, t, <i>J</i> = 7.9), 7.00â6.93 (2 H, m), 6.82â6.74 (1 H, m), 5.07 (1 H, q, <i>J</i> = 8.3), 3.73 (3 H, s), 3.59â3.52 (4 H, m), 2.35â2.25 (6 H, m), 1.96 (2 H, dq, <i>J</i> = 25.6, 7.3). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.49, 164.53 (d, <i>J</i> = 234.7, 1), 159.72, 152.64 (d, <i>J</i> = 8.6, 5), 148.70 (d, <i>J</i> = 15.7), 145.90, 138.82, 136.05, 129.71, 128.59, 127.52,120.23 (d, <i>J</i> = 3.8), 119.25, 112.85, 112.37,107.32 (d, <i>J</i> = 38.7), 66.70, 55.91, 55.43, 53.89, 52.30, 33.15. <sup>19</sup>F NMR (376 MHz, DMSO) â68.57. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>3</sub> 450.21147, found 450.21169.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (<i>R</i>)-Propyl 3-(<i>tert</i>-Butoxycarbonylamino)-3-(3-propoxyphenyl)propanoate</h3><div class="NLM_p last">A mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-hydroxyphenyl)propanoic acid (2.5 g, 8.9 mmol), 1-iodopropane (3.47 mL, 35.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (6.14 g, 44.4 mmol) in DMF (15 mL) was heated at 60 Â°C overnight. Water (100 mL) was added and the mixture extracted with EtOAc (3 Ã 30 mL). The combined organic layers were concentrated and purified on silica gel (0â25% EtOAc/heptane as eluent) to afford the title compound (2.48 g, 76%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.68 min. MS <i>m</i>/<i>z</i>: 366.22 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.41 (d, <i>J</i> = 8.9, 1H), 7.18 (t, <i>J</i> = 7.9, 1H), 6.86 (d, <i>J</i> = 1.8, 1H), 6.83 (d, <i>J</i> = 7.7, 1H), 6.76 (dd, <i>J</i> = 1.9, 8.2, 1H), 4.87 (dd, <i>J</i> = 8.2, 15.5, 1H), 3.97â3.90 (m, 2H), 3.88 (t, <i>J</i> = 6.5, 2H), 2.75â2.58 (m, 2H), 1.76â1.64 (m, 2H), 1.56â1.45 (m, 2H), 1.33 (s, 9H), 0.95 (t, <i>J</i> = 7.4, 3H), 0.82 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>R</i>)-3-(<i>tert</i>-Butoxycarbonylamino)-3-(3-propoxyphenyl)propanoic Acid</h3><div class="NLM_p last">To a solution of (<i>R</i>)-propyl 3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propanoate (2.48 g, 6.79 mmol) in THF (45 mL) was added lithium hydroxide hydrate (1.42 g, 33.9 mmol) followed by water (15 mL). The mixture was then stirred at RT overnight. The organic solvent was removed under reduced pressure and the residue diluted with water (50 mL) and adjusted to pH 7 with 6 M HCl. The reaction mixture was extracted with EtOAc (3 Ã 30 mL) and the combined organic layers washed with brine (30 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford the title compound (2.09 g, 95%) as a gummy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method d): <i>R</i><sub>t</sub> = 2.23 min. MS <i>m</i>/<i>z</i>: 322.2 (M â H)<sup>â</sup>.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (<i>R</i>)-<i>tert</i>-Butyl 3-Hydroxy-1-(3-propoxyphenyl)propylcarbamate</h3><div class="NLM_p last">To a cold solution (0 Â°C) of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propanoic acid (2.09 g, 6.47 mmol) in THF (10 mL) was added <i>N</i>-methylmorpholine (0.78 mL, 7.11 mmol) followed by isobutyl carbonochloridate (0.93 mL, 7.11 mmol). After stirring at 0 Â°C for 30 min, the precipitate was filtered off and washed with a small amount of THF. The mixture was cooled to 0 Â°C and treated with a suspension of NaBH<sub>4</sub> (0.37 g, 9.70 mmol) in water (2 mL) in one portion. The mixture was stirred at RT for 3 h. Water (50 mL) was added and the mixture extracted with EtOAc (3 Ã 25 mL). The combined organic layers were evaporated to dryness to give a colorless oil that was purified on silica gel (25â50% EtOAc/heptane as eluent). Removal of solvent afforded the title compound (1.74 g, 87%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.45 min. MS <i>m</i>/<i>z</i>: 310.20 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.28 (d, <i>J</i> = 8.5, 1H), 7.19 (t, <i>J</i> = 7.8, 1H), 6.86â6.78 (m, 2H), 6.75 (dd, <i>J</i> = 2.3, 8.1, 1H), 4.56 (dd, <i>J</i> = 8.1, 14.9, 1H), 4.44 (t, <i>J</i> = 4.9, 1H), 3.89 (t, <i>J</i> = 6.5, 2H), 3.41â3.24 (m, 2H), 1.85â1.61 (m, 4H), 1.35 (s, 9H), 0.98 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (<i>R</i>)-3-(<i>tert</i>-Butoxycarbonylamino)-3-(3-propoxyphenyl)propyl Methanesulfonate</h3><div class="NLM_p last">A solution of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-propoxyphenyl)propylcarbamate (1.4 g, 4.52 mmol) in DCM (15 mL) was cooled to 0 Â°C. Et<sub>3</sub>N (0.76 mL, 5.43 mmol) was added followed by dropwise addition of methanesulfonyl chloride (0.42 mL, 5.43 mmol). The mixture was stirred at 0 Â°C for 6 h and then diluted with DCM (20 mL), washed with water (20 mL), and saturated NaHCO<sub>3</sub> (20 mL). The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated to dryness to afford an oil. Ether (20 mL) was added and then concentrated to dryness to afford the title compound (1.89 g, 100%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.53 min.(no ionization). <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.47 (d, <i>J</i> = 9.1, 1H), 7.22 (t, <i>J</i> = 7.8, 1H), 6.90â6.81 (m, 2H), 6.79 (dd, <i>J</i> = 2.3, 8.2, 1H), 4.58 (dd, <i>J</i> = 6.1, 14.0, 1H), 4.19 (dd, <i>J</i> = 7.0, 16.5, 1H), 4.14â4.04 (m, 1H), 3.91 (t, <i>J</i> = 6.5, 2H), 3.15 (s, 3H), 2.09â1.89 (m, 2H), 1.72 (dd, <i>J</i> = 7.3, 14.0, 2H), 1.36 (s, 9H), 0.98 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (<i>R</i>)-<i>tert</i>-Butyl 3-(Piperidin-1-yl)-1-(3-propoxyphenyl)propylcarbamate</h3><div class="NLM_p last">To a mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propyl methanesulfonate (1.89 g, 4.89 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.35 g, 9.78 mmol) in MeCN (20 mL) was added piperidine (0.97 mL, 9.78 mmol) dropwise. The mixture was then heated at 50 Â°C overnight, filtered, washed with MeCN, and concentrated. The residue was partitioned between DCM (50 mL) and 0.1 M HCl (50 mL), the layers separated, and the organic layer concentrated to give an oil that was purified on silica gel (0â5% 7 M NH<sub>3</sub> in methanol/DCM as eluent) to afford the title compound (1.20 g, 66%) as a semisolid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.37 min. MS <i>m</i>/<i>z</i>: 377.24 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.41 (d, <i>J</i> = 8.7, 1H), 7.18 (t, <i>J</i> = 7.9, 1H), 6.84 (d, <i>J</i> = 1.3, 1H), 6.81 (d, <i>J</i> = 7.6, 1H), 6.75 (dd, <i>J</i> = 2.2, 7.9, 1H), 4.48 (dd, <i>J</i> = 7.7, 14.9, 1H), 3.89 (t, <i>J</i> = 6.5, 2H), 2.25 (s, 4H), 2.14 (t, <i>J</i> = 6.9, 2H), 1.78â1.65 (m, 5H), 1.48 (dt, <i>J</i> = 5.5, 10.7, 5H), 1.35 (s, 9H), 0.97 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (<i>R</i>)-3-(Piperidin-1-yl)-1-(3-propoxyphenyl)propan-1-amine Dihydrochloride</h3><div class="NLM_p last">To a vial charged with (<i>R</i>)-<i>tert</i>-butyl 3-(piperidin-1-yl)-1-(3-propoxyphenyl)propylcarbamate (1.21 g, 3.21 mmol) was added HCl (4.0 M in dioxane) (8.01 mL, 32.1 mmol). The solution was stirred at RT for 15 min, and then the solvent was removed under reduced pressure to give a white solid. Trituration with ether gave a solid that was collected by filtration affording the title compound (1.13 g, 100%) as an off-white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.04 min. MS <i>m</i>/<i>z</i>: 277.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (<i>R</i>)-4-(2-Fluoropyridin-4-yl)-<i>N</i>-(3-(piperidin-1-yl)-1-(3-propoxyphenyl)propyl)benzamide (<b>40</b>)</h3><div class="NLM_p last">To a flask containing 4-(2-fluoropyridin-4-yl)benzoic acid hydrochloride (85 mg, 0.33 mmol), EDC (96 mg, 0.50 mmol), (<i>R</i>)-3-(piperidin-1-yl)-1-(3-propoxyphenyl)propan-1-amine dihydrochloride (123 mg, 0.35 mmol), and HOBt (56.4 mg, 0.37 mmol) was added DIEA (0.234 mL, 1.34 mmol) followed by DMF (2 mL). The mixture was stirred at RT overnight then diluted with water (30 mL). The reaction mixture was then extracted with DCM (3 Ã 20 mL) and the organic layers combined, dried (MgSO<sub>4</sub>), filtered, and concentrated to give an orange oil that was purified on silica gel (0â5% MeOH/DCM as eluent). This gave an oil that was triturated several times with ether to afford the title compound (96 mg, 57%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.93 min. MS <i>m</i>/<i>z</i>: 476.24 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.99 (1 H, d, <i>J</i> = 8.1), 8.32 (1 H, d, <i>J</i> = 5.2), 8.04â7.93 (4 H, m), 7.75 (1 H, d, <i>J</i> = 5.3), 7.59 (1 H, s), 7.20 (1 H, t, <i>J</i> = 7.8), 6.98â6.89 (2 H, m), 6.77 (1 H, dd, <i>J</i> = 7.9, 2.1), 5.05 (1 H, q, <i>J</i> = 7.9), 3.89 (2 H, t, <i>J</i> = 6.5), 2.44â2.17 (6 H, m), 2.12â1.87 (2 H, m), 1.70 (2 H, h, <i>J</i> = 7.1), 1.56â1.43 (4 H, m), 1.39â1.34 (2 H, m), 0.95 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.45, 164.53 (d, <i>J</i> = 234.7), 159.15, 152.62 (d, <i>J</i> = 8.5), 148.71 (d, <i>J</i> = 15.7), 145.77, 138.86 (d, <i>J</i> = 3.4), 136.02, 129.68, 128.57, 127.53, 120.23 (d, <i>J</i> = 3.8), 119.11, 113.30, 112.89, 107.32 (d, <i>J</i> = 38.8), 69.26, 55.98, 54.47, 52.45, 33.19, 25.87, 24.30, 22.52, 10.87. <sup>19</sup>F NMR (376 MHz, DMSO) Î´ â68.57. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>35</sub>FN<sub>3</sub>O<sub>2</sub> 476.26351, found 476.2633. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, b): 98% ee, negative (â) optical rotation.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>tert</i>-Butyl (<i>R</i>)-(1-(3-Fluorophenyl)-3-hydroxypropyl)carbamate</h3><div class="NLM_p last">A solution of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-fluorophenyl)propanoic acid (10 g, 35.3 mmol) (Chem Impex) in DME (80 mL) was cooled to 5 Â°C and <i>N</i>-methylmorpholine (4.27 mL, 38.8 mmol) and isobutyl carbonochloridate (5.30 g, 38.8 mmol) added sequentially. The mixture was stirred at 5 Â°C for 30 min then filtered. The filtrate was cooled in ice bath and NaBH<sub>4</sub> (2.0 g, 52.9 mmol) in water (10 mL) added slowly as a slurry. The suspension was stirred at 5 Â°C for 1 h then partitioned between water (30 mL) and EtOAc (30 mL). The layers were separated and the aqueous layer extracted with EtOAc (3 Ã 30 mL). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and concentrated to dryness. The residue was purified on silica gel (55â60% EtOAc/heptane as eluent). Fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (9.3 g, 98%) as an oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.03 min. MS <i>m</i>/<i>z</i>: 270.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (<i>R</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-3-(3-fluorophenyl)propyl Methanesulfonate</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(3-fluorophenyl)-3-hydroxypropylcarbamate (6.2 g, 23.02 mmol) in DCM (60 mL) was cooled to 0 Â°C in an ice bath and then Et<sub>3</sub>N (2.33 g, 23.02 mmol) added dropwise. Methanesulfonyl chloride (3.16 g, 27.6 mmol) was then added dropwise via a syringe. The resulting suspension was stirred at 5 Â°C for 3 h then at RT overnight. The reaction was partitioned between DCM (50 mL) and water (50 mL) and the layers separated. The organic layer was washed with 0.5 M HCl (25 mL), saturated NaHCO<sub>3</sub> solution (20 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated to dryness to afford the title compound (7.7 g, 96%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.27 min. MS <i>m</i>/<i>z</i>: 346.15 (M â H)<sup>â</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.33 (dd, <i>J</i> = 7.9, 14.1, 1H), 7.07 (d, <i>J</i> = 7.6, 1H), 6.98 (t, <i>J</i> = 7.9, 2H), 4.90 (s, 2H), 4.33â4.16 (m, 2H), 3.01 (d, <i>J</i> = 4.9, 3H), 2.20 (d, <i>J</i> = 6.1, 2H), 1.42 (s, 9H).</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>tert</i>-Butyl (<i>R</i>)-(1-(3-Fluorophenyl)-3-(pyrrolidin-1-yl)propyl)carbamate</h3><div class="NLM_p last">Potassium carbonate (3.02 g, 21.88 mmol) was added in one portion to stirred mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-fluorophenyl)propyl methanesulfonate (3.8 g, 10.94 mmol) and MeCN (50 mL). Pyrrolidine (1.56 g, 21.88 mmol) was added dropwise via syringe and the mixture heated at 50 Â°C overnight. The mixture was filtered and the solids washed with MeCN. The filtrate was concentrated and partitioned between DCM (50 mL) and water (50 mL). The layers were separated and the organic layer dried (MgSO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that was purified on silica gel (0â20% MeOH/DCM as eluent). The fractions containing the desired product were combined and evaporated to dryness to afford the title compound (3.5 g, 99%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.73 min. MS <i>m</i>/<i>z</i>: 323.19 (M + H)<sup>+</sup>.</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> (<i>R</i>)-1-(3-Fluorophenyl)-3-(pyrrolidin-1-yl)propan-1-amine Hydrochloride</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(3-fluorophenyl)-3-(pyrrolidin-1-yl)propylcarbamate (3.3 g, 10.24 mmol) and 4 M HCl in dioxane (20 mL, 82 mmol) were stirred at RT for 1 h. The reaction mixture was concentrated, chased with ether, and the suspension stirred overnight. The mixture was filtered and washed with ether and dried in vacuo to afford the title compound (1.8 g, 68%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 0.46 min. MS <i>m</i>/<i>z</i>: 223.18 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.82â8.57 (m, 1H), 7.57â7.41 (m, 2H), 7.39 (s, 1H), 7.30â7.21 (m, 1H), 4.61â4.36 (m, 1H), 3.55â3.46 (m, 2H), 3.25â3.03 (m, 1H), 3.01â2.80 (m, 3H), 2.46â2.34 (m, 1H), 2.34â2.19 (m, 1H), 2.04â1.91 (m, 2H), 1.92â1.78 (m, 2H).</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>N</i>-(1-(3-Fluorophenyl)-3-(pyrrolidin-1-yl)propyl)-4-(2-fluoropyridin-4-yl)benzamide (<b>41</b>)</h3><div class="NLM_p last">To a flask containing 4-(2-fluoropyridin-4-yl)benzoic acid hydrochloride (85 mg, 0.33 mmol), EDC (96 mg, 0.50 mmol), (<i>R</i>)-1-(3-fluorophenyl)-3-(pyrrolidin-1-yl)propan-1-amine dihydrochloride (109 mg, 0.37 mmol), and HOBt (56 mg, 0.37 mmol) was added DIEA (0.23 mL, 1.34 mmol) followed by DMF (2 mL). The mixture was stirred at RT overnight and then water added (10 mL). The mixture was extracted with DCM (3 Ã 15 mL) and the organic layers combined and concentrated to give an orange oil that was purified on silica gel (0â5% MeOH/DCM as eluent). The fractions containing the desired compound were combined to give an oil that was dried under vacuum to afford the title compound (115.1 mg, 81%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.79 min. MS <i>m</i>/<i>z</i>: 422.21 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.15 (1 H, d, <i>J</i> = 7.8), 8.32 (1 H, d, <i>J</i> = 5.2), 8.02â7.93 (4 H, m), 7.75 (1 H, d, <i>J</i> = 5.2), 7.59 (1 H, s), 7.41â7.31 (1 H, m), 7.28â7.17 (2 H, m), 7.08â6.99 (1 H, m), 5.13 (1 H, q, <i>J</i> = 8.0), 2.43 (6 H, t, <i>J</i> = 5.1), 2.07â1.89 (2 H, m), 1.71â1.66 (4 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 164.80 (d, <i>J</i> = 180.4), 162.42 (d, <i>J</i> = 188.8), 152.61 (d, <i>J</i> = 8.4), 148.71 (d, <i>J</i> = 15.8), 147.30 (d, <i>J</i> = 6.7), 138.95 (d, <i>J</i> = 3.4), 135.82, 130.61 (d, <i>J</i> = 8.3), 128.52, 127.56, 123.07 (d, <i>J</i> = 2.6), 120.24 (d, <i>J</i> = 3.8), 113.74 (d, <i>J</i> = 11.0), 113.74 (d, <i>J</i> = 53.5), 107.34 (d, <i>J</i> = 38.7), 54.04, 53.05, 52.25, 34.97, 23.62. <sup>19</sup>F NMR (376 MHz, DMSO) Î´ â68.56. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>26</sub>F<sub>2</sub>N<sub>3</sub>O 422.19657, found 422.19722.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Propyl (<i>R</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-3-(3-propoxyphenyl)propanoate</h3><div class="NLM_p last">A mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-hydroxyphenyl)propanoic acid (2.5 g, 8.9 mmol), 1-iodopropane (3.47 mL, 35.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (6.14 g, 44.4 mmol) in DMF (15 mL) was heated at 60 Â°C overnight. Water (100 mL) was added and the mixture extracted with EtOAc (3 Ã 30 mL). The combined organic layers were concentrated and purified on silica gel (0â25% EtOAc/heptane as eluent). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (2.48 g, 76%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.68 min. MS <i>m</i>/<i>z</i>: 366.22 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.41 (d, <i>J</i> = 8.9, 1H), 7.18 (t, <i>J</i> = 7.9, 1H), 6.86 (d, <i>J</i> = 1.8, 1H), 6.83 (d, <i>J</i> = 7.7, 1H), 6.76 (dd, <i>J</i> = 1.9, 8.2, 1H), 4.87 (dd, <i>J</i> = 8.2, 15.5, 1H), 3.97â3.90 (m, 2H), 3.88 (t, <i>J</i> = 6.5, 2H), 2.75â2.58 (m, 2H), 1.76â1.64 (m, 2H), 1.56â1.45 (m, 2H), 1.33 (s, 9H), 0.95 (t, <i>J</i> = 7.4, 3H), 0.82 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (<i>R</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-3-(3-propoxyphenyl)propanoic Acid</h3><div class="NLM_p last">To a solution of (<i>R</i>)-propyl 3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propanoate (2.48 g, 6.8 mmol) in THF (45 mL) was added lithium hydroxide hydrate (1.42 g, 33.9 mmol) followed by water (15 mL). The mixture was stirred at RT overnight. Removal of the organic solvent under reduced pressure gave a residue that was diluted with water (50 mL), adjusted to pH 7 with 6 M HCl, and extracted with DCM (3 Ã 30 mL). The combined organic layers were washed with saturated brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford the title compound (2.09 g, 95%) as a gummy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method d): <i>R</i><sub>t</sub> = 2.23 min. MS <i>m</i>/<i>z</i>: 322.2 (M â H)<sup>â</sup>.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>tert</i>-Butyl (<i>R</i>)-(3-Hydroxy-1-(3-propoxyphenyl)propyl)carbamate</h3><div class="NLM_p last">To a cold solution (0 Â°C) of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propanoic acid (2.09 g, 6.47 mmol) in THF (10 mL) was added <i>N</i>-methylmorpholine (0.78 mL, 7.11 mmol) followed by isobutyl carbonochloridate (0.93 mL, 7.11 mmol). The mixture was stirred at 0 Â°C for 30 min, the precipitate filtered off and washed with a small amount of THF. After cooling to 0 Â°C, a suspension of NaBH<sub>4</sub> (0.367 g, 9.70 mmol) in water (2 mL) was added in one portion. The mixture was stirred at RT for 3 h. Water (50 mL) was then added and the mixture extracted with EtOAc (3 Ã 25 mL). The combined organic layers were evaporated to dryness to give a colorless oil that was purified on silica gel (25â50% EtOAc/heptane as eluent). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (1.74 g, 87%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.45 min. MS <i>m</i>/<i>z</i>: 310.20 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.28 (d, <i>J</i> = 8.5, 1H), 7.19 (t, <i>J</i> = 7.8, 1H), 6.86â6.78 (m, 2H), 6.75 (dd, <i>J</i> = 2.3, 8.1, 1H), 4.56 (dd, <i>J</i> = 8.1, 14.9, 1H), 4.44 (t, <i>J</i> = 4.9, 1H), 3.89 (t, <i>J</i> = 6.5, 2H), 3.41â3.24 (m, 2H), 1.85â1.61 (m, 4H), 1.35 (s, 9H), 0.98 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (<i>R</i>)-3-Amino-3-(3-propoxyphenyl)propan-1-ol Hydrochloride</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-propoxyphenyl)propylcarbamate (0.30 g, 0.97 mmol) and 4 M HCL in dioxane (1.21 mL, 4.85 mmol) was stirred at RT for 1 h. The volatiles were removed under reduced pressure to afford the title compound as a white solid that was used directly in the next step.</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> (<i>R</i>)-4-(2-Fluoropyridin-4-yl)-<i>N</i>-(3-hydroxy-1-(3-propoxyphenyl)propyl)benzamide (<b>42</b>)</h3><div class="NLM_p last">A mixture of 4-(2-fluoropyridin-4-yl)benzoic acid hydrochloride (100 mg, 0.39 mmol), EDC (113 mg, 0.59 mmol), (<i>R</i>)-3-amino-3-(3-propoxyphenyl)propan-1-ol hydrochloride (102 mg, 0.41 mmol), HOBt (66.4 mg, 0.43 mmol), DIEA (0.20 mL, 1.18 mmol), and DMF (2 mL) was stirred at RT over the weekend. Water was added (30 mL) and the mixture extracted with EtOAc (3 Ã 30 mL). The combined organic layers were concentrated to give an orange oil that was purified on silica gel (0â75% EtOAc/hexane as eluent). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (109 mg, 67%) as a white fluffy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.22 min. MS <i>m</i>/<i>z</i>: 409.19 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.83 (1 H, d, <i>J</i> = 8.2), 8.32 (1 H, d, <i>J</i> = 5.3), 8.04â7.92 (4 H, m), 7.74 (1 H, d, <i>J</i> = 5.3), 7.59 (1 H, s), 7.20 (1 H, t, <i>J</i> = 7.9), 6.98â6.89 (2 H, m), 6.76 (1 H, dd, <i>J</i> = 8.1, 2.2), 5.13 (1 H, q, <i>J</i> = 8.4), 4.53 (1 H, t, <i>J</i> = 4.9), 3.89 (2 H, t, <i>J</i> = 6.5), 3.41 (2 H, dq, <i>J</i> = 10.8, 5.3), 3.28 (2 H, s), 2.03 (1 H, td, <i>J</i> = 14.3, 5.7), 1.89 (1 H, dq, <i>J</i> = 13.5, 6.6), 1.70 (2 H, q, <i>J</i> = 6.9), 0.95 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 164.53 (d, <i>J</i> = 234.7), 165.45, 159.14,152.65 (d, <i>J</i> = 8.4),148.70 (d, <i>J</i> = 15.7), 146.06, 138.80 (d, <i>J</i> = 3.4), 136.07, 129.66, 128.58, 127.50, 120.23 (d, <i>J</i> = 3.8), 119.17, 113.35, 112.77, 107.31 (d, <i>J</i> = 38.7), 69.25, 58.34, 50.88, 22.52, 10.87. <sup>19</sup>F NMR (376 MHz, DMSO) Î´ â68.57. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>2</sub>O<sub>3</sub> 409.18492, found 409.18542. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, c): >99% ee, negative (â) optical rotation.</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Propyl (<i>R</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-3-(3-propoxyphenyl)propanoate</h3><div class="NLM_p last">A stirred mixture of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-hydroxyphenyl)propanoic acid (2.36 g, 8.4 mmol), 1-iodopropane (2.45 mL, 25.2 mmol), and K<sub>2</sub>CO<sub>3</sub> (5.79 g, 41.9 mmol) in MeCN (40 mL) was heated at 60 Â°C overnight. The solvent was removed under reduced pressure and the residue partitioned between DCM (50 mL) and water (50 mL). The layers were separated and the aqueous layer extracted with DCM (3 Ã 25 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated to dryness, and purified on silica gel (0â25% EtOAc/hexane as eluent). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (2.36 g, 77%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.68 min. MS <i>m</i>/<i>z</i>: 366.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> (<i>R</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-3-(3-propoxyphenyl)propanoic Acid</h3><div class="NLM_p last">To a solution of (<i>R</i>)-propyl 3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propanoate (2.87 g, 7.9 mmol) in THF (45 mL) was added lithium hydroxide hydrate (1.65 g, 39.3 mmol) followed by water (15 mL). The mixture was stirred at RT overnight and then heated at 50 Â°C for 1 h. The organic solvent was removed under reduced pressure and the residue diluted with water (50 mL) and adjusted to pH 7 with 6 M HCl. The mixture was extracted with DCM (3 Ã 30 mL) and the combined organic layers washed with brine (40 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford the title compound (2.54 g, 100%) as a gummy solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.44 min. MS <i>m</i>/<i>z</i>: 322.19 (M â H)<sup>â</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 12.19 (s, 1H), 7.39 (d, <i>J</i> = 8.9, 1H), 7.19 (t, <i>J</i> = 7.8, 1H), 6.86 (d, <i>J</i> = 1.9, 1H), 6.84 (d, <i>J</i> = 7.7, 1H), 6.77 (dd, <i>J</i> = 2.4, 8.2, 1H), 4.84 (dd, <i>J</i> = 8.5, 15.6, 1H), 3.89 (t, <i>J</i> = 6.5, 2H), 2.59 (ddd, <i>J</i> = 7.5, 15.6, 22.1, 2H), 1.81â1.69 (m, 2H), 1.35 (s, 9H), 0.97 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> <i>tert</i>-Butyl (<i>R</i>)-(3-Hydroxy-1-(3-propoxyphenyl)propyl)carbamate</h3><div class="NLM_p last">To a cold solution (0 Â°C) of (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-3-(3-propoxyphenyl)propanoic acid (2.54 g, 7.87 mmol) in DME (20 mL) was added <i>N</i>-methylmorpholine (0.95 mL, 8.65 mmol) followed by isobutyl carbonochloridate (1.18 g, 8.65 mmol). The mixture was stirred at 0 Â°C for 1 h, the precipitate filtered off, and washed with a small amount of DME. After cooling to 0 Â°C, a suspension of NaBH<sub>4</sub> (0.446 g, 11.80 mmol) in water (3 mL) was added in one portion. The mixture was stirred at RT for 3.5 h then water (50 mL) was added. The mixture was extracted with EtOAc (3 Ã 25 mL) and the combined organic layers evaporated to dryness to give a colorless oil that was purified on silica gel (25â50% EtOAc/heptane as eluent). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (2.08 g, 86%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.44 min. MS <i>m</i>/<i>z</i>: 310.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> (<i>R</i>)-4-(3-Fluoropyridin-4-yl)-<i>N</i>-(3-hydroxy-1-(3-propoxyphenyl)propyl)benzamide (<b>43</b>)</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-propoxyphenyl)propylcarbamate (74 mg, 0.24 mmol) and 4 M HCL in dioxane (0.3 mL, 1.19 mmol) was stirred at RT for 30 min. The solvent was removed under reduced pressure to afford a residue. A mixture of 4-(3-fluoropyridin-4-yl)benzoic acid hydrochloride (55 mg, 0.22 mmol), HATU (99 mg, 0.26 mmol), and DMF (2 mL) was stirred at RT for 2 min then added to the residue. Et<sub>3</sub>N (0.15 mL, 1.08 mmol) was added and the mixture stirred at RT overnight. Water (15 mL) was added and the mixture extracted with EtOAc (4 Ã 15 mL). The combined organic layers were concentrated and purified on silica gel (50â100% EtOAc/heptane as eluent). A minor impurity was identified by NMR and the residue further purified by HPLC (30â80% MeCN/10 mM ammonium acetate over 30 min; flow rate 21 mL/min). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (32 mg, 36%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.36 min. MS <i>m</i>/<i>z</i>: 409.18 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.83 (1 H, d, <i>J</i> = 8.2), 8.67 (1 H, d, <i>J</i> = 2.4), 8.52 (1 H, d, <i>J</i> = 4.9), 8.00 (2 H, d, <i>J</i> = 8.3), 7.76 (2 H, d, <i>J</i> = 7.4), 7.66 (1 H, dd, <i>J</i> = 6.8, 5.1), 7.20 (1 H, t, <i>J</i> = 7.8), 6.98â6.90 (2 H, m), 6.76 (1 H, dd, <i>J</i> = 8.2, 2.1), 5.13 (1 H, q, <i>J</i> = 8.4), 4.53 (1 H, t, <i>J</i> = 4.6), 3.89 (2 H, t, <i>J</i> = 6.5), 3.42 (2 H, tt, <i>J</i> = 10.3, 5.4), 2.02 (1 H, td, <i>J</i> = 14.4, 5.6), 1.89 (1 H, dq, <i>J</i> = 13.0, 6.4), 1.70 (2 H, q, <i>J</i> = 6.9), 0.95 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.58, 159.14, 156.49 (d, <i>J</i> = 256.3), 146.86 (d, <i>J</i> = 5.2), 146.06, 139.20 (d, <i>J</i> = 25.2), 135.72, 135.32, 134.76 (d, <i>J</i> = 10.4), 129.66, 129.20 (d, <i>J</i> = 3.2), 128.28, 124.91, 119.16, 113.33, 112.78, 69.25, 58.34, 50.88, 22.52, 10.87. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ â133.29. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>2</sub>O<sub>3</sub> 409.18492, found 409.18468.</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> (<i>R</i>)-<i>N</i>-(1-(3-Propoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>44</b>)</h3><div class="NLM_p last">A mixture of 4-(pyridin-4-yl)benzoic acid (250 mg, 1.25 mmol), EDC (361 mg, 1.88 mmol), (<i>R</i>)-1-(3-propoxyphenyl)ethanamine hydrochloride (298 mg, 1.38 mmol), HOBt (211 mg, 1.38 mmol), DIEA (0.44 mL, 2.51 mmol), and DMF (5 mL) was stirred at RT overnight. The volatiles were removed under reduced pressure and water (50 mL) added. The mixture was extracted with DCM (3 Ã 30 mL) and the combined organic layers concentrated and purified on silica gel (0â5% MeOH/DCM as eluent) to give an oil that was dried on a high vacuum pump overnight. This afforded the title compound (246 mg, 54%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.52 min. MS <i>m</i>/<i>z</i>: 361.19 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.84 (1 H, d, <i>J</i> = 8.1), 8.68â8.62 (2 H, m), 8.01 (2 H, d, <i>J</i> = 8.4), 7.90 (2 H, d, <i>J</i> = 8.4), 7.78â7.72 (2 H, m), 7.20 (1 H, t, <i>J</i> = 7.8), 6.98â6.90 (2 H, m), 6.77 (1 H, ddd, <i>J</i> = 8.2, 2.6, 1.0), 5.14 (1 H, p, <i>J</i> = 7.2), 3.89 (2 H, t, <i>J</i> = 6.5), 1.70 (2 H, h, <i>J</i> = 7.1), 1.46 (3 H, d, <i>J</i> = 7.0), 0.95 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 165.36, 159.19, 150.78, 146.96, 146.52, 140.10, 135.46, 129.72, 128.68, 127.16, 121.79, 118.69, 112.97, 112.73, 69.27, 48.98, 22.74, 22.52, 10.87. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub> 361.1911, found 361.1911.</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> (<i>R</i>)-2-(4-(Aminomethyl)piperidin-1-yl)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>46</b>)</h3><div class="NLM_p last">A mixture of (<i>R</i>)-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (97 mg, 0.28 mmol), K<sub>2</sub>CO<sub>3</sub> (77 mg, 0.55 mmol), <i>tert</i>-butyl piperidin-4-ylmethylcarbamate (71 mg, 0.33 mmol), and ethanol (3 mL) was heated in a CEM microwave at 160 Â°C for 3 h (250 psi maximum pressure, 2 min ramp, 300 max watts). The reaction mixture was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> solution and extracted with DCM (2 Ã 50 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated and purified by prep-HPLC (21.2 mm Ã 250 mm Hypersil C<sub>18</sub> HS column, 8 Î¼m particles, 0â100% B over 35 min, 20 mL/min flow rate). Mobile phase A was 0.05 M aqueous ammonium acetate buffer (pH 4.5) and mobile phase B was MeCN). The fractions containing the desired compound were combined and pH adjusted to 8 with saturated Na<sub>2</sub>CO<sub>3</sub> solution. The mixture was extracted with DCM (2 Ã 150 mL) and the combined organic layers concentrated and purified on silica gel (0â10% MeOH/DCM as eluent). The fractions containing the desired compound were combined, concentrated, and dried in a vacuum oven at RT for 2 h to afford the title compound (17 mg, 14%) as an oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.54 min. MS <i>m</i>/<i>z</i>: 445.39 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.11 (d, <i>J</i> = 7.3 Hz, 1H), 8.67â8.60 (m, 2H), 7.91 (d, <i>J</i> = 8.0 Hz, 1H), 7.77â7.71 (m, 2H), 7.64 (d, <i>J</i> = 1.8 Hz, 1H), 7.58 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.26 (t, <i>J</i> = 7.8 Hz, 1H), 7.00â6.94 (m, 2H), 6.83 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 5.09 (p, <i>J</i> = 6.9 Hz, 1H), 3.10 (dd, <i>J</i> = 28.5, 11.8 Hz, 4H), 2.88â2.69 (m, 3H), 2.32 (d, <i>J</i> = 6.5 Hz, 2H), 1.77 (d, <i>J</i> = 12.8 Hz, 1H), 1.61 (d, <i>J</i> = 13.2 Hz, 1H), 1.48 (d, <i>J</i> = 6.9 Hz, 2H), 1.35â1.09 (m, 4H), 0.79 (qd, <i>J</i> = 12.1, 11.6, 3.7 Hz, 2H).</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> (<i>R</i>)-2-((2-Aminoethyl)amino)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>47</b>)</h3><div class="NLM_p last">A mixture of <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (352 mg, 2.72 mmol), ethane-1,2-diamine (157 mg, 2.61 mmol), (<i>R</i>)-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (305 mg, 0.87 mmol), and DMSO (5 mL) was stirred at 110 Â°C overnight. The mixture was quenched with water (20 mL) and the aqueous layer extracted with DCM (3 Ã 30 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and purified by HPLC (21.2 Ã 250 mm Hypersil C<sub>18</sub> HS column, 8 Î¼m particles. 0â80% B over 35 min (20 mL/min flow rate). Mobile phase A was 0.05 M aqueous ammonium acetate buffer (pH 4.5) and mobile phase B was MeCN. The fractions containing the desired compound were combined and the pH adjusted to 8 with saturated Na<sub>2</sub>CO<sub>3</sub> solution. The mixture was extracted with DCM (2 Ã 150 mL), concentrated, dissolved in MeCN (50 mL), and concentrated then dried under vacuum at RT overnight. This afforded the title compound (81 mg, 24%) as a yellow solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.60 min. MS <i>m</i>/<i>z</i>: 391.19 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.86 (s, 0H), 8.70â8.60 (m, 2H), 8.42 (s, 0H), 7.85 (s, 1H), 7.50â7.40 (m, 3H), 7.27 (d, <i>J</i> = 8.8 Hz, 1H), 7.02â6.86 (m, 3H), 6.81 (td, <i>J</i> = 8.0, 2.0 Hz, 2H), 6.38 (d, <i>J</i> = 7.4 Hz, 1H), 5.26 (p, <i>J</i> = 7.0 Hz, 1H), 3.99 (s, 0H), 3.81 (s, 3H), 3.63 (s, 0H), 3.30 (q, <i>J</i> = 5.8 Hz, 2H), 3.17 (s, 0H), 3.00 (t, <i>J</i> = 6.0 Hz, 2H), 2.83 (s, 0H), 1.59 (d, <i>J</i> = 6.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 168.41, 159.91, 150.25, 150.20, 148.14, 144.88, 142.50, 129.80, 128.14, 121.65, 118.31, 115.45, 113.36, 112.42, 112.28, 110.03, 55.22, 48.97, 46.13, 41.15, 21.94. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> 391.2129, found 391.2126.</div></div><div id="sec4_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> (<i>R</i>)-2-((3-Aminopropyl)amino)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>48</b>)</h3><div class="NLM_p last">As for compound <b>47</b> except <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (221 mg, 1.71 mmol), propane-1,3-diamine (127 mg, 1.71 mmol), and (<i>R</i>)-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (200 mg, 0.57 mmol) This afforded the title compound (193 mg, 84%) as a yellow solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.65 min. MS <i>m</i>/<i>z</i>: 405.28 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.70â8.60 (m, 2H), 7.71 (s, 1H), 7.57â7.39 (m, 3H), 7.35â7.23 (m, 1H), 7.03â6.86 (m, 3H), 6.81 (ddd, <i>J</i> = 12.2, 8.1, 1.8 Hz, 2H), 6.36 (d, <i>J</i> = 7.4 Hz, 1H), 5.25 (p, <i>J</i> = 7.0 Hz, 1H), 3.99 (s, 0H), 3.81 (d, <i>J</i> = 1.5 Hz, 3H), 3.63 (s, 0H), 3.48â3.22 (m, 2H), 2.87 (t, <i>J</i> = 6.8 Hz, 2H), 1.85 (q, <i>J</i> = 6.8 Hz, 2H), 1.59 (d, <i>J</i> = 6.8 Hz, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 168.47, 159.92, 150.18, 148.21, 144.90, 142.50, 129.81, 128.06, 121.67, 118.32, 115.16, 113.10, 112.43, 112.28, 109.88, 55.23, 48.96, 40.72, 39.98, 32.86, 21.95. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> 405.2285, found 405.2285.</div></div><div id="sec4_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> (<i>R</i>)-2-((4-Aminobutyl)amino)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (<b>49</b>)</h3><div class="NLM_p last">As for compound <b>47</b> except (<i>R</i>)-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyridin-4-yl)benzamide (100 mg, 0.285 mmol) and butane-1,4-diamine. This afforded the title compound (25 mg, 21%) as a solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.69 min. MS <i>m</i>/<i>z</i>: 419.39 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.65 (d, <i>J</i> = 5.8 Hz, 2H), 7.71 (s, 1H), 7.46 (dd, <i>J</i> = 15.2, 7.0 Hz, 3H), 7.03 (s, 0H), 7.02â6.90 (m, 2H), 6.90â6.73 (m, 3H), 6.34 (d, <i>J</i> = 7.4 Hz, 1H), 5.25 (p, <i>J</i> = 7.0 Hz, 1H), 3.99 (s, 0H), 3.81 (s, 3H), 3.71 (q, <i>J</i> = 7.0 Hz, 2H), 3.63 (s, 0H), 3.22 (t, <i>J</i> = 6.8 Hz, 2H), 2.74 (t, <i>J</i> = 6.9 Hz, 2H), 1.74 (dt, <i>J</i> = 14.8, 6.9 Hz, 2H), 1.59 (d, <i>J</i> = 6.8 Hz, 6H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) Î´ 168.47, 159.91, 150.17, 148.25, 144.90, 142.49, 129.79, 128.05, 121.67, 118.32, 115.02, 113.01, 112.42, 112.28, 109.81, 58.29, 55.23, 48.95, 42.91, 41.94, 31.38, 26.50, 21.95, 18.41. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>4</sub>O<sub>2</sub> 419.2442, found 419.2439.</div></div><div id="sec4_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> (<i>R</i>)-4-Bromo-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide</h3><div class="NLM_p last">To a stirred mixture of 4-bromo-2-fluorobenzoic acid (8.0 g, 36.5 mmol) in DMF (50 mL) was added 1-hydroxybenzotriazole hydrate (6.15 g, 40.2 mmol) and <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>â²-ethylcarbodiimide hydrochloride (7.70 g, 40.2 mmol) and the resulting mixture stirred at 20 Â°C for 15 min. <i>N</i>,<i>N</i>-Diisopropylethylamine (19 mL, 110 mmol) and (<i>R</i>)-1-(3-methoxyphenyl)ethanamine (5.52 g, 36.5 mmol) were then added and the mixture stirred at 20 Â°C overnight. The mixture was quenched with water (300 mL) and extracted with DCM (2 Ã 300 mL). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, evaporated to dryness, and purified on silica gel (0â10% MeOH/DCM as eluent). The fractions containing the desired compound were evaporated to dryness and dried in a vacuum oven at 55 Â°C overnight to afford the title compound (8.0 g, 61%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.52 min. MS <i>m</i>/<i>z</i>: 354.07 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.83 (d, <i>J</i> = 8.1, 1H), 7.67 (d, <i>J</i> = 9.9, 1H), 7.51 (t, <i>J</i> = 6.3, 2H), 7.25 (t, <i>J</i> = 8.1, 1H), 6.95 (d, <i>J</i> = 7.3, 2H), 6.87â6.74 (m, 1H), 5.07 (p, <i>J</i> = 7.1, 1H), 3.75 (d, <i>J</i> = 8.2, 3H), 1.41 (d, <i>J</i> = 7.0, 3H).</div></div><div id="sec4_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> (<i>R</i>)-<i>tert</i>-Butyl 4-(5-Bromo-2-(1-(3-methoxyphenyl)ethylcarbamoyl)phenylamino)butylcarbamate</h3><div class="NLM_p last">A mixture of (<i>R</i>)-4-bromo-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (1.44 g, 4.09 mmol), <i>tert</i>-butyl 4-aminobutylcarbamate (1.54 g, 8.18 mmol), DIPEA (2 mL, 11.45 mmol), and DMSO (10 mL) was stirred at 110 Â°C for overnight. The reaction was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> solution (20 mL), and the aqueous phase was extracted with ether (2 Ã 30 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and purified on silica gel (0â50% EtOAc/heptane as eluent). The fractions containing the desired compound were combined and dried under vacuum at RT for 1 h to afford the title compound (1.9 g, 89%) as white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.96 min. MS <i>m</i>/<i>z</i>: 523.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> (<i>R</i>)-<i>tert</i>-Butyl 4-(2-(1-(3-Methoxyphenyl)ethylcarbamoyl)-5-(pyrimidin-4-yl)phenylamino)butylcarbamate</h3><div class="NLM_p last">A mixture of potassium acetate (528 mg, 5.38 mmol), Pd(dppf) (110 mg, 0.13 mmol), 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) (342 mg, 1.34 mmol), (<i>R</i>)-<i>tert</i>-butyl 4-(5-bromo-2-(1-(3-methoxyphenyl)ethylcarbamoyl)phenylamino)butylcarbamate (700 mg, 1.34 mmol), and 1,4-dioxane (10 mL) was stirred at 65 Â°C for 3 h. Cesium carbonate (1.75 g, 5.38 mmol), PdCl<sub>2</sub>(dppf)âDCM adduct (110 mg, 0.13 mmol), 4-chloropyrimidine hydrochloride (203 mg, 1.34 mmol) (Medinorh), and water (4 mL) were each added sequentially in one portion. The mixture was stirred at 80 Â°C overnight then quenched with water (20 mL). The layers were separated and the aqueous layer extracted with DCM (2 Ã 250 mL). The combined organic were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and purified on silica gel (0â5% MeOH/DCM as eluent). The fractions containing the desired compound were combined, concentrated, and dried under vacuum at RT for 3 h to afford the title compound (270 mg, 36%) as sticky oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.54 min. MS <i>m</i>/<i>z</i>: 518.3 (M â H)<sup>â</sup>.</div></div><div id="sec4_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> (<i>R</i>)-2-((4-Aminobutyl)amino)-<i>N</i>-(1-(3-methoxyphenyl)ethyl)-4-(pyrimidin-4-yl)benzamide (<b>54</b>)</h3><div class="NLM_p last">A mixture of (<i>R</i>)-<i>tert</i>-butyl 4-(2-(1-(3-methoxyphenyl)ethylcarbamoyl)-5-(pyrimidin-4-yl)phenylamino)butylcarbamate (270 mg, 0.48 mmol) and TFA (2 mL, 26.0 mmol) in DCM (10 mL) was stirred at RT for 6 h. The reaction mixture was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> solution, and the aqueous phase was extracted with DCM (2 Ã 50 mL). The organic layers were combined, dried, (Na<sub>2</sub>SO<sub>4</sub>), filtered, concentrated, and purified on silica gel (DCM/MeOH/7 M NH<sub>3</sub> in MeOH 300/10/10 as eluent). The fractions containing the desired compound were combined evaporated to dryness and dried in a vacuum oven at 55 Â°C overnight to afford the title compound (181 mg, 90 mmol). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.68 min. MS <i>m</i>/<i>z</i>: 420.49 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.25 (1 H, s), 8.85 (1 H, d, <i>J</i> = 5.4), 8.73 (1 H, d, <i>J</i> = 7.9), 8.10 (1 H, d, <i>J</i> = 5.3), 7.82 (1 H, d, <i>J</i> = 8.2), 7.76 (1 H, t, <i>J</i> = 4.9), 7.45 (1 H, s), 7.37 (1 H, d, <i>J</i> = 8.2), 7.22 (1 H, t, <i>J</i> = 8.1), 6.98â6.92 (2 H, m), 6.83â6.74 (1 H, m), 5.11 (1 H, p, <i>J</i> = 7.1), 3.73 (3 H, s), 3.17 (2 H, q, <i>J</i> = 6.6), 2.56 (2 H, t, <i>J</i> = 6.8), 1.60 (2 H, p, <i>J</i> = 7.1), 1.48â1.37 (5 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 168.30, 162.83, 159.74, 159.14, 158.50, 150.09, 147.09, 139.71, 129.79, 129.73, 118.73, 118.07, 117.22, 112.90, 112.42, 112.23, 109.44, 55.43, 48.64, 42.71, 41.79, 31.25, 26.54, 22.72. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>30</sub>N<sub>5</sub>O<sub>2</sub> 420.23213, found 420.2327.</div></div><div id="sec4_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> 3-Propoxybenzaldehyde</h3><div class="NLM_p last">A mixture of 1-iodopropane (23.9 mL, 246 mmol), 3-hydroxybenzaldehyde (25.0 g, 205 mmol), and K<sub>2</sub>CO<sub>3</sub> (42.4 g, 307 mmol) in anhydrous DMF (82 mL) was stirred at RT for 18 h. TLC indicated starting material still remained and additional iodopropane (10.6 g; 82 mmol) was added and the reaction mixture stirred at RT for an additional 18 h. The reaction mixture was poured into water (500 mL) and extracted with EtOAc (3 Ã 90 mL). The combined organic layers were washed with 2.5 M NaOH (3 Ã 80 mL), water (4 Ã 90 mL), dried (MgSO<sub>4</sub>), filtered, evaporated to dryness, and dried in a vacuum oven at 60 Â°C to afford the title compound (31.3 g, 88%) as an orange oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.53 min. MS <i>m</i>/<i>z</i>: 165 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 9.98 (s, 1H), 7.51 (dd, <i>J</i> = 3.0, 5.3, 2H), 7.43â7.41 (m, 1H), 7.27 (dt, <i>J</i> = 2.5, 7.1, 1H), 4.01 (t, <i>J</i> = 6.5, 2H), 1.76 (dd, <i>J</i> = 6.6, 14.0, 2H), 0.99 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> (<i>S</i>,<i>E</i>)-2-Methyl-<i>N</i>-(3-propoxybenzylidene)propane-2-sulfinamide</h3><div class="NLM_p last">To a solution of (<i>S</i>)-2-methylpropane-2-sulfinamide (10.08 g, 83 mmol) and 3-propoxybenzaldehyde (13.0 g, 79 mmol) in THF (128 mL) was added tetraethoxytitanium (32.8 mL, 158 mmol). The mixture was stirred at RT overnight then poured into water (200 mL) and stirred for 30 min. The mixture was filtered through a Celite pad and the filter cake washed with EtOAc (3 Ã 100 mL). The layers were separated and the aqueous layer extracted with EtOAc (2 Ã 50 mL). The combined organic layers were washed with water (3 Ã 50 mL), dried (MgSO<sub>4</sub>), filtered, and solvent removed in vacuo to afford the title compound (20.3 g, 94%) as a yellow oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.63 min. MS <i>m</i>/<i>z</i>: 268.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 8.55 (s, 1H), 7.39 (dd, <i>J</i> = 3.0, 6.3, 2H), 7.08â7.04 (m, 1H), 3.98 (q, <i>J</i> = 6.3, 2H), 1.83 (dd, <i>J</i> = 6.9, 14.1, 2H), 1.27 (s, 9H), 1.06 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> (<i>S</i>)-2-Methyl-<i>N</i>-((<i>R</i>)-1-(3-propoxyphenyl)ethyl)propane-2-sulfinamide</h3><div class="NLM_p last">A mixture of (<i>S</i>,<i>E</i>)-2-methyl-<i>N</i>-(3-propoxybenzylidene)propane-2-sulfinamide (5.3 g, 19.82 mmol) in DCM (100 mL) was cooled to â45 Â°C in a dry ice/MeCN bath. Methylmagnesium bromide in diethyl ether (50 mL, 149 mmol) was added dropwise via syringe over 45 min to the solution and the resulting mixture stirred at â48 Â°C for 5 h. The mixture was allowed to warm slowly to RT and stirred overnight. The reaction was quenched with saturated NH<sub>4</sub>Cl slowly in an ice bath. The mixture was partitioned between EtOAc (50 mL) and water (50 mL), filtered, and layers separated. The aqueous layer was extracted with EtOAc (3 Ã 50 mL) and the combined organic layers dried (MgSO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that was purified on silica gel (0â50% EtOAc/heptane as eluent). The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (4.8 g, 85%) as an oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 2.37 min. MS <i>m</i>/<i>z</i>: 284.16 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 7.18 (t, <i>J</i> = 7.9, 1H), 6.88 (dd, <i>J</i> = 5.0, 9.3, 2H), 6.75 (dd, <i>J</i> = 2.1, 7.8, 1H), 5.28 (d, <i>J</i> = 5.3, 1H), 4.44â4.24 (m, 1H), 3.99â3.76 (m, 2H), 1.78â1.61 (m, 2H), 1.41 (d, <i>J</i> = 6.7, 3H), 1.15â1.06 (m, 9H), 0.95 (t, <i>J</i> = 7.4, 3H). Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, d): >99% de, positive (+) optical rotation.</div></div><div id="sec4_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> (<i>R</i>)-1-(3-Propoxyphenyl)ethan-1-amine Hydrochloride</h3><div class="NLM_p last">First, a 4 M hydrochloric acid in dioxane (13 mL, 50.8 mmol) was added in one portion to a solution of (<i>S</i>)-2-methyl-<i>N</i>-((<i>R</i>)-1-(3-propoxyphenyl)ethyl)propane-2-sulfinamide (4.8 g, 16.94 mmol) and MeOH (12 mL). The mixture was stirred at 20 Â°C for 30 min. Removal of solvent gave a residue that was triturated with ether to afford a solid that was collected by filtration. The solid was dried at 60 Â°C overnight in a vacuum oven to afford the title compound (3.18 g, 87%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method b): <i>R</i><sub>t</sub> = 1.48 min. MS <i>m</i>/<i>z</i>: 180.12 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.46 (s, 3H), 7.31 (t, <i>J</i> = 7.9, 1H), 7.15â7.11 (m, 1H), 7.04 (d, <i>J</i> = 7.8, 1H), 6.92 (dd, <i>J</i> = 2.2, 8.0, 1H), 4.33 (q, <i>J</i> = 6.8, 1H), 3.94 (t, <i>J</i> = 6.5, 2H), 1.80â1.67 (m, 2H), 1.49 (d, <i>J</i> = 6.8, 3H), 0.98 (t, <i>J</i> = 7.4, 3H). Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, e): >99% ee.</div></div><div id="sec4_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> (<i>R</i>)-4-Bromo-2-fluoro-<i>N</i>-(1-(3-propoxyphenyl)ethyl)benzamide</h3><div class="NLM_p last">HOBT (388 mg, 2.54 mmol) and EDC (486 mg, 2.54 mmol) were each added sequentially in one portion to a solution of 4-bromo-2-fluorobenzoic acid (509 mg, 2.325 mmol) in DMF (10 mL) and stirred at RT for 1 h, after which (<i>R</i>)-1-(3-propoxyphenyl)ethanamine hydrochloride (456 mg, 2.11 mmol) and DIPEA (1.1 mL, 6.34 mmol) were added. The reaction mixture was stirred at RT overnight and then quenched with water (20 mL). The aqueous phase was extracted with EtOAc (3 Ã 30 mL) and the combined organic layers washed with brine (30 mL), concentrated, and purified on silica gel (0â4 EtOAc/heptane as eluent The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (714 mg, 89%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.60 min. MS <i>m</i>/<i>z</i>: 380.06 (M + H)<sup>+</sup>.</div></div><div id="sec4_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> <i>tert</i>-Butyl (((<i>S</i>)-1-(5-Bromo-2-(((<i>R</i>)-1-(3-propoxyphenyl)ethyl)carbamoyl)phenyl)pyrrolidin-3-yl)methyl)carbamate</h3><div class="NLM_p last">A mixture of (<i>R</i>)-4-bromo-2-fluoro-<i>N</i>-(1-(3-propoxyphenyl)ethyl)benzamide (1.0 g, 2.63 mmol), (<i>R</i>)-<i>tert</i>-butyl pyrrolidin-3-ylmethylcarbamate (1.05 g, 5.26 mmol) (Astatech), <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (1.02 g, 7.89 mmol), and DMSO (20 mL) was stirred at 100 Â°C overnight. The reaction was quenched with water (20 mL) and extracted with ether (3 Ã 30 mL). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that was purified on silica gel (0â50% EtOAc/heptane as eluent). The fractions containing the desired compound were combined and evaporated to dryness and dried in a vacuum oven at 60 Â°C for 1 h to afford the title compound (1.4 g, 95%) as a white solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 3.03 min. MS <i>m</i>/<i>z</i>: 560.16 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO) Î´ 8.69 (d, <i>J</i> = 8.3, 1H), 7.22 (t, <i>J</i> = 7.8, 1H), 7.03 (d, <i>J</i> = 8.0, 1H), 6.93 (d, <i>J</i> = 7.6, 3H), 6.78 (ddd, <i>J</i> = 1.7, 9.1, 12.3, 3H), 5.10â4.97 (m, 1H), 3.91 (t, <i>J</i> = 6.5, 2H), 3.17 (dd, <i>J</i> = 8.3, 15.2, 3H), 2.86 (dd, <i>J</i> = 9.0, 16.3, 3H), 2.32â2.17 (m, 1H), 1.85 (dd, <i>J</i> = 5.9, 12.1, 1H), 1.80â1.66 (m, 2H), 1.52 (dd, <i>J</i> = 7.8, 12.2, 1H), 1.39 (d, <i>J</i> = 5.1, 12H), 0.98 (t, <i>J</i> = 7.4, 3H).</div></div><div id="sec4_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> <i>tert</i>-Butyl (((<i>S</i>)-1-(2-(((<i>R</i>)-1-(3-Propoxyphenyl)ethyl)carbamoyl)-5-(pyrimidin-4-yl)phenyl)pyrrolidin-3-yl)methyl)carbamate</h3><div class="NLM_p last">A mixture of potassium acetate (273 mg, 2.78 mmol), <i>tert</i>-butyl ((<i>S</i>)-1-(5-bromo-2-((<i>R</i>)-1-(3-propoxyphenyl)ethylcarbamoyl)phenyl)pyrrolidin-3-yl)methylcarbamate (390 mg, 0.70 mmol), Pd(dppf) (56.8 mg, 0.07 mmol), 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) (177 mg, 0.70 mmol), and 1,4-dioxane (10 mL) was stirred at 60 Â°C for 2 h. Cesium carbonate (907 mg, 2.78 mmol), PdCl<sub>2</sub>(dppf)âDCM adduct (57 mg, 0.07 mmol), 4-chloropyrimidine hydrochloride (105 mg, 0.70 mmol), and water (2 mL) were then each added sequentially and the mixture stirred at 80 Â°C overnight. The reaction mixture was quenched with water (20 mL) and the aqueous layer extracted with DCM (2 Ã 250 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to afford a residue that was purified on silica gel. The fractions containing the desired compound were combined and evaporated to dryness to afford the title compound (160 mg, 41%) as an oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.66 min. MS <i>m</i>/<i>z</i>: 560.8 (M + H)<sup>+</sup>.</div></div><div id="sec4_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> 2-((<i>S</i>)-3-(Aminomethyl)pyrrolidin-1-yl)-<i>N</i>-((<i>R</i>)-1-(3-propoxyphenyl)ethyl)-4-(pyrimidin-4-yl)benzamide (<b>55</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((<i>S</i>)-1-(2-((<i>R</i>)-1-(3-propoxyphenyl)ethylcarbamoyl)-5-(pyrimidin-4-yl)phenyl)pyrrolidin-3-yl)methylcarbamate (160 mg, 0.29 mmol) in DCM (10 mL) was cooled to 0 Â°C in an ice bath. TFA (0.4 mL, 5.19 mmol) was added dropwise and the mixture stirred at about RT overnight. The reaction mixture was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> (50 mL) and the aqueous layer extracted with DCM (2 Ã 50 mL). The combined organic were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that was purified on silica gel (DCM/MeOH/7 M NH<sub>3</sub> in MeOH 300/10/5 as eluent). The fractions containing the desired compound were combined and evaporated to dryness then dried in a vacuum oven at 60 Â°C overnight to afford the title compound (93 mg, 72%) as a solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.76 min. MS <i>m</i>/<i>z</i>: 458.3 (M â H)<sup>â</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.22 (1 H, s), 8.82 (1 H, d, <i>J</i> = 5.4), 8.76 (1 H, d, <i>J</i> = 8.3), 8.05 (1 H, d, <i>J</i> = 4.5), 7.48 (1 H, s), 7.44 (1 H, d, <i>J</i> = 7.9), 7.26 (1 H, d, <i>J</i> = 7.9), 7.22 (1 H, t, <i>J</i> = 7.9), 6.99â6.91 (2 H, m), 6.78 (1 H, dd, <i>J</i> = 8.1, 2.0), 5.11â5.03 (1 H, m), 3.91 (2 H, t, <i>J</i> = 6.5), 3.32â3.19 (3 H, m), 2.96 (1 H, dd, <i>J</i> = 16.8, 9.5), 2.22â2.06 (1 H, m), 1.96â1.82 (1 H, m), 1.72 (2 H, h, <i>J</i> = 7.1), 1.62â1.50 (1 H, m), 1.40 (3 H, d, <i>J</i> = 7.0), 0.97 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 168.97, 163.12, 159.16, 159.12, 158.38, 146.58, 146.56, 137.44, 130.30, 129.68, 126.36, 118.81, 117.82, 114.40, 112.94, 112.22, 69.27, 53.71, 49.30, 48.72, 45.02, 42.04, 29.22, 22.72, 22.54, 10.89. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>2</sub> 460.26343, found 460.26348. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, g): 95% ee, positive (+) optical rotation.</div></div><div id="sec4_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> <i>tert</i>-Butyl (((<i>R</i>)-1-(5-Bromo-2-(((<i>R</i>)-1-(3-propoxyphenyl)ethyl)carbamoyl)phenyl)pyrrolidin-3-yl)methyl)carbamate</h3><div class="NLM_p last">A mixture of <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (1.06 g, 8.21 mmol), (<i>S</i>)-<i>tert</i>-butyl pyrrolidin-3-ylmethylcarbamate (1.0 g, 4.99 mmol), (<i>R</i>)-4-bromo-2-fluoro-<i>N</i>-(1-(3-propoxyphenyl)ethyl)benzamide (1.04 g, 2.74 mmol). and DMSO (20 mL) was stirred at 100 Â°C for 48 h then quenched with water (20 mL). The aqueous phase was extracted with ether (2 Ã 80 mL) and the combined organic layers dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated to dryness. and purified on silica gel (0â50% EtOAc/heptane as eluent). The fractions containing the desired compound were evaporated to dryness to afford the title compound (0.9 g, 59%) as a solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 3.01 min. MS <i>m</i>/<i>z</i>: 562.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> <i>tert</i>-Butyl (((<i>R</i>)-1-(2-(((<i>R</i>)-1-(3-Propoxyphenyl)ethyl)carbamoyl)-5-(pyrimidin-4-yl)phenyl)pyrrolidin-3-yl)methyl)carbamate</h3><div class="NLM_p last">A mixture of potassium acetate (273 mg, 2.78 mmol), 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) (177 mg, 0.70 mmol), <i>tert</i>-butyl ((<i>R</i>)-1-(5-bromo-2-((<i>R</i>)-1-(3-propoxyphenyl)ethylcarbamoyl)phenyl)pyrrolidin-3-yl)methylcarbamate (390 mg, 0.70 mmol), Pd(dppf) (56.8 mg, 0.070 mmol), and 1,4-dioxane (10 mL) was stirred at 65 Â°C for 2 h. Cesium carbonate (907 mg, 2.78 mmol), PdCl<sub>2</sub>(dppf)âDCM adduct (56.8 mg, 0.07 mmol), 4-chloropyrimidine hydrochloride (105 mg, 0.70 mmol), and water (94 mL) were then each added sequentially and the mixture stirred at 80 Â°C for overnight. The reaction mixture was quenched with water (20 mL) and the aqueous layer extracted with DCM (2 Ã 250 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that was purified on silica gel (0â100 EtOAc/DCM as eluent). The fractions containing the desired compound were evaporated to dryness and dried in vacuum oven at RT for 2 h to afford the title compound (180 mg, 46%) as yellow solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.67 min. MS <i>m</i>/<i>z</i>: 560.8 (M + H)<sup>+</sup>.</div></div><div id="sec4_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> 2-((<i>R</i>)-3-(Aminomethyl)pyrrolidin-1-yl)-<i>N</i>-((<i>R</i>)-1-(3-propoxyphenyl)ethyl)-4-(pyrimidin-4-yl)benzamide (<b>56</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((<i>R</i>)-1-(2-((<i>R</i>)-1-(3-propoxyphenyl)ethylcarbamoyl)-5-(pyrimidin-4-yl)phenyl)pyrrolidin-3-yl)methylcarbamate (180 mg, 0.32 mmol) and DCM (10 mL) was cooled to 0 Â°C in an ice bath. TFA (0.4 mL, 5.19 mmol) was added dropwise and the mixture stirred at RT overnight. The mixture was partitioned between DCM (20 mL) and 1 M HCl (20 mL). The aqueous layer was adjusted to pH 9 with saturated Na<sub>2</sub>CO<sub>3</sub> and extracted with DCM (2 Ã 50 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that was purified on silica gel (DCM/MeOH/7 M NH<sub>3</sub> in MeOH 300/10/5 as eluent). The fractions containing the desired compound were evaporated to dryness and dried in vacuum oven at 60 Â°C overnight to afford the title compound (100 mg, 68%) as a solid. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.76 min. MS <i>m</i>/<i>z</i>: 460.3 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.22 (1 H, s), 8.82 (1 H, d, <i>J</i> = 5.4), 8.77 (1 H, d, <i>J</i> = 8.2), 8.05 (1 H, d, <i>J</i> = 5.0), 7.47 (1 H, s), 7.44 (1 H, d, <i>J</i> = 7.8), 7.28 (1 H, d, <i>J</i> = 7.9), 7.20 (1 H, t, <i>J</i> = 7.8), 6.97â6.89 (2 H, m), 6.77 (1 H, dd, <i>J</i> = 7.9, 2.0), 5.04 (1 H, p, <i>J</i> = 7.0), 3.89 (2 H, t, <i>J</i> = 6.5), 3.27â3.14 (3 H, m), 3.00â2.92 (1 H, m), 2.49â2.44 (2 H, m), 2.15â2.04 (1 H, m), 1.88 (1 H, d, <i>J</i> = 5.8), 1.71 (2 H, h, <i>J</i> = 6.9), 1.49 (1 H, dd, <i>J</i> = 11.9, 8.3), 1.41 (3 H, d, <i>J</i> = 7.0), 0.96 (3 H, t, <i>J</i> = 7.4). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 168.96, 163.13, 159.12, 158.38, 146.60, 146.58, 137.45, 130.37, 129.60, 126.28, 118.83, 117.82, 114.36, 112.92, 112.90, 112.18, 69.26, 53.61, 49.43, 48.85, 44.90, 42.05, 29.31, 22.70, 22.54, 10.89. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>2</sub> 460.26343, found 460.26301. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, g): 90% ee, negative (â) optical rotation</div></div><div id="sec4_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> <i>tert</i>-Butyl ((1-(5-Bromo-2-(((<i>R</i>)-1-(3-methoxyphenyl)ethyl)carbamoyl)phenyl)piperidin-3-yl)methyl)carbamate</h3><div class="NLM_p last">A mixture of <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (550 mg, 4.26 mmol), <i>tert</i>-butyl piperidin-3-ylmethylcarbamate (608 mg, 2.84 mmol), (<i>R</i>)-4-bromo-2-fluoro-<i>N</i>-(1-(3-methoxyphenyl)ethyl)benzamide (500 mg, 1.42 mmol), and DMSO (10 mL) was stirred at 110 Â°C overnight. The reaction mixture was quenched with water (30 mL) and extracted with ether (2 Ã 50 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that purified on silica gel (0â50% EtOAc/heptane as eluent). The fractions containing the desired compound were evaporated to dryness and dried in a vacuum oven at RT for 1 h to afford the title compound (0.76 g, 98%) as a sticky oil. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 2.47 min. MS <i>m</i>/<i>z</i>: 549.0 (M + H)<sup>+</sup>. <i>tert</i>-Butyl (((<i>R</i>)-1-(2-(((<i>R</i>)-1-(3-methoxyphenyl)ethyl)carbamoyl)-5-(pyrimidin-4-yl)phenyl)piperidin-3-yl)methyl)carbamate and <i>tert</i>-butyl (((<i>S</i>)-1-(2-(((<i>R</i>)-1-(3-methoxyphenyl)ethyl)carbamoyl)-5-(pyrimidin-4-yl)phenyl)piperidin-3-yl)methyl)carbamate. A mixture of 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane) (353 mg, 1.39 mmol), potassium acetate (546 mg, 5.56 mmol), Pd(dppf) (114 mg, 0.14 mmol), <i>tert</i>-butyl (1-(5-bromo-2-((<i>R</i>)-1-(3-methoxyphenyl)ethylcarbamoyl)phenyl)piperidin-3-yl)methylcarbamate (760 mg, 1.39 mmol), and 1,4-dioxane (60 mL) was stirred at 65 Â°C for 3 h. Cesium carbonate (1.8 g, 5.56 mmol), PdCl<sub>2</sub>(dppf)âDCM adduct (114 mg, 0.14 mmol), 4-chloropyrimidine hydrochloride (210 mg, 1.39 mmol), and water (4 mL) were then added and the mixture stirred at 80 Â°C overnight. The mixture was quenched with water (30 mL) and extracted with DCM (2 Ã 250 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that purified on silica gel (0â5% MeOH/DCM as eluent). The fractions containing the desired compound were evaporated to dryness and dried in a vacuum oven at 60 Â°C for 48 h to afford a residue that was purified by chiral HPLC. Chiral separation details and analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, f). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.63 min. MS <i>m</i>/<i>z</i>: 446.6 (M + H)<sup>+</sup>. LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.63 min. MS <i>m</i>/<i>z</i>: 446.6 (M + H)<sup>+</sup>.</div></div><div id="sec4_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> 2-((<i>R</i>)-3-(Aminomethyl)piperidin-1-yl)-<i>N</i>-((<i>R</i>)-1-(3-methoxyphenyl)ethyl)-4-(pyrimidin-4-yl)benzamide (<b>57</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((<i>R</i>)-1-(2-((<i>R</i>)-1-(3-methoxyphenyl)ethylcarbamoyl)-5-(pyrimidin-4-yl)phenyl)piperidin-3-yl)methylcarbamate (115 mg, 0.211 mmol) (rotation (â), >99%ee), TFA (0.5 mL, 6.49 mmol), and DCM (5 mL) was stirred at RT overnight. The mixture was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> (20 mL) and extracted with DCM (2 Ã 60 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that purified by HPLC (21.2 mm Ã 250 mm Hypersil C<sub>18</sub> HS column (8 Î¼M particles, gradient 0â80% B over 35 min, 20 mL/min flow rate, mobile phase A 0.05 M aqueous ammonium acetate buffer (pH 4.5), and mobile phase B MeCN). The fractions containing the desired compound were evaporated to dryness and partitioned between saturated Na<sub>2</sub>CO<sub>3</sub> (20 mL) and DCM (20 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated to dryness, and dried in a vacuum oven at 60 Â°C overnight to afford the title compound (54 mg, 57%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.63 min. MS <i>m</i>/<i>z</i>: 446.65 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.09 (1 H, d, <i>J</i> = 7.8), 9.26 (1 H, s), 8.88 (1 H, d, <i>J</i> = 5.4), 8.15 (1 H, d, <i>J</i> = 6.6), 8.11 (1 H, d, <i>J</i> = 11.4), 8.01â7.89 (2 H, m), 7.26 (1 H, t, <i>J</i> = 7.9), 7.02â6.92 (2 H, m), 6.86â6.79 (1 H, m), 5.16â5.07 (1 H, m), 3.73 (3 H, s), 3.16 (1 H, d, <i>J</i> = 11.6), 3.09 (1 H, d, <i>J</i> = 10.8), 2.74 (1 H, t, <i>J</i> = 10.4), 2.47â2.25 (3 H, m), 1.75â1.64 (2 H, m), 1.49 (4 H, d, <i>J</i> = 6.9), 1.32â1.15 (1 H, m), 1.15â0.87 (1 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 164.99, 162.13, 159.90, 159.22, 158.69, 153.12, 146.12, 139.20, 131.29, 131.21, 129.99, 122.65, 120.01, 118.92, 118.08, 112.69, 112.66, 58.07, 55.49, 54.19, 49.04, 46.08, 40.01, 28.06, 25.59, 22.62. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>32</sub>N<sub>5</sub>O<sub>2</sub> 446.24778, found 446.24798. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, h): >99% ee, negative (â) optical rotation.</div></div><div id="sec4_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> 2-((<i>S</i>)-3-(Aminomethyl)piperidin-1-yl)-<i>N</i>-((<i>R</i>)-1-(3-methoxyphenyl)ethyl)-4-(pyrimidin-4-yl)benzamide (<b>58</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl ((<i>S</i>)-1-(2-((<i>R</i>)-1-(3-methoxyphenyl)ethylcarbamoyl)-5-(pyrimidin-4-yl)phenyl)piperidin-3-yl)methylcarbamate (114 mg, 0.209 mmol) (rotation (+), >99%ee), TFA (0.5 mL, 6.49 mmol), and DCM (5 mL) was stirred at RT overnight. The mixture was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> (20 mL) extracted with DCM (2 Ã 60 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to dryness to afford a residue that purified by HPLC (21.2 mm Ã 250 mm Hypersil C<sub>18</sub> HS column (8 Î¼M particles), gradient 0â80% B over 35 min (20 mL/min flow rate), mobile phase A 0.05 M aqueous ammonium acetate buffer (pH 4.5), and mobile phase B MeCN). The fractions containing the desired compound were evaporated to dryness and partitioned between saturated Na<sub>2</sub>CO<sub>3</sub> (20 mL) and DCM (20 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, evaporated to dryness, and dried in a vacuum oven at 60 Â°C overnight to afford the title compound (52 mg, 56%). LCMS (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, method c): <i>R</i><sub>t</sub> = 1.65 min. MS <i>m</i>/<i>z</i>: 446.65 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.12 (1 H, d, <i>J</i> = 7.5), 9.26 (1 H, s), 8.88 (1 H, d, <i>J</i> = 5.4), 8.18â8.07 (2 H, m), 8.02â7.86 (2 H, m), 7.30â7.18 (1 H, m), 7.01â6.93 (2 H, m), 6.86â6.79 (1 H, m), 5.15â5.07 (1 H, m), 3.76â3.67 (4 H, m), 3.30â3.20 (1 H, m), 3.02 (1 H, d, <i>J</i> = 12.3), 2.74â2.63 (1 H, m), 2.59â2.37 (7 H, m), 1.67â1.55 (3 H, m), 1.50 (3 H, d, <i>J</i> = 6.9), 1.30â1.16 (1 H, m), 1.06â0.92 (1 H, m). <sup>13</sup>C NMR (101 MHz, DMSO) Î´ 164.96, 162.12, 159.90, 159.22, 158.69, 153.14, 146.10, 139.23, 131.30, 131.23, 129.99, 122.75, 120.15, 118.88, 118.08, 112.74, 112.50, 57.54, 55.47, 54.79, 49.06, 45.97, 40.12, 28.07, 25.19, 22.82. HRMS (ESI/Q-TOF) <i>m</i>/<i>z</i>: [M + H]<sub>+</sub> calcd for C<sub>26</sub>H<sub>32</sub>N<sub>5</sub>O<sub>2</sub> 446.24778, found 446.24776. Chiral analysis (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, h): >99% ee, positive (+) optical rotation.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01098" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01098" class="ext-link">10.1021/acs.jmedchem.8b01098</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HTRF assay protocol; optic nerve crush model protocol; kinome panel protocol and data; PK protocol and curves for compound <b>16</b>; MYPT1 cell assay protocol; crystallization methods and X-ray crystallography diffraction statistics for compound <b>12</b> in ROCK1, ROCK2, and PKA; X-ray crystallography diffraction statistics for compound <b>47</b> in PKA; <sup>1</sup>H NMR for compounds <b>12</b>, <b>16</b>, <b>43</b>, <b>44</b>, <b>54</b>, and <b>56</b>; <sup>13</sup>C NMR for compounds <b>12</b>, <b>16</b>, <b>43</b>, <b>44</b>, <b>54</b>, and <b>56</b>; <sup>19</sup>F NMR for compounds <b>12</b> and <b>43</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_001.pdf">jm8b01098_si_001.pdf (1.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_002.csv">jm8b01098_si_002.csv (4.13 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes: <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a, compound <b>12</b>, in active site of PKA, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9L">6E9L</a>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b, compound <b>12</b>, in active site of ROCK1, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9W">6E9W</a>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c, compound <b>12</b>, in active site of ROCK2, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ED6">6ED6</a>; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>47</b>, in active site of PKA, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E99">6E99</a>. Structures for ROCK1, ROCK2, and PKA with compound <b>12</b> and PKA with compound <b>47</b> have been deposited in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b01098" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81707" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81707" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian D. Hobson</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3948-0577" title="Orcid link">http://orcid.org/0000-0003-3948-0577</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#640500160d050a4a0c0b06170b0a24050606120d014a070b09"><span class="__cf_email__" data-cfemail="b8d9dccad1d9d696d0d7dacbd7d6f8d9dadaced1dd96dbd7d5">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Russell A. Judge</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana L. Aguirre</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian S. Brown</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifang Cui</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ping Ding</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span>;Â 
    <span>Present Address:
                        For P.D.: DowDupont, 455 Forest Street, Marlborough, Massachusetts 01752, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Dominguez</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Enrico DiGiammarino</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Egan</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gail M. Freiberg</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sujatha M. Gopalakrishnan</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher M. Harris</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie P. Honore</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen L. Kage</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span>;Â 
    <span>Present Address:
                        For K.L.K.: Altor Bioscience, 2810 North Commerce Parkway, Miramar, Florida 33025, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicolas J. Kapecki</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Ling</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junli Ma</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helmut Mack</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mulugeta Mamo</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span>;Â 
    <span>Present Address:
                        For M.M.: Novartis Institute for Biomedical Research, 4560 Horton Street, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Maurus</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bradford McRae</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nigel S. Moore</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernhard K. Mueller</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</span>;Â 
    <span>Present Address:
                        For B.K.M.: Swiss ReGen Therapeutics, 8404 Winterthur, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reinhold Mueller</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Deutschland GmbH & Co. KG, Knollstrasse 50, 67061, Ludwigshafen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marian T. Namovic</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kaushal Patel</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve D. Pratt</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">C. Brent Putman</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kara L. Queeney</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathy K. Sarris</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa M. Schaffter</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincent Stoll</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anil Vasudevan</span> - <span class="hlFld-Affiliation affiliation">AbbVie,
Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0004-0497" title="Orcid link">http://orcid.org/0000-0002-0004-0497</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Wang</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lu Wang</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Wirthl</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kimberly Yach</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">Animal Welfare: All animal experiments performed in the manuscript were conducted in compliance with institutional guidelines.<br /></br>The authors declare the following competing financial interest(s): Authors A.D.H., R.A.J., A.L.A., B.B., Y.C., P.D., E. Dominguez, E. DiGiammarino, D.A.E., G.M.F., S.M.G., C.M.H., M.P.H., K.L.K., N.J.K., C.L., J.M., H.M., M.M., S.M., B.M., N.S.M., B.K.M., R.M., M.T.N., K.P., S.D.P., C.B.P., K.L.Q., K.K.S., L.M.S., V.S., A.V., Lei Wang, Lu Wang, W.W., and K.Y. are/were employees of AbbVie (or Abbott Laboratories prior to separation) and may own AbbVie/Abbott stocks or stock options and participated in the interpretation of data, review, and approval of the publication.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i128">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">X-ray diffraction data were collected at the beamlines in the facilities of the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) and the Life Sciences Collaborative Access Team (LS-CAT) at the Advanced Photon Source, Argonne, IL. The financial support for this work was provided by AbbVie.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ALARM NMR</td><td class="NLM_def"><p class="first last">a La assay to detect reactive molecules by nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BEI</td><td class="NLM_def"><p class="first last">binding efficiency index</p></td></tr><tr><td class="NLM_term">tBuXPhos</td><td class="NLM_def"><p class="first last">2-di<i>tert</i>-butylphosphino-2â²,4â²,6â²-triisopropylbiphenyl</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EDAC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">Fsp<sup>3</sup></td><td class="NLM_def"><p class="first last">fraction sp<sub>3</sub> carbon</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term">HT-ADME</td><td class="NLM_def"><p class="first last">high throughput absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">HTC</td><td class="NLM_def"><p class="first last">high throughput chemistry</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screen</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography mass spectrometry</p></td></tr><tr><td class="NLM_term">NAR</td><td class="NLM_def"><p class="first last">number of aromatic rings</p></td></tr><tr><td class="NLM_term">O/N</td><td class="NLM_def"><p class="first last">overnight</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last">tris(dibenzylideneacetone)dipalladium(0)</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">PS-DCC</td><td class="NLM_def"><p class="first last">polymer supported dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">NRB</td><td class="NLM_def"><p class="first last">number of rotatable bonds</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60860" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60860" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakafuku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span> <span> </span><span class="NLM_article-title">Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2208</span>â <span class="NLM_lpage">2216</span>, <span class="refDoi">Â DOI: 10.1002/j.1460-2075.1996.tb00574.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1002%2Fj.1460-2075.1996.tb00574.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=2208-2216&author=T.+Matsuiauthor=M.+Amanoauthor=T.+Yamamotoauthor=K.+Chiharaauthor=M.+Nakafukuauthor=M.+Itoauthor=T.+Nakanoauthor=K.+Okawaauthor=A.+Iwamatsuauthor=K.+Kaibuchi&title=Rho-associated+kinase%2C+a+novel+serine%2Fthreonine+kinase%2C+as+a+putative+target+for+small+GTP+binding+protein+Rho&doi=10.1002%2Fj.1460-2075.1996.tb00574.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb00574.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb00574.x%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DChihara%26aufirst%3DK.%26aulast%3DNakafuku%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DOkawa%26aufirst%3DK.%26aulast%3DIwamatsu%26aufirst%3DA.%26aulast%3DKaibuchi%26aufirst%3DK.%26atitle%3DRho-associated%2520kinase%252C%2520a%2520novel%2520serine%252Fthreonine%2520kinase%252C%2520as%2520a%2520putative%2520target%2520for%2520small%2520GTP%2520binding%2520protein%2520Rho%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D2208%26epage%3D2216%26doi%3D10.1002%2Fj.1460-2075.1996.tb00574.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narumiya, S.</span></span> <span> </span><span class="NLM_article-title">ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">193</span>, <span class="refDoi">Â DOI: 10.1016/0014-5793(96)00811-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2F0014-5793%2896%2900811-3" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=1996&pages=189-193&author=O.+Nakagawaauthor=K.+Fujisawaauthor=T.+Ishizakiauthor=Y.+Saitoauthor=K.+Nakaoauthor=S.+Narumiya&title=ROCK-I+and+ROCK-II%2C+two+isoforms+of+Rho-associated+coiled-coil+forming+protein+serine%2Fthreonine+kinase+in+mice&doi=10.1016%2F0014-5793%2896%2900811-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2896%2900811-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252896%252900811-3%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DO.%26aulast%3DFujisawa%26aufirst%3DK.%26aulast%3DIshizaki%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DNakao%26aufirst%3DK.%26aulast%3DNarumiya%26aufirst%3DS.%26atitle%3DROCK-I%2520and%2520ROCK-II%252C%2520two%2520isoforms%2520of%2520Rho-associated%2520coiled-coil%2520forming%2520protein%2520serine%252Fthreonine%2520kinase%2520in%2520mice%26jtitle%3DFEBS%2520Lett.%26date%3D1996%26volume%3D392%26spage%3D189%26epage%3D193%26doi%3D10.1016%2F0014-5793%2896%2900811-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manser, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span> <span> </span><span class="NLM_article-title">The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5313</span>â <span class="NLM_lpage">5127</span>, <span class="refDoi">Â DOI: 10.1128/MCB.16.10.5313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1128%2FMCB.16.10.5313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=8816443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADyaK28XlvFamt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=5313-5127&author=T.+Leungauthor=X.+Q.+Chenauthor=E.+Manserauthor=L.+Lim&title=The+p160+RhoA-binding+kinase+ROK+alpha+is+a+member+of+a+kinase+family+and+is+involved+in+the+reorganization+of+the+cytoskeleton&doi=10.1128%2FMCB.16.10.5313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The p160 RhoA-binding kinase ROKÎ± is a member of a kinase family and is involved in the reorganization of the cytoskeleton</span></div><div class="casAuthors">Leung, Thomas; Chen, Xiang-Qun; Manser, Edward; Lim, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5313-5327</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The GTPase RhoA has been implicated in various cellular activity, including the formation of stress fiber,s motility, and cytokinesis.  We recently reported on a p150 serine/threonine kinase (termed ROKÎ±) binding RhoA only in its active GTP-bound state and on its cDNA; introduction of RhoA into HeLa cells resulted in translocation of the cytoplasmic kinase to plasma membranes, consistent with ROKÎ± being a target for RhoA (T. Leung, E. Manser, L. Tan, and L. Lim, J. Biol. Chem. 256:29051-29054, 1995).  Reanal. of the cDNA revealed that ROKÎ± contains an addnl. N-terminal region.  We also isolated another cDNA which encoded a protein (ROKÎ²) with 90% identity of ROKÎ± in the kinase domain.  Both ROKÎ± and ROKÎ², which has a mol. mass of 160 kDa, contained a highly conserved cysteine/histidine-rich domain located within a putative pleckstrin homol. domain.  The kinases bound Rho, RhoB, and RhoC but not Rac1 and Cdc42.  The Rho-binding domain comprises about 30 amino acids.  Mutations within this domain caused partial or complete loss of Rho binding.  The morphol. effects of ROKÎ± were investigated by microinjecting HeLa cells with DNA constructs encoding various forms of ROKÎ±.  Full-length ROKÎ± promoted formation of stress fibers and focal adhesion complexes, consistent with its being an effector of RhoA.  ROKÎ± truncated at the C terminus promoted this formation and also extensive condensation of actin microfilaments and nuclear disruption.  The proteins exhibited protein kinase activity which was required for stress fiber formation; the kinase-dead ROKÎ±K112A and N-terminally truncated mutants showed no such promotion.  The latter mutant instead induced disassembly of stress fibers and focal adhesion complexes, accompanied by cell spreading.  These effects were mediated by the C-terminal region contg. Rho-binding, cysteine/histidine-rich, and pleckstrin homol. domains.  Thus, the multidomained ROKÎ± appears to be involved in reorganization of the cytoskeleton, with the N and C termini acting as pos. and neg. regulators, resp., of the kinase domain whose activity is crucial for formation of stress fibers and focal adhesion complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojaok4XDTUh7Vg90H21EOLACvtfcHk0ljBqFeSryEu2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvFamt7g%253D&md5=ff30cf0f5819581e9d74001197154a25</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.10.5313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.10.5313%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%2BQ.%26aulast%3DManser%26aufirst%3DE.%26aulast%3DLim%26aufirst%3DL.%26atitle%3DThe%2520p160%2520RhoA-binding%2520kinase%2520ROK%2520alpha%2520is%2520a%2520member%2520of%2520a%2520kinase%2520family%2520and%2520is%2520involved%2520in%2520the%2520reorganization%2520of%2520the%2520cytoskeleton%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D5313%26epage%3D5127%26doi%3D10.1128%2FMCB.16.10.5313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manser, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span> <span> </span><span class="NLM_article-title">A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">29051</span>â <span class="NLM_lpage">29054</span>, <span class="refDoi">Â DOI: 10.1074/jbc.270.49.29051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1074%2Fjbc.270.49.29051" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=29051-29054&author=T.+Leungauthor=E.+Manserauthor=L.+Tanauthor=L.+Lim&title=A+novel+serine%2Fthreonine+kinase+binding+the+Ras-related+RhoA+GTPase+which+translocates+the+kinase+to+peripheral+membranes&doi=10.1074%2Fjbc.270.49.29051"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.49.29051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.49.29051%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DT.%26aulast%3DManser%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DLim%26aufirst%3DL.%26atitle%3DA%2520novel%2520serine%252Fthreonine%2520kinase%2520binding%2520the%2520Ras-related%2520RhoA%2520GTPase%2520which%2520translocates%2520the%2520kinase%2520to%2520peripheral%2520membranes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D29051%26epage%3D29054%26doi%3D10.1074%2Fjbc.270.49.29051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakafuku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span> <span> </span><span class="NLM_article-title">Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">248</span>, <span class="refDoi">Â DOI: 10.1126/science.273.5272.245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1126%2Fscience.273.5272.245" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=245-248&author=K.+Kimuraauthor=M.+Itoauthor=M.+Amanoauthor=K.+Chiharaauthor=Y.+Fukataauthor=M.+Nakafukuauthor=B.+Yamamoriauthor=J.+Fengauthor=T.+Nakanoauthor=K.+Okawaauthor=A.+Iwamatsuauthor=K.+Kaibuchi&title=Regulation+of+myosin+phosphatase+by+Rho+and+Rho-associated+kinase+%28Rho-kinase%29&doi=10.1126%2Fscience.273.5272.245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.245%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DChihara%26aufirst%3DK.%26aulast%3DFukata%26aufirst%3DY.%26aulast%3DNakafuku%26aufirst%3DM.%26aulast%3DYamamori%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DOkawa%26aufirst%3DK.%26aulast%3DIwamatsu%26aufirst%3DA.%26aulast%3DKaibuchi%26aufirst%3DK.%26atitle%3DRegulation%2520of%2520myosin%2520phosphatase%2520by%2520Rho%2520and%2520Rho-associated%2520kinase%2520%2528Rho-kinase%2529%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D245%26epage%3D248%26doi%3D10.1126%2Fscience.273.5272.245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span> <span> </span><span class="NLM_article-title">Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">670</span>â <span class="NLM_lpage">676</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M007074200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1074%2Fjbc.M007074200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=670-676&author=T.+Sumiauthor=K.+Matsumotoauthor=T.+Nakamura&title=Specific+activation+of+LIM+kinase+2+via+phosphorylation+of+threonine+505+by+ROCK%2C+a+Rho-dependent+protein+kinase&doi=10.1074%2Fjbc.M007074200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M007074200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M007074200%26sid%3Dliteratum%253Aachs%26aulast%3DSumi%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DSpecific%2520activation%2520of%2520LIM%2520kinase%25202%2520via%2520phosphorylation%2520of%2520threonine%2520505%2520by%2520ROCK%252C%2520a%2520Rho-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D670%26epage%3D676%26doi%3D10.1074%2Fjbc.M007074200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">361</span>, <span class="refDoi">Â DOI: 10.1083/jcb.145.2.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1083%2Fjcb.145.2.347" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1999&pages=347-361&author=Y.+Fukataauthor=N.+Oshiroauthor=N.+Kinoshitaauthor=Y.+Kawanoauthor=Y.+Matsuokaauthor=V.+Bennettauthor=Y.+Matsuuraauthor=K.+Kaibuchi&title=Phosphorylation+of+adducin+by+Rho-kinase+plays+a+crucial+role+in+cell+motility&doi=10.1083%2Fjcb.145.2.347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1083%2Fjcb.145.2.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.145.2.347%26sid%3Dliteratum%253Aachs%26aulast%3DFukata%26aufirst%3DY.%26aulast%3DOshiro%26aufirst%3DN.%26aulast%3DKinoshita%26aufirst%3DN.%26aulast%3DKawano%26aufirst%3DY.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DBennett%26aufirst%3DV.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DKaibuchi%26aufirst%3DK.%26atitle%3DPhosphorylation%2520of%2520adducin%2520by%2520Rho-kinase%2520plays%2520a%2520crucial%2520role%2520in%2520cell%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1999%26volume%3D145%26spage%3D347%26epage%3D361%26doi%3D10.1083%2Fjcb.145.2.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, T. C.</span></span> <span> </span><span class="NLM_article-title">Rho kinase activates ezrin-radixin-moesin (ERM) proteins and mediates their function in cortical neuron growth, morphology and motility in vitro</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">46</span>, <span class="refDoi">Â DOI: 10.1002/jnr.21102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1002%2Fjnr.21102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17075902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVyhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2007&pages=34-46&author=M.+A.+Haasauthor=J.+C.+Vickersauthor=T.+C.+Dickson&title=Rho+kinase+activates+ezrin-radixin-moesin+%28ERM%29+proteins+and+mediates+their+function+in+cortical+neuron+growth%2C+morphology+and+motility+in+vitro&doi=10.1002%2Fjnr.21102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase activates ezrin-radixin-moesin (ERM) proteins and mediates their function in cortical neuron growth, morphology and motility in vitro</span></div><div class="casAuthors">Haas, Matilda A.; Vickers, James C.; Dickson, Tracey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-46</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ezrin-radixin-moesin (ERM) family of proteins contribute to cytoskeletal processes underlying many vital cellular functions.  Their previously elucidated roles in non-neuronal cells are an indication of their potential importance in CNS neurons.  The specific mechanisms of their activation are unknown, but are likely to depend on factors such as the cell type and biol. context.  For ERM proteins to become active they must be phosphorylated at a specific C-terminal threonine residue.  In non-neuronal cells, several kinases, including the Rho GTPase family member Rho kinase, have been identified as capable of phosphorylating the C-terminal threonine.  In these expts. we have investigated specifically the potential role of Rho kinase mediated ERM activation in cortical neurons, utilizing a new pharmacol. inhibitor of Rho kinase and quant. anal. of aspects of neuronal functions potentially mediated by ERM proteins.  Rho kinase inhibition significantly suppressed aspects of neuronal development including neurite initiation and outgrowth, as well as growth cone morphol., with a concomitant loss of phosphorylated ERM immunolabeling in areas assocd. with neuronal growth.  The ability of the Rho kinase inhibitor to decrease the amt. of pERM protein was shown by immunoblotting.  Post-injury responses were neg. affected by Rho kinase inhibition, namely by a significant decrease in the no. of regenerative neurites.  We investigated a novel role for ERM proteins in neuron migration using a post-injury motility assay, where Rho kinase inhibition resulted in significant and drastic redn. in neuron motility and phosphorylated ERM immunolabeling.  Thus, Rho kinase is an important activator of ERMs in mediating specific neuronal functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt00xr3lqJjLVg90H21EOLACvtfcHk0lgKD7jYdQ91ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVyhuw%253D%253D&md5=9fe29b0df3c0cf9b85228eed08279ddc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fjnr.21102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.21102%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DM.%2BA.%26aulast%3DVickers%26aufirst%3DJ.%2BC.%26aulast%3DDickson%26aufirst%3DT.%2BC.%26atitle%3DRho%2520kinase%2520activates%2520ezrin-radixin-moesin%2520%2528ERM%2529%2520proteins%2520and%2520mediates%2520their%2520function%2520in%2520cortical%2520neuron%2520growth%252C%2520morphology%2520and%2520motility%2520in%2520vitro%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2007%26volume%3D85%26spage%3D34%26epage%3D46%26doi%3D10.1002%2Fjnr.21102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span> <span> </span><span class="NLM_article-title">Rho kinase (ROCK) inhibitors</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">24</span>, <span class="refDoi">Â DOI: 10.1097/FJC.0b013e318070d1bd</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1097%2FFJC.0b013e318070d1bd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17666911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFGju7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=17-24&author=J.+K.+Liaoauthor=M.+Setoauthor=K.+Noma&title=Rho+kinase+%28ROCK%29+inhibitors&doi=10.1097%2FFJC.0b013e318070d1bd"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase (ROCK) inhibitors</span></div><div class="casAuthors">Liao, James K.; Seto, Minoru; Noma, Kensuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-24</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The Rho kinase (ROCK) isoforms, ROCK1 and ROCK2, were initially discovered as downstream targets of the small GTP-binding protein Rho.  Because ROCKs mediate various important cellular functions such as cell shape, motility, secretion, proliferation, and gene expression, it is likely that this pathway will intersect with other signaling pathways known to contribute to cardiovascular disease.  Indeed, ROCKs have already been implicated in the regulation of vascular tone, proliferation, inflammation, and oxidative stress.  However, it is not entirely clear how ROCKs are regulated, what some of their downstream targets are, and whether ROCK1 and ROCK2 mediate different cellular functions.  Clin., inhibition of ROCK pathway is believed to contribute to some of the cardiovascular benefits of statin therapy that are independent of lipid lowering (ie, pleiotropic effects).  To what extent ROCK activity is inhibited in patients on statin therapy is not known, but it may have important clin. implications.  Indeed, several pharmaceutical companies are already actively engaged in the development of ROCK inhibitors as the next generation of therapeutic agents for cardiovascular disease because evidence from animal studies suggests the potential involvement of ROCK in hypertension and atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqni4R9YzHCArVg90H21EOLACvtfcHk0lj-9W4u2VCr5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFGju7o%253D&md5=2eb3df6bf289cd09427daae4ec16e707</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FFJC.0b013e318070d1bd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFJC.0b013e318070d1bd%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BK.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DNoma%26aufirst%3DK.%26atitle%3DRho%2520kinase%2520%2528ROCK%2529%2520inhibitors%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2007%26volume%3D50%26spage%3D17%26epage%3D24%26doi%3D10.1097%2FFJC.0b013e318070d1bd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohmura, E.</span></span> <span> </span><span class="NLM_article-title">Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride</span>. <i>Neurosurgery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">214</span>â <span class="NLM_lpage">223</span>, <span class="refDoi">Â DOI: 10.1227/01.NEU.0000147975.24556.BC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1227%2F01.NEU.0000147975.24556.BC" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=214-223&author=K.+Tanakaauthor=H.+Minamiauthor=M.+Kotaauthor=K.+Kuwamuraauthor=E.+Kohmura&title=Treatment+of+cerebral+vasospasm+with+intra-arterial+fasudil+hydrochloride&doi=10.1227%2F01.NEU.0000147975.24556.BC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1227%2F01.NEU.0000147975.24556.BC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1227%252F01.NEU.0000147975.24556.BC%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DH.%26aulast%3DKota%26aufirst%3DM.%26aulast%3DKuwamura%26aufirst%3DK.%26aulast%3DKohmura%26aufirst%3DE.%26atitle%3DTreatment%2520of%2520cerebral%2520vasospasm%2520with%2520intra-arterial%2520fasudil%2520hydrochloride%26jtitle%3DNeurosurgery%26date%3D2005%26volume%3D56%26spage%3D214%26epage%3D223%26doi%3D10.1227%2F01.NEU.0000147975.24556.BC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokushige, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanihara, H.</span></span> <span> </span><span class="NLM_article-title">Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">964</span>â <span class="NLM_lpage">970</span>, <span class="refDoi">Â DOI: 10.3109/02713683.2011.599106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.3109%2F02713683.2011.599106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=21950703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ggsb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=964-970&author=H.+Tokushigeauthor=M.+Wakiauthor=Y.+Takayamaauthor=H.+Tanihara&title=Effects+of+Y-39983%2C+a+selective+Rho-associated+protein+kinase+inhibitor%2C+on+blood+flow+in+optic+nerve+head+in+rabbits+and+axonal+regeneration+of+retinal+ganglion+cells+in+rats&doi=10.3109%2F02713683.2011.599106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Blood Flow in Optic Nerve Head in Rabbits and Axonal Regeneration of Retinal Ganglion Cells in Rats</span></div><div class="casAuthors">Tokushige, Hideki; Waki, Mitsunori; Takayama, Yoshiko; Tanihara, Hidenobu</div><div class="citationInfo"><span class="NLM_cas:title">Current Eye Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">964-970</span>CODEN:
                <span class="NLM_cas:coden">CEYRDM</span>;
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">To investigate the effects of Y-39983, a selective Rho-assocd. coiled coil-forming protein kinase inhibitor, on blood flow in the optic nerve head (ONH) in rabbits and axonal regeneration of retinal ganglion cells (RGCs) in rats.  Blood flow in ONH was measured by the laser speckle method after topical administration of 0.05% Y-39983 soln. or its vehicle in rabbit eyes.  To investigate the effects of Y-39983 on axonal regeneration of RGCs, RGCs purified from rat eyes were cultured with or without 10 Î¼M Y-39983 and morphol. obsd. by phase-contrast microscopy.  Moreover, the effects of intravitreal administration of Y-39983 were evaluated using an in vivo model of axotomized RGCs in peripheral nerve-grafted rats.  Topical administration of 0.05% Y-39983 soln. significantly increased blood flow in ONH compared with the vehicle group in rabbits.  Maximum increase in blood flow in the 0.05% Y-39983 group was 122.84 Â± 5.98% (Mean Â± S.E.) at 90 min after administration compared with before administration.  Neurites in rat RGCs treated with 10 Î¼M Y-39983 were extended compared with those without Y-39983 treatment of RGCs in vitro.  Y-39983 dose-dependently increased the no. of RGCs with regenerating axons in vivo.  The nos. of RGCs with regenerating axons in 10 and 100 Î¼M Y-39983-treated rats were 99.3 Â± 10.5 and 169.5 Â± 43.3 cells/mm2 (Mean Â± S.D.), resp., and significantly increased compared with those in saline-treated rats (43.3 Â± 6.0 cells/mm2).  Y-39983 may be a candidate drug not only for lowering of IOP but also for increasing of blood flow in ONH in the treatment of glaucoma.  Moreover, Y-39983 may have therapeutic potential for axonal regeneration of RGCs in the treatment of diseases with degenerating axons of RGCs including glaucoma, although improvements of formulation or route of administration are needed in order to reach an effective concn. in retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOzPXxK8ZBM7Vg90H21EOLACvtfcHk0lj-9W4u2VCr5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ggsb%252FE&md5=05042fb5ee8f28ddf604a0fbeede3ab9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3109%2F02713683.2011.599106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02713683.2011.599106%26sid%3Dliteratum%253Aachs%26aulast%3DTokushige%26aufirst%3DH.%26aulast%3DWaki%26aufirst%3DM.%26aulast%3DTakayama%26aufirst%3DY.%26aulast%3DTanihara%26aufirst%3DH.%26atitle%3DEffects%2520of%2520Y-39983%252C%2520a%2520selective%2520Rho-associated%2520protein%2520kinase%2520inhibitor%252C%2520on%2520blood%2520flow%2520in%2520optic%2520nerve%2520head%2520in%2520rabbits%2520and%2520axonal%2520regeneration%2520of%2520retinal%2520ganglion%2520cells%2520in%2520rats%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D2011%26volume%3D36%26spage%3D964%26epage%3D970%26doi%3D10.3109%2F02713683.2011.599106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teusch, T.</span></span> <span> </span><span class="NLM_article-title">Rho kinase, a promising drug target for neurological disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">398</span>, <span class="refDoi">Â DOI: 10.1038/nrd1719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1038%2Fnrd1719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15864268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1OktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=387-398&author=B.+K.+Muellerauthor=H.+Mackauthor=T.+Teusch&title=Rho+kinase%2C+a+promising+drug+target+for+neurological+disorders&doi=10.1038%2Fnrd1719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase, a promising drug target for neurological disorders</span></div><div class="casAuthors">Mueller, Bernhard K.; Mack, Helmut; Teusch, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">387-398</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rho kinases (ROCKs), the first Rho effectors to be described, are serine/threonine kinases that are important in fundamental processes of cell migration, cell proliferation and cell survival.  Abnormal activation of the Rho/ROCK pathway has been obsd. in various disorders of the central nervous system.  Injury to the adult vertebrate brain and spinal cord activates ROCKs, thereby inhibiting neurite growth and sprouting.  Inhibition of ROCKs results in accelerated regeneration and enhanced functional recovery after spinal-cord injury in mammals, and inhibition of the Rho/ROCK pathway has also proved to be efficacious in animal models of stroke, inflammatory and demyelinating diseases, Alzheimer's disease and neuropathic pain.  ROCK inhibitors therefore have potential for preventing neurodegeneration and stimulating neuroregeneration in various neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3XJk9e8s-qLVg90H21EOLACvtfcHk0lhrYCItSWExzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1OktLw%253D&md5=605b180f2f817091aadfc143df6d0205</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1719%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DB.%2BK.%26aulast%3DMack%26aufirst%3DH.%26aulast%3DTeusch%26aufirst%3DT.%26atitle%3DRho%2520kinase%252C%2520a%2520promising%2520drug%2520target%2520for%2520neurological%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D387%26epage%3D398%26doi%3D10.1038%2Fnrd1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, A.</span></span> <span> </span><span class="NLM_article-title">Rho kinase and hypertension</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1802</i></span>,  <span class="NLM_fpage">1276</span>â <span class="NLM_lpage">1284</span>, <span class="refDoi">Â DOI: 10.1016/j.bbadis.2010.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bbadis.2010.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=20460153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKkt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1802&publication_year=2010&pages=1276-1284&author=A.+Wirth&title=Rho+kinase+and+hypertension&doi=10.1016%2Fj.bbadis.2010.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase and hypertension</span></div><div class="casAuthors">Wirth, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1802</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1276-1284</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Arterial hypertension is a multifactorial disease that is characterized by increased peripheral vascular resistance often accompanied by smooth muscle cell hypertrophy and proliferation.  Rho kinases (ROCKs) are the most extensively studied effectors of the small G-protein RhoA and abnormalities in RhoA/ROCK signaling were obsd. in various cardiovascular disease including hypertension.  The RhoA/ROCK-pathway is a key player in different smooth muscle cell functions including contractility, proliferation and migration.  Furthermore, there is extensive crosstalk between RhoA/ROCK- and NO-signaling.  Therefore, not only ROCK inhibitors but also NO-donators or pleiotropic agents like statins exert their beneficial effects on the cardiovascular system at least in part via Rho/Rho-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptzXz8fiHcHLVg90H21EOLACvtfcHk0lhrYCItSWExzQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKkt7rN&md5=311f8b1d2dd850738baf997e9fd7198c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2010.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2010.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DA.%26atitle%3DRho%2520kinase%2520and%2520hypertension%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2010%26volume%3D1802%26spage%3D1276%26epage%3D1284%26doi%3D10.1016%2Fj.bbadis.2010.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Quy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh-Xuan, A. T.</span></span> <span> </span><span class="NLM_article-title">Role of Rho-kinase and its inhibitors in pulmonary hypertension</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">352</span>â <span class="NLM_lpage">364</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2012.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.pharmthera.2012.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=23261521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2qtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2013&pages=352-364&author=S.+Duong-Quyauthor=Y.+Beiauthor=Z.+Liuauthor=A.+T.+Dinh-Xuan&title=Role+of+Rho-kinase+and+its+inhibitors+in+pulmonary+hypertension&doi=10.1016%2Fj.pharmthera.2012.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Rho-kinase and its inhibitors in pulmonary hypertension</span></div><div class="casAuthors">Duong-Quy, Sy; Bei, Yihua; Liu, Zhongmin; Dinh-Xuan, Anh Tuan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-364</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Pulmonary hypertension (PH) is an incurable disease with a dreadful survival rate.  The disease is characterized by sustained vasoconstriction, progressive vascular remodeling, and irreversible right heart dysfunction.  While hypoxic pulmonary vasoconstriction (HPV) is known to be the main pathophysiol. factor causing the rise in pulmonary arterial pressure, biol. mechanisms leading to HPV and vascular remodeling are multiple and complex and, as yet, incompletely understood.  It is thought that mol. interactions and cross talks are involved in the pathogenesis of PH, perturbing the physiol. balance between substances controlling vascular tone, cell growth and apoptosis.  This balance is achieved by subtle interactions between factors acting as both vasodilators and inhibitors of cell growth like nitric oxide, prostacyclin, vasoactive intestinal peptide and mols. with potent vasoconstrictor and cell growth activities like endothelin-1.  Recent in vivo studies showed that the Rho GTPase/RhoA pathway and its downstream effectors, the Rho-kinases (ROCK-1 and ROCK-2), had an important role in PH, due to its lasting effects on vasoconstriction and pulmonary cell proliferation leading to vascular remodeling.  Beneficial effects obtained in vivo with Rho-kinase inhibitors (e.g.Y-27632 and fasudil) in exptl. PH will hopefully lead to future clin. trials with new compds. selectively targeting this pathway, which is now proven to be detrimental when over-activated in both exptl. animals and human patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO29d7VxfcKbVg90H21EOLACvtfcHk0ljvVtU92YYAzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2qtA%253D%253D&md5=124b129eb40fd189081eb60c0ba17747</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2012.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2012.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Quy%26aufirst%3DS.%26aulast%3DBei%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDinh-Xuan%26aufirst%3DA.%2BT.%26atitle%3DRole%2520of%2520Rho-kinase%2520and%2520its%2520inhibitors%2520in%2520pulmonary%2520hypertension%26jtitle%3DPharmacol.%2520Ther.%26date%3D2013%26volume%3D137%26spage%3D352%26epage%3D364%26doi%3D10.1016%2Fj.pharmthera.2012.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, O.</span></span> <span> </span><span class="NLM_article-title">Rho kinase (ROCK) inhibitors and their therapeutic potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2269</span>â <span class="NLM_lpage">2300</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00683</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00683" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2269-2300&author=Y.+Fengauthor=P.+V.+LoGrassoauthor=O.+Defertauthor=O.+Li&title=Rho+kinase+%28ROCK%29+inhibitors+and+their+therapeutic+potential&doi=10.1021%2Facs.jmedchem.5b00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential</span></div><div class="casAuthors">Feng, Yangbo; LoGrasso, Philip V.; Defert, Olivier; Li, Rongshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2269-2300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates.  As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathol. conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis.  To date, two ROCK inhibitors have been approved for clin. use in Japan (fasudil and ripasudil) and one in China (fasudil).  In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014.  In this Perspective, we present a comprehensive review of the physiol. and biol. functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXh2BorYftcbVg90H21EOLACvtfcHk0ljvVtU92YYAzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ&md5=99b0e10dca303023b1bf382fcb255771</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00683%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DDefert%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DO.%26atitle%3DRho%2520kinase%2520%2528ROCK%2529%2520inhibitors%2520and%2520their%2520therapeutic%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2269%26epage%3D2300%26doi%3D10.1021%2Facs.jmedchem.5b00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frackowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2355</span>â <span class="NLM_lpage">2360</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2006.12.043" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2355-2360&author=Y.+Fengauthor=M.+D.+Cameronauthor=B.+Frackowiakauthor=E.+Griffinauthor=L.+Linauthor=C.+Ruizauthor=T.+Schr%C3%B6terauthor=P.+LoGrasso&title=Structure-activity+relationships%2C+and+drug+metabolism+and+pharmacokinetic+properties+for+indazole+piperazine+and+indazole+piperidine+inhibitors+of+ROCK-II&doi=10.1016%2Fj.bmcl.2006.12.043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DFrackowiak%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DLoGrasso%26aufirst%3DP.%26atitle%3DStructure-activity%2520relationships%252C%2520and%2520drug%2520metabolism%2520and%2520pharmacokinetic%2520properties%2520for%2520indazole%2520piperazine%2520and%2520indazole%2520piperidine%2520inhibitors%2520of%2520ROCK-II%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2355%26epage%3D2360%26doi%3D10.1016%2Fj.bmcl.2006.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaitanopoulos, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semus, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fries, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span> <span> </span><span class="NLM_article-title">Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1021/jm0609014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0609014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlansbnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6-9&author=K.+B.+Goodmanauthor=H.+Cuiauthor=S.+E.+Dowdellauthor=D.+E.+Gaitanopoulosauthor=R.+L.+Ivyauthor=C.+A.+Sehonauthor=R.+A.+Stavengerauthor=G.+Z.+Wangauthor=A.+Q.+Vietauthor=W.+Xuauthor=G.+Yeauthor=S.+F.+Semusauthor=C.+Evansauthor=H.+E.+Friesauthor=L.+J.+Jolivetteauthor=R.+B.+Kirkpatrickauthor=E.+Dulauthor=S.+S.+Khandekarauthor=T.+Yiauthor=D.+K.+Jungauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=D.+J.+Behmauthor=R.+Bentleyauthor=C.+P.+Doeauthor=E.+Huauthor=D.+Lee&title=Development+of+dihydropyridone+indazole+amides+as+selective+Rho-kinase+inhibitors&doi=10.1021%2Fjm0609014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors</span></div><div class="casAuthors">Goodman, Krista B.; Cui, Haifeng; Dowdell, Sarah E.; Gaitanopoulos, Dimitri E.; Ivy, Robert L.; Sehon, Clark A.; Stavenger, Robert A.; Wang, Gren Z.; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Semus, Simon F.; Evans, Christopher; Fries, Harvey E.; Jolivette, Larry J.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Bentley, Ross; Doe, Christopher P.; Hu, Erding; Lee, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinase (ROCK1) mediates vascular smooth muscle contraction and is a potential target for the treatment of hypertension and related disorders.  Indazole amide 3 was identified as a potent and selective ROCK1 inhibitor but possessed poor oral bioavailability.  Optimization of this lead resulted in the discovery of a series of dihydropyridones, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead.  Indazole substitution played a crit. role in decreasing clearance and improving oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgOGlkSgS6prVg90H21EOLACvtfcHk0liCEZ9xhF8J1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlansbnF&md5=4a2b2f5636a4631f95e521ec98068e0e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm0609014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0609014%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DDowdell%26aufirst%3DS.%2BE.%26aulast%3DGaitanopoulos%26aufirst%3DD.%2BE.%26aulast%3DIvy%26aufirst%3DR.%2BL.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DG.%2BZ.%26aulast%3DViet%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DSemus%26aufirst%3DS.%2BF.%26aulast%3DEvans%26aufirst%3DC.%26aulast%3DFries%26aufirst%3DH.%2BE.%26aulast%3DJolivette%26aufirst%3DL.%2BJ.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DKhandekar%26aufirst%3DS.%2BS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DDoe%26aufirst%3DC.%2BP.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520dihydropyridone%2520indazole%2520amides%2520as%2520selective%2520Rho-kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6%26epage%3D9%26doi%3D10.1021%2Fjm0609014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwakubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Rho kinase inhibitors (II)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">350</span>â <span class="NLM_lpage">364</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2006.09.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmc.2006.09.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=350-364&author=M.+Iwakuboauthor=A.+Takamiauthor=Y.+Okadaauthor=T.+Kawataauthor=Y.+Tagamiauthor=H.+Ohashiauthor=M.+Satoauthor=T.+Sugiyamaauthor=K.+Fukushimaauthor=H.+Iijima&title=Design+and+synthesis+of+Rho+kinase+inhibitors+%28II%29&doi=10.1016%2Fj.bmc.2006.09.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.052%26sid%3Dliteratum%253Aachs%26aulast%3DIwakubo%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DTagami%26aufirst%3DY.%26aulast%3DOhashi%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DT.%26aulast%3DFukushima%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Rho%2520kinase%2520inhibitors%2520%2528II%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D350%26epage%3D364%26doi%3D10.1016%2Fj.bmc.2006.09.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaitanopoulos, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semus, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">5</span>, <span class="refDoi">Â DOI: 10.1021/jm060873p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060873p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2-5&author=R.+A.+Stavengerauthor=H.+Cuiauthor=S.+E.+Dowdellauthor=R.+G.+Franzauthor=D.+E.+Gaitanopoulosauthor=K.+B.+Goodmanauthor=M.+A.+Hilfikerauthor=R.+L.+Ivyauthor=J.+D.+Leberauthor=J.+P.+Marinoauthor=H.+Ohauthor=A.+Q.+Vietauthor=W.+Xuauthor=G.+Yeauthor=D.+Zhangauthor=Y.+Zhaoauthor=L.+J.+Jolivetteauthor=M.+S.+Headauthor=S.+F.+Semusauthor=P.+A.+Elkinsauthor=R.+B.+Kirkpatrickauthor=E.+Dulauthor=S.+S.+Khandekarauthor=T.+Yiauthor=D.+K.+Jungauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=D.+J.+Behmauthor=C.+P.+Doeauthor=R.+Bentleyauthor=Z.+X.+Chenauthor=E.+Huauthor=D.+Lee&title=Discovery+of+aminofurazan-azabenzimidazoles+as+inhibitors+of+Rho-kinase+with+high+kinase+selectivity+and+antihypertensive+activity&doi=10.1021%2Fjm060873p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity</span></div><div class="casAuthors">Stavenger, Robert A.; Cui, Haifeng; Dowdell, Sarah E.; Franz, Robert G.; Gaitanopoulos, Dimitri E.; Goodman, Krista B.; Hilfiker, Mark A.; Ivy, Robert L.; Leber, Jack D.; Marino, Joseph P., Jr.; Oh, Hye-Ja; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Zhang, Daohua; Zhao, Yongdong; Jolivette, Larry J.; Head, Martha S.; Semus, Simon F.; Elkins, Patricia A.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Doe, Christopher P.; Bentley, Ross; Chen, Zunxuan X.; Hu, Erding; Lee, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented.  Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases.  Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzfD1mp8bYv7Vg90H21EOLACvtfcHk0lhcbKnYN-7sXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE&md5=055d95d44fc906aba4e0bdbf0bc1aac9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm060873p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060873p%26sid%3Dliteratum%253Aachs%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DDowdell%26aufirst%3DS.%2BE.%26aulast%3DFranz%26aufirst%3DR.%2BG.%26aulast%3DGaitanopoulos%26aufirst%3DD.%2BE.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DHilfiker%26aufirst%3DM.%2BA.%26aulast%3DIvy%26aufirst%3DR.%2BL.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DOh%26aufirst%3DH.%26aulast%3DViet%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJolivette%26aufirst%3DL.%2BJ.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DSemus%26aufirst%3DS.%2BF.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DKhandekar%26aufirst%3DS.%2BS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DDoe%26aufirst%3DC.%2BP.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520aminofurazan-azabenzimidazoles%2520as%2520inhibitors%2520of%2520Rho-kinase%2520with%2520high%2520kinase%2520selectivity%2520and%2520antihypertensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Fjm060873p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uehata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narumiya, S.</span></span> <span> </span><span class="NLM_article-title">Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">990</span>â <span class="NLM_lpage">994</span>, <span class="refDoi">Â DOI: 10.1038/40187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1038%2F40187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=9353125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADyaK2sXntVarsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=990-994&author=M.+Uehataauthor=T.+Ishizakiauthor=H.+Satohauthor=T.+Onoauthor=T.+Kawaharaauthor=T.+Morishitaauthor=H.+Tamakawaauthor=K.+Yamagamiauthor=J.+Inuiauthor=M.+Maekawaauthor=S.+Narumiya&title=Calcium+sensitization+of+smooth+muscle+mediated+by+a+Rho-associated+protein+kinase+in+hypertension&doi=10.1038%2F40187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension</span></div><div class="casAuthors">Uehata, Masayoshi; Ishizaki, Toshimasa; Satoh, Miroyuki; Ono, Takashi; Kawahara, Toshio; Morishita, Tamami; Tamakawa, Hiroki; Yamagami, Keiji; Inui, Jun; Maekawa, Midori; Narumiya, Shuh</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6654</span>),
    <span class="NLM_cas:pages">990-994</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Abnormal smooth-muscle contractility may be a major cause of disease states such as hypertension, and a smooth-muscle relaxant that modulates this process would be useful therapeutically.  Smooth-muscle contraction is regulated by the cytosolic Ca2+ concn. and by the Ca2+ sensitivity of myofilaments: the former activates myosin light-chain kinase and the latter is achieved partly by inhibition of myosin phosphatase.  The small GTPase Rho and its target, Rho-assocd. kinase, participate in this latter mechanism in vitro, but their participation has not been demonstrated in intact muscles.  Here the authors show that a pyridine deriv., Y-27632, selectively inhibits smooth-muscle contraction by inhibiting Ca2+ sensitization.  The authors identified the Y-27632 target as a Rho-assocd. protein kinase, p160ROCK.  Y-27632 consistently suppresses Rho-induced, p160ROCK-mediated formation of stress fibers in cultured cells and dramatically corrects hypertension in several hypertensive rat models.  The authors' findings indicate that p160ROCK-mediated Ca2+ sensitization is involved in the pathophysiol. of hypertension and suggest that compds. that inhibit this process might be useful therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2FDG7oWwZ6bVg90H21EOLACvtfcHk0liR0V8bqYVTCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVarsbY%253D&md5=9a5664b84a72d3486df1433579364943</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F40187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F40187%26sid%3Dliteratum%253Aachs%26aulast%3DUehata%26aufirst%3DM.%26aulast%3DIshizaki%26aufirst%3DT.%26aulast%3DSatoh%26aufirst%3DH.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DKawahara%26aufirst%3DT.%26aulast%3DMorishita%26aufirst%3DT.%26aulast%3DTamakawa%26aufirst%3DH.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DInui%26aufirst%3DJ.%26aulast%3DMaekawa%26aufirst%3DM.%26aulast%3DNarumiya%26aufirst%3DS.%26atitle%3DCalcium%2520sensitization%2520of%2520smooth%2520muscle%2520mediated%2520by%2520a%2520Rho-associated%2520protein%2520kinase%2520in%2520hypertension%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D990%26epage%3D994%26doi%3D10.1038%2F40187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avedissian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thouin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulanger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essagian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerracher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubell, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 4-(1-aminoalkyl)-<i>N</i>-(4-pyridyl)cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4931</span>â <span class="NLM_lpage">4934</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2004.07.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4931-4934&author=K.+Gingrasauthor=H.+Avedissianauthor=E.+Thouinauthor=V.+Boulangerauthor=C.+Essagianauthor=L.+McKerracherauthor=W.+D.+Lubell&title=Synthesis+and+evaluation+of+4-%281-aminoalkyl%29-N-%284-pyridyl%29cyclohexanecarboxamides+as+Rho+kinase+inhibitors+and+neurite+outgrowth+promoters&doi=10.1016%2Fj.bmcl.2004.07.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DGingras%26aufirst%3DK.%26aulast%3DAvedissian%26aufirst%3DH.%26aulast%3DThouin%26aufirst%3DE.%26aulast%3DBoulanger%26aufirst%3DV.%26aulast%3DEssagian%26aufirst%3DC.%26aulast%3DMcKerracher%26aufirst%3DL.%26aulast%3DLubell%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25204-%25281-aminoalkyl%2529-N-%25284-pyridyl%2529cyclohexanecarboxamides%2520as%2520Rho%2520kinase%2520inhibitors%2520and%2520neurite%2520outgrowth%2520promoters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4931%26epage%3D4934%26doi%3D10.1016%2Fj.bmcl.2004.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼rer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5727</span>â <span class="NLM_lpage">5737</span>, <span class="refDoi">Â DOI: 10.1021/jm100579r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100579r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5727-5737&author=X.+Fangauthor=Y.+Yinauthor=Y.+T.+Chenauthor=L.+Yaoauthor=B.+Wangauthor=M.+D.+Cameronauthor=L.+Linauthor=S.+Khanauthor=C.+Ruizauthor=T.+Schr%C3%B6terauthor=W.+Grantauthor=A.+Weiserauthor=J.+Pocasauthor=A.+Pachoriauthor=S.+Sch%C3%BCrerauthor=P.+LoGrassoauthor=Y.+Feng&title=Tetrahydroisoquinoline+derivatives+as+highly+selective+and+potent+Rho+kinase+inhibitors&doi=10.1021%2Fjm100579r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Derivatives As Highly Selective and Potent Rho Kinase Inhibitors</span></div><div class="casAuthors">Fang, Xingang; Yin, Yan; Chen, Yen Ting; Yao, Lei; Wang, Bo; Cameron, Michael D.; Lin, Li; Khan, Susan; Ruiz, Claudia; Schroter, Thomas; Grant, Wayne; Weiser, Amiee; Pocas, Jennifer; Pachori, Alok; Schurer, Stephan; Lo Grasso, Philip; Feng, Yangbo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5727-5737</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinase (ROCK) is a promising drug target for the treatment of many diseases including hypertension, multiple sclerosis, cancer, and glaucoma.  The structure-activity relationships (SAR) around a series of tetrahydroisoquinolines were evaluated utilizing biochem. and cell-based assays to measure ROCK inhibition.  These novel ROCK inhibitors possess high potency, high selectivity, and appropriate pharmacokinetic properties for glaucoma applications.  The lead compd., 35, had subnanomolar potency in enzyme ROCK-II assays as well as excellent cell-based potency (IC50 = 51 nM).  In a kinase panel profiling, 35 had an off-target hit rate of only 1.6% against 442 kinases.  Pharmacol. studies showed that compd. 35 was efficacious in reducing intraocular pressure (IOP) in rats with reasonably long duration of action.  These results suggest that compd. 35 may serve as a promising agent for further development in the treatment of glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8rKBfPtO8L7Vg90H21EOLACvtfcHk0liR0V8bqYVTCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWksLo%253D&md5=2278d64dd3ac09f0e5d8406f7e21eca9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm100579r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100579r%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DGrant%26aufirst%3DW.%26aulast%3DWeiser%26aufirst%3DA.%26aulast%3DPocas%26aufirst%3DJ.%26aulast%3DPachori%26aufirst%3DA.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%26aulast%3DLoGrasso%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26atitle%3DTetrahydroisoquinoline%2520derivatives%2520as%2520highly%2520selective%2520and%2520potent%2520Rho%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5727%26epage%3D5737%26doi%3D10.1021%2Fjm100579r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiratsuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totsuka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, H.</span></span> <span> </span><span class="NLM_article-title">Development of specific Rho-kinase inhibitors and their clinical application</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">252</span>, <span class="refDoi">Â DOI: 10.1016/j.bbapap.2005.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bbapap.2005.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=16213195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=245-252&author=M.+Tamuraauthor=H.+Nakaoauthor=H.+Yoshizakiauthor=M.+Shiratsuchiauthor=H.+Shigyoauthor=H.+Yamadaauthor=T.+Ozawaauthor=J.+Totsukaauthor=H.+Hidaka&title=Development+of+specific+Rho-kinase+inhibitors+and+their+clinical+application&doi=10.1016%2Fj.bbapap.2005.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of specific Rho-kinase inhibitors and their clinical application</span></div><div class="casAuthors">Tamura, Masahiro; Nakao, Hiroshi; Yoshizaki, Hideo; Shiratsuchi, Masami; Shigyo, Hiromichi; Yamada, Hajime; Ozawa, Takatoshi; Totsuka, Junko; Hidaka, Hiroyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">245-252</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hexahydro-1-(isoquinoline-5-sulfonyl)-1H-1,4-diazepine, HA-1077, is a known selective inhibitor of Rho-kinase.  Although its IC50 value against Rho-kinase is more than 10 times lower than those for kinases such as PKA, PKB, PKC, PKG, MLCK, CaMKII and others, the mol. still retains relative potent inhibition activities against these kinases.  In order to produce highly specific Rho-kinase inhibitors, several HA-1077 analogs were synthesized and their kinase inhibition properties evaluated.  (S)-Hexahydro-1-(4-ethenylisoquinoline-5-sulfonyl)-2-methyl-1H-1,4-diazepine was found to be a potent Rho-kinase inhibitor.  The IC50 value against Rho-kinase was 6 nM, while those against other kinases remained at almost the same level as that of HA-1077.  Furthermore, we designed HA-1077 analogs on the basis of the complex structure of PKA and HA-1077.  Amongst these, (S)-hexahydro-4-glycyl-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1H-1,4-diazepine and other glycine derivs. were found to be highly specific Rho-kinase inhibitors.  These Rho-kinase specific inhibitors were applied to rabbit ocular hypertensive models and were shown to reduce intraocular pressure.  These results demonstrate that the new 5-isoquinolinesulfonylamides are not only potent ROCK selective compds., but are also useful compds. for clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc5VQGumuqnbVg90H21EOLACvtfcHk0ljypxEuhRftfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7bK&md5=467ca0607a8aa691fbe0b1b3bb340405</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DM.%26aulast%3DNakao%26aufirst%3DH.%26aulast%3DYoshizaki%26aufirst%3DH.%26aulast%3DShiratsuchi%26aufirst%3DM.%26aulast%3DShigyo%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DH.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DTotsuka%26aufirst%3DJ.%26aulast%3DHidaka%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520specific%2520Rho-kinase%2520inhibitors%2520and%2520their%2520clinical%2520application%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D245%26epage%3D252%26doi%3D10.1016%2Fj.bbapap.2005.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Rho kinase inhibitors (I)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2115</span>â <span class="NLM_lpage">2137</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2004.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmc.2004.02.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2115-2137&author=A.+Takamiauthor=M.+Iwakuboauthor=Y.+Okadaauthor=T.+Kawataauthor=H.+Odaiauthor=N.+Takahashiauthor=K.+Shindoauthor=K.+Kimuraauthor=Y.+Tagamiauthor=M.+Miyakeauthor=K.+Fukushimaauthor=M.+Inagakiauthor=M.+Amanoauthor=K.+Kaibuchiauthor=H.+Iijima&title=Design+and+synthesis+of+Rho+kinase+inhibitors+%28I%29&doi=10.1016%2Fj.bmc.2004.02.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DTakami%26aufirst%3DA.%26aulast%3DIwakubo%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DOdai%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DShindo%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DTagami%26aufirst%3DY.%26aulast%3DMiyake%26aufirst%3DM.%26aulast%3DFukushima%26aufirst%3DK.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DKaibuchi%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Rho%2520kinase%2520inhibitors%2520%2528I%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2115%26epage%3D2137%26doi%3D10.1016%2Fj.bmc.2004.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwakubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of rho kinase inhibitors (III)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1022</span>â <span class="NLM_lpage">1033</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2006.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmc.2006.10.028" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=1022-1033&author=M.+Iwakuboauthor=A.+Takamiauthor=Y.+Okadaauthor=T.+Kawataauthor=Y.+Tagamiauthor=M.+Satoauthor=T.+Sugiyamaauthor=K.+Fukushimaauthor=S.+Tayaauthor=M.+Amanoauthor=K.+Kaibuchiauthor=H.+Iijima&title=Design+and+synthesis+of+rho+kinase+inhibitors+%28III%29&doi=10.1016%2Fj.bmc.2006.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DIwakubo%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DTagami%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DT.%26aulast%3DFukushima%26aufirst%3DK.%26aulast%3DTaya%26aufirst%3DS.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DKaibuchi%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520rho%2520kinase%2520inhibitors%2520%2528III%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D1022%26epage%3D1033%26doi%3D10.1016%2Fj.bmc.2006.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokuyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochizuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, A.</span></span> <span> </span><span class="NLM_article-title">Effects of Y-27632, a Rho/Rho kinase inhibitor, on leukotriene D(4)- and histamine-induced airflow obstruction and airway microvascular leakage in guinea pigs in vivo</span>. <i>Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.1159/000056170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1159%2F000056170" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2002&pages=189-195&author=K.+Tokuyamaauthor=H.+Nishimuraauthor=K.+Iizukaauthor=M.+Katoauthor=H.+Arakawaauthor=R.+Sagaauthor=H.+Mochizukiauthor=A.+Morikawa&title=Effects+of+Y-27632%2C+a+Rho%2FRho+kinase+inhibitor%2C+on+leukotriene+D%284%29-+and+histamine-induced+airflow+obstruction+and+airway+microvascular+leakage+in+guinea+pigs+in+vivo&doi=10.1159%2F000056170"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1159%2F000056170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000056170%26sid%3Dliteratum%253Aachs%26aulast%3DTokuyama%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DIizuka%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DH.%26aulast%3DSaga%26aufirst%3DR.%26aulast%3DMochizuki%26aufirst%3DH.%26aulast%3DMorikawa%26aufirst%3DA.%26atitle%3DEffects%2520of%2520Y-27632%252C%2520a%2520Rho%252FRho%2520kinase%2520inhibitor%252C%2520on%2520leukotriene%2520D%25284%2529-%2520and%2520histamine-induced%2520airflow%2520obstruction%2520and%2520airway%2520microvascular%2520leakage%2520in%2520guinea%2520pigs%2520in%2520vivo%26jtitle%3DPharmacology%26date%3D2002%26volume%3D64%26spage%3D189%26epage%3D195%26doi%3D10.1159%2F000056170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldie, R. G.</span></span> <span> </span><span class="NLM_article-title">A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">74</span>, <span class="refDoi">Â DOI: 10.1016/j.pupt.2004.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.pupt.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15607129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOntbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=67-74&author=P.+J.+Henryauthor=T.+S.+Mannauthor=R.+G.+Goldie&title=A+Rho+kinase+inhibitor%2C+Y-27632+inhibits+pulmonary+eosinophilia%2C+bronchoconstriction+and+airways+hyperresponsiveness+in+allergic+mice&doi=10.1016%2Fj.pupt.2004.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice</span></div><div class="casAuthors">Henry, Peter J.; Mann, Tracy S.; Goldie, Roy G.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Asthma is a complex inflammatory disorder involving obstruction, constriction, edema, remodelling and hyperresponsiveness of the airways.  These effects are induced by a raft of mediators, many of which exert their actions by stimulating specific G-protein-coupled receptors linked to a signal transduction pathway involving the monomeric GTPase; rho, and a downstream effector; rho kinase.  The aim of this study was to det. whether administration of a selective inhibitor of rho kinase, Y-27632, attenuates airway inflammation, bronchoconstriction and hyperresponsiveness in a murine model of acute allergic inflammation.  Intranasal administration of Y-27632 caused a dose-dependent inhibition in the no. of eosinophils recovered from bronchoalveolar lavage fluid of ovalbumin-sensitized and challenged (allergic) mice.  These inhibitory effects of intranasal Y-27632 on pulmonary eosinophilia were accompanied by a significant inhibition of the development of airways hyperresponsiveness in allergic mice.  In addnl. studies, intranasal Y-27632 inhibited methacholine-induced increases in airways resistance in a time-dependent manner.  In conclusion, these findings indicate that activation of rho kinase contributes to bronchoconstriction and eosinophil trafficking in murine models of acute allergic airway inflammation and to the development of airway hyperresponsiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaprMOYMJNI7Vg90H21EOLACvtfcHk0ljLtsE0fcM_6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOntbnJ&md5=0ba740a88658e8d4e389914e12134ad1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DP.%2BJ.%26aulast%3DMann%26aufirst%3DT.%2BS.%26aulast%3DGoldie%26aufirst%3DR.%2BG.%26atitle%3DA%2520Rho%2520kinase%2520inhibitor%252C%2520Y-27632%2520inhibits%2520pulmonary%2520eosinophilia%252C%2520bronchoconstriction%2520and%2520airways%2520hyperresponsiveness%2520in%2520allergic%2520mice%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D18%26spage%3D67%26epage%3D74%26doi%3D10.1016%2Fj.pupt.2004.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafferty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygielko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span> <span> </span><span class="NLM_article-title">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1124/jpet.106.110635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1124%2Fjpet.106.110635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17018693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=89-98&author=C.+Doeauthor=R.+Bentleyauthor=D.+J.+Behmauthor=R.+Laffertyauthor=R.+Stavengerauthor=D.+Jungauthor=M.+Bamfordauthor=T.+Panchalauthor=E.+Grygielkoauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=Z.+Chenauthor=C.+Webbauthor=S.+Khandekarauthor=T.+Yiauthor=R.+Kirkpatrickauthor=E.+Dulauthor=L.+Jolivetteauthor=J.+P.+Marinoauthor=R.+Willetteauthor=D.+Leeauthor=E.+Hu&title=Novel+Rho+kinase+inhibitors+with+anti-inflammatory+and+vasodilatory+activities&doi=10.1124%2Fjpet.106.110635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span></div><div class="casAuthors">Doe, Chris; Bentley, Ross; Behm, David J.; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L.; Smith, Gary K.; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivette, Larry; Marino, Joseph P., Jr.; Willette, Robert; Lee, Dennis; Hu, Erding</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis.  We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension.  In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compds. that potently inhibit ROCK enzymic activity.  GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, resp.  GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases.  In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-Î±.  Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, resp.  Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent redn. of systemic blood pressure in spontaneously hypertensive rats.  At doses of 1, 3, and 30 mg/kg, both compds. induced a redn. in blood pressure of approx. 10, 20, and 50 mm Hg.  In addn., administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats.  SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuPjuVLTrwrVg90H21EOLACvtfcHk0ljLtsE0fcM_6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D&md5=ab8ba12bca20241815721e2cc9273774</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.110635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.110635%26sid%3Dliteratum%253Aachs%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DLafferty%26aufirst%3DR.%26aulast%3DStavenger%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DD.%26aulast%3DBamford%26aufirst%3DM.%26aulast%3DPanchal%26aufirst%3DT.%26aulast%3DGrygielko%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWebb%26aufirst%3DC.%26aulast%3DKhandekar%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DKirkpatrick%26aufirst%3DR.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DJolivette%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DWillette%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DE.%26atitle%3DNovel%2520Rho%2520kinase%2520inhibitors%2520with%2520anti-inflammatory%2520and%2520vasodilatory%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D89%26epage%3D98%26doi%3D10.1124%2Fjpet.106.110635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkinson, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinker, A. C.</span></span> <span> </span><span class="NLM_article-title">Components of successful lead generation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">439</span>, <span class="refDoi">Â DOI: 10.2174/1568026053828411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.2174%2F1568026053828411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15892684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFGhtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=421-439&author=A.+M.+Davisauthor=D.+J.+Keelingauthor=J.+Steeleauthor=N.+P.+Tomkinsonauthor=A.+C.+Tinker&title=Components+of+successful+lead+generation&doi=10.2174%2F1568026053828411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Components of successful lead generation</span></div><div class="casAuthors">Davis, Andrew M.; Keeling, David J.; Steele, John; Tomkinson, Nicholas P.; Tinker, Alan C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">421-439</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review aims to give an overview of current good practice in the prosecution of Lead Generation.  It will assess experiences across the field as judged from the contents of the limited no. of peer-review disclosures to date.  It will also rely heavily on the experiences of the authors from many campaigns within this organization.  Its focus will be on the assembly of an appropriate compd. collection for application in High Throughput Screening (HTS), the prosecution of HTS, the profiling of HTS output and, lastly the Hit-to-Lead optimization of selected HTS output.  Excluded from the scope are detailed aspects of library design [1], parallel synthesis [2], virtual library applications [3], virtual screening [4] and fragment screening [5] approaches, all of which have been the subject of recent reviews.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5UYz5NF4m7Vg90H21EOLACvtfcHk0liPSK6wefPfEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFGhtL4%253D&md5=ef29c85464f4ecbc63787210fda1b778</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1568026053828411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026053828411%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DKeeling%26aufirst%3DD.%2BJ.%26aulast%3DSteele%26aufirst%3DJ.%26aulast%3DTomkinson%26aufirst%3DN.%2BP.%26aulast%3DTinker%26aufirst%3DA.%2BC.%26atitle%3DComponents%2520of%2520successful%2520lead%2520generation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D421%26epage%3D439%26doi%3D10.2174%2F1568026053828411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency indices as guideposts for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>â <span class="NLM_lpage">469</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(05)03386-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+efficiency+indices+as+guideposts+for+drug+discovery&doi=10.1016%2FS1359-6446%2805%2903386-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2eYPrneV4TH0sbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520efficiency%2520indices%2520as%2520guideposts%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469%26doi%3D10.1016%2FS1359-6446%2805%2903386-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4406</span>â <span class="NLM_lpage">4409</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lgctvhETRTtUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajduk, P. J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based drug design: how big is too big?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6972</span>â <span class="NLM_lpage">6976</span>, <span class="refDoi">Â DOI: 10.1021/jm060511h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060511h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6972-6976&author=P.+J.+Hajduk&title=Fragment-based+drug+design%3A+how+big+is+too+big%3F&doi=10.1021%2Fjm060511h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Design: How Big Is Too Big?</span></div><div class="casAuthors">Hajduk, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6972-6976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Much has been discussed about the proper physicochem. properties (e.g., mol. wt., hydrophobicity, etc.) that should be considered when utilizing fragment leads in drug design.  However, little has been reported as to what emphasis, if any, should be placed on the potency of the resulting fragment leads.  In this report, a retrospective anal. of 18 highly optimized inhibitors is described in which the compds. were systematically deconstructed until the minimal binding elements could be identified.  An anal. of the potency changes that were obsd. as the leads were reduced in size indicate that a nearly linear relationship exists between mol. wt. and binding affinity over the entire range of sizes and potencies represented in the dataset.  On the basis of these observations, prediction maps can be constructed that enable crit. and quant. assessments of the process of lead identification and optimization.  These data place well-defined limits on the ideal size and potency of fragment leads that are being considered for use in fragment-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCz9NMtBgNrVg90H21EOLACvtfcHk0lgctvhETRTtUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbJ&md5=b27d4ca6446a033b82e0ea223da5e6de</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm060511h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060511h%26sid%3Dliteratum%253Aachs%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DFragment-based%2520drug%2520design%253A%2520how%2520big%2520is%2520too%2520big%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6972%26epage%3D6976%26doi%3D10.1021%2Fjm060511h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span>Maybridge
Chemical Company, <a href="http://www.maybridge.com/" class="extLink">http://www.maybridge.com/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maybridge%0AChemical+Company%2C+http%3A%2F%2Fwww.maybridge.com%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span>Ryan
Scientific, <a href="https://www.ryansci.com" class="extLink">https://www.ryansci.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ryan%0AScientific%2C+https%3A%2F%2Fwww.ryansci.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mack, H.</span>; <span class="NLM_string-name">Teusch, N.</span>; <span class="NLM_string-name">Mueller, B. K.</span>; <span class="NLM_string-name">Hornberger, W.</span>; <span class="NLM_string-name">Jarvis, M. F.</span>; <span class="NLM_string-name">Sauer, D.</span>; <span class="NLM_string-name">Swann, S.</span>; <span class="NLM_string-name">Bonafoux, D.</span>; <span class="NLM_string-name">Keddy, R.</span>; <span class="NLM_string-name">Hobson, A. D.</span>; <span class="NLM_string-name">Vasudevan, A.</span></span> <span> </span><span class="NLM_article-title">4-(4-Pyridinyl)-benzamides and their Use as Rock Activity Modulators</span>. US Patent <span class="NLM_patent">US 8445686 B2</span>, May 21, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Mack&author=N.+Teusch&author=B.+K.+Mueller&author=W.+Hornberger&author=M.+F.+Jarvis&author=D.+Sauer&author=S.+Swann&author=D.+Bonafoux&author=R.+Keddy&author=A.+D.+Hobson&author=A.+Vasudevan&title=4-%284-Pyridinyl%29-benzamides+and+their+Use+as+Rock+Activity+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMack%26aufirst%3DH.%26atitle%3D4-%25284-Pyridinyl%2529-benzamides%2520and%2520their%2520Use%2520as%2520Rock%2520Activity%2520Modulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼rer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span> <span> </span><span class="NLM_article-title">Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6686</span>â <span class="NLM_lpage">6690</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.09.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2009.09.115" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6686-6690&author=Y.+Yinauthor=L.+Linauthor=C.+Ruizauthor=M.+D.+Cameronauthor=J.+Pocasauthor=W.+Grantauthor=T.+Schr%C3%B6terauthor=W.+Chenauthor=D.+Duckettauthor=S.+Sch%C3%BCrerauthor=P.+LoGrassoauthor=Y.+Feng&title=Benzothiazoles+as+Rho-associated+kinase+%28ROCK-II%29+inhibitors&doi=10.1016%2Fj.bmcl.2009.09.115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.115%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPocas%26aufirst%3DJ.%26aulast%3DGrant%26aufirst%3DW.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDuckett%26aufirst%3DD.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%26aulast%3DLoGrasso%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26atitle%3DBenzothiazoles%2520as%2520Rho-associated%2520kinase%2520%2528ROCK-II%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6686%26epage%3D6690%26doi%3D10.1016%2Fj.bmcl.2009.09.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frackowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span> <span> </span><span class="NLM_article-title">The development of benzimidazoles as selective rho kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1939</span>â <span class="NLM_lpage">1943</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.01.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2010.01.124" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1939-1943&author=E.+H.+Sessionsauthor=M.+Smolinskiauthor=B.+Wangauthor=B.+Frackowiakauthor=S.+Chowdhuryauthor=Y.+Yinauthor=Y.+T.+Chenauthor=C.+Ruizauthor=L.+Linauthor=J.+Pocasauthor=T.+Schr%C3%B6terauthor=M.+D.+Cameronauthor=P.+LoGrassoauthor=Y.+Fengauthor=T.+D.+Bannister&title=The+development+of+benzimidazoles+as+selective+rho+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.01.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.124%26sid%3Dliteratum%253Aachs%26aulast%3DSessions%26aufirst%3DE.%2BH.%26aulast%3DSmolinski%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFrackowiak%26aufirst%3DB.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DPocas%26aufirst%3DJ.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DLoGrasso%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26atitle%3DThe%2520development%2520of%2520benzimidazoles%2520as%2520selective%2520rho%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1939%26epage%3D1943%26doi%3D10.1016%2Fj.bmcl.2010.01.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsinman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GonzÃ¡lez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrigues, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, V.</span></span> <span> </span><span class="NLM_article-title">PAMPA-a drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">441</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2003.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.ejps.2003.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=14998573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslWntb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=429-441&author=M.+Bermejoauthor=A.+Avdeefauthor=A.+Ruizauthor=R.+Naldaauthor=J.+A.+Ruellauthor=O.+Tsinmanauthor=I.+Gonz%C3%A1lezauthor=C.+Fern%C3%A1ndezauthor=G.+S%C3%A1nchezauthor=T.+M.+Garriguesauthor=V.+Merino&title=PAMPA-a+drug+absorption+in+vitro+model%3A+7.+Comparing+rat+in+situ%2C+Caco-2%2C+and+PAMPA+permeability+of+fluoroquinolones&doi=10.1016%2Fj.ejps.2003.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">PAMPA-a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones</span></div><div class="casAuthors">Bermejo, Marival; Avdeef, Alex; Ruiz, Ana; Nalda, Ricardo; Ruell, Jeffrey A.; Tsinman, Oksana; Gonzalez, Isabel; Fernandez, Carlos; Sanchez, Gloria; Garrigues, Teresa M.; Merino, Virginia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-441</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parallel artificial membrane permeability assay (PAMPA) was used to measure the effective permeability, Pe, as a function of pH from 4 to 10, of 17 fluoroquinolones, including three congeneric series with systematically varied alkyl chain length at the 4'N-position of the piperazine residue.  The permeability values spanned over three orders of magnitude.  The intrinsic permeability, Po, and the membrane permeability, Pm, were detd. from the pH dependence of the effective permeability.  The pKa values were detd. potentiometrically.  The PAMPA method employed stirring, adjusted such that the unstirred water layer (UWL) thickness matched the 30-100 Î¼m range estd. to be in the human small intestine.  The intrinsic permeability coeffs. (10-6 cm/s), representing the permeability of the uncharged form of the drug, are for 4'N-R-norfloxacin: 0.7 (R=H), 49 (Me), 132 (n-Pr), 365 (n-Bu); 4'N-R-ciprofloxacin: 2.7 (H), 37 (Me), 137 (n-Pr), 302 (n-Bu); 4'N-R-3'-methylciprofloxacin: 3.8 (H), 20 (Me), 51 (Et), 160 (n-Pr), 418 (n-Bu).  Increasing the alkyl chain length in the congeneric series resulted in increased permeability, averaging about 0.34 log units per methylene group, except that of the first (H-to-Me), which was about 1.2 log units.  These results were compared to Caco-2 and rat in situ permeability measurements.  The in situ closed loop technique used for obtaining permeability values in rat showed a water layer thickness effect quite consistent with in vivo expectations.  The rat-PAMPA correlation (r2=0.87) was better than that of rat-Caco-2 (r2=0.63).  Caco-2-PAMPA correlation indicated r2=0.66.  The latter correlation improved significantly (r2=0.82) when the Caco-2 data were cor. for the UWL effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FSWu8uWj6bVg90H21EOLACvtfcHk0lh8ySSPaP5Cew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslWntb8%253D&md5=ec6df386f69a99de284e53dfdccbd352</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2003.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2003.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DBermejo%26aufirst%3DM.%26aulast%3DAvdeef%26aufirst%3DA.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DNalda%26aufirst%3DR.%26aulast%3DRuell%26aufirst%3DJ.%2BA.%26aulast%3DTsinman%26aufirst%3DO.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DI.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DG.%26aulast%3DGarrigues%26aufirst%3DT.%2BM.%26aulast%3DMerino%26aufirst%3DV.%26atitle%3DPAMPA-a%2520drug%2520absorption%2520in%2520vitro%2520model%253A%25207.%2520Comparing%2520rat%2520in%2520situ%252C%2520Caco-2%252C%2520and%2520PAMPA%2520permeability%2520of%2520fluoroquinolones%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D21%26spage%3D429%26epage%3D441%26doi%3D10.1016%2Fj.ejps.2003.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sevrioukova, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span> <span> </span><span class="NLM_article-title">Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3733</span>â <span class="NLM_lpage">3741</span>, <span class="refDoi">Â DOI: 10.1021/jm400288z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400288z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVylsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3733-3741&author=I.+F.+Sevrioukovaauthor=T.+L.+Poulos&title=Pyridine-substituted+desoxyritonavir+is+a+more+potent+inhibitor+of+cytochrome+P450+3A4+than+ritonavir&doi=10.1021%2Fjm400288z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than Ritonavir</span></div><div class="casAuthors">Sevrioukova, Irina F.; Poulos, Thomas L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3733-3741</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilization of the cytochrome P 450 3A4 (CYP3A4) inhibitor ritonavir as a pharmacoenhancer for anti-HIV drugs revolutionized the treatment of HIV infection.  However, owing to ritonavir-related complications, there is a need for development of new CYP3A4 inhibitors with improved pharmacochem. properties, which requires a full understanding of the CYP3A4 inactivation mechanisms and the unraveling of possible inhibitor binding modes.  We investigated the mechanism of CYP3A4 interaction with three desoxyritonavir analogs, contg. the heme-ligating imidazole, oxazole, or pyridine group instead of the thiazole moiety (compds. 1, 2, and 3, resp.).  Our data show that compd. 3 is superior to ritonavir in terms of binding affinity and inhibitory potency owing to greater flexibility and the ability to adopt a conformation that minimizes steric clashing and optimizes protein-ligand interactions.  Addnl., Ser119 was identified as a key residue assisting binding of ritonavir-like inhibitors, which emphasizes the importance of polar interactions in the CYP3A4-ligand assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx1sbUve3zPLVg90H21EOLACvtfcHk0ljjM081uKM1fQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVylsrc%253D&md5=77a94516a246e5823502f4c89cadc5c0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm400288z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400288z%26sid%3Dliteratum%253Aachs%26aulast%3DSevrioukova%26aufirst%3DI.%2BF.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26atitle%3DPyridine-substituted%2520desoxyritonavir%2520is%2520a%2520more%2520potent%2520inhibitor%2520of%2520cytochrome%2520P450%25203A4%2520than%2520ritonavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3733%26epage%3D3741%26doi%3D10.1021%2Fjm400288z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taslimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J.</span></span> <span> </span><span class="NLM_article-title">The structure of dimeric ROCK1 reveals the mechanism for ligand selectivity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">260</span>â <span class="NLM_lpage">268</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M508847200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1074%2Fjbc.M508847200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=260-268&author=M.+Jacobsauthor=K.+Hayakawaauthor=L.+Swensonauthor=S.+Bellonauthor=M.+Flemingauthor=P.+Taslimiauthor=J.+Doran&title=The+structure+of+dimeric+ROCK1+reveals+the+mechanism+for+ligand+selectivity&doi=10.1074%2Fjbc.M508847200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508847200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508847200%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DFleming%26aufirst%3DM.%26aulast%3DTaslimi%26aufirst%3DP.%26aulast%3DDoran%26aufirst%3DJ.%26atitle%3DThe%2520structure%2520of%2520dimeric%2520ROCK1%2520reveals%2520the%2520mechanism%2520for%2520ligand%2520selectivity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D260%26epage%3D268%26doi%3D10.1074%2Fjbc.M508847200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguirre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassar, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce-Rustay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobson, A. D.</span></span> <span> </span><span class="NLM_article-title">Design of aminobenzothiazole inhibitors of Rho Kinases 1 and 2 utilizing PKA as a structure surrogate</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">613</span>â <span class="NLM_lpage">621</span>, <span class="refDoi">Â DOI: 10.1002/cbic.201700547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1002%2Fcbic.201700547" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=613-621&author=R.+A.+Judgeauthor=A.+Vasudevanauthor=V.+E.+Scottauthor=G.+H.+Simlerauthor=S.+D.+Prattauthor=M.+T.+Namovicauthor=C.+B.+Putmanauthor=A.+Aguirreauthor=V.+S.+Stollauthor=M.+Mamoauthor=S.+I.+Swannauthor=S.+C.+Cassarauthor=C.+R.+Faltynekauthor=K.+L.+Kageauthor=J.+M.+Boyce-Rustayauthor=A.+D.+Hobson&title=Design+of+aminobenzothiazole+inhibitors+of+Rho+Kinases+1+and+2+utilizing+PKA+as+a+structure+surrogate&doi=10.1002%2Fcbic.201700547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201700547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201700547%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DR.%2BA.%26aulast%3DVasudevan%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DV.%2BE.%26aulast%3DSimler%26aufirst%3DG.%2BH.%26aulast%3DPratt%26aufirst%3DS.%2BD.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DPutman%26aufirst%3DC.%2BB.%26aulast%3DAguirre%26aufirst%3DA.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DSwann%26aufirst%3DS.%2BI.%26aulast%3DCassar%26aufirst%3DS.%2BC.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DKage%26aufirst%3DK.%2BL.%26aulast%3DBoyce-Rustay%26aufirst%3DJ.%2BM.%26aulast%3DHobson%26aufirst%3DA.%2BD.%26atitle%3DDesign%2520of%2520aminobenzothiazole%2520inhibitors%2520of%2520Rho%2520Kinases%25201%2520and%25202%2520utilizing%2520PKA%2520as%2520a%2520structure%2520surrogate%26jtitle%3DChemBioChem%26date%3D2018%26volume%3D19%26spage%3D613%26epage%3D621%26doi%3D10.1002%2Fcbic.201700547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtucio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnagin, K.</span></span> <span> </span><span class="NLM_article-title">Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">615</span>â <span class="NLM_lpage">625</span>, <span class="refDoi">Â DOI: 10.1124/jpet.113.207662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1124%2Fjpet.113.207662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=24049062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=615-625&author=T.+Akamaauthor=C.+Dongauthor=C.+Virtucioauthor=D.+Sullivanauthor=Y.+Zhouauthor=Y.+K.+Zhangauthor=F.+Rockauthor=Y.+Freundauthor=L.+Liuauthor=W.+Buauthor=A.+Wuauthor=X.+Q.+Fanauthor=K.+Jarnagin&title=Linking+phenotype+to+kinase%3A+identification+of+a+novel+benzoxaborole+hinge-binding+motif+for+kinase+inhibition+and+development+of+high-potency+rho+kinase+inhibitors&doi=10.1124%2Fjpet.113.207662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors</span></div><div class="casAuthors">Akama, Tsutomu; Dong, Chen; Virtucio, Charlotte; Sullivan, David; Zhou, Yasheen; Zhang, Yong-Kang; Rock, Fernando; Freund, Yvonne; Liu, Liang; Bu, Wei; Wu, Anne; Fan, Xiao-Qing; Jarnagin, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">615-625</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Benzoxaboroles are a novel class of drug-like compds. that have been rich sources of novel inhibitors for various enzymes and of new drugs.  While examg. benzoxaborole activity in phenotypic screens, our attention was attracted by the (aminomethylphenoxy)benzoxaborole family, which potently inhibited Toll-like receptor-stimulated cytokine secretion from leukocytes.  After considering their structure-activity relationships and the central role of kinases in leukocyte biol., we performed a kinome-wide screen to investigate the members of the (aminomethylphenoxy)benzoxaborole family.  This technique identified Rho-activated kinase (ROCK) as a target.  We showed competitive behavior, with respect to ATP, and then detd. the ROCK2-drug cocrystal structure.  The drug occupies the ATP site in which the oxaborole moiety provides hydrogen bond donors and acceptors to the hinge, and the aminomethyl group interacts with the magnesium/ATP-interacting aspartic acid common to protein kinases.  The series exhibits excellent selectivity against most of the kinome, with greater than 15-fold selectivity against the next best member of the AGC protein kinase subfamily.  Medicinal chem. efforts with structure-based design resulted in a compd. with a Ki of 170 nM.  Cellular studies revealed strong enzyme inhibition rank correlation with suppression of intracellular phosphorylation of a ROCK substrate.  The biochem. potencies of these compds. also translated to functional activity, causing smooth muscle relaxation in rat aorta and guinea pig trachea.  The series exhibited oral availability and one member reduced rat blood pressure, consistent with ROCK's role in smooth muscle contraction.  Thus, the benzoxaborole moiety represents a novel hinge-binding kinase scaffold that may have potential for therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqksYEBV0FP2bVg90H21EOLACvtfcHk0liF-5pWYfPymA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jI&md5=75a9f55dcbaee29e4703aabb16f2276b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207662%26sid%3Dliteratum%253Aachs%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DVirtucio%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DRock%26aufirst%3DF.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DX.%2BQ.%26aulast%3DJarnagin%26aufirst%3DK.%26atitle%3DLinking%2520phenotype%2520to%2520kinase%253A%2520identification%2520of%2520a%2520novel%2520benzoxaborole%2520hinge-binding%2520motif%2520for%2520kinase%2520inhibition%2520and%2520development%2520of%2520high-potency%2520rho%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D615%26epage%3D625%26doi%3D10.1124%2Fjpet.113.207662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castermans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panitti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanormelingen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4309</span>â <span class="NLM_lpage">4324</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOhtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4309-4324&author=S.+Bolandauthor=A.+Bourinauthor=J.+Alenauthor=J.+Geraetsauthor=P.+Schroedersauthor=K.+Castermansauthor=N.+Kindtauthor=N.+Boumansauthor=L.+Panittiauthor=S.+Fransenauthor=J.+Vanormelingenauthor=J.+M.+Stassenauthor=D.+Leysenauthor=O.+Defert&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel%2C+highly+active+soft+ROCK+inhibitors&doi=10.1021%2Facs.jmedchem.5b00308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel, Highly Active Soft ROCK Inhibitors</span></div><div class="casAuthors">Boland, Sandro; Bourin, Arnaud; Alen, Jo; Geraets, Jacques; Schroeders, Pieter; Castermans, Karolien; Kindt, Nele; Boumans, Nicki; Panitti, Laura; Fransen, Silke; Vanormelingen, Jessica; Stassen, Jean Marie; Leysen, Dirk; Defert, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4309-4324</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ROCK1 and ROCK2 play important roles in numerous cellular functions, including smooth muscle cell contraction, cell proliferation, adhesion, and migration.  Consequently, ROCK inhibitors are of interest for treating multiple indications including cardiovascular diseases, inflammatory and autoimmune diseases, lung diseases, and eye diseases.  However, systemic inhibition of ROCK is expected to result in significant side effects.  Strategies allowing reduced systemic exposure are therefore of interest.  In a continuing effort toward identification of ROCK inhibitors, we here report the design, synthesis, and evaluation of novel soft ROCK inhibitors displaying an ester function allowing their rapid inactivation in the systemic circulation.  Those compds., e.g. I, display subnanomolar activity against ROCK and strong differences of functional activity between parent compds. and expected metabolites.  The binding mode of a representative compd. was detd. exptl. in a single-crystal X-ray diffraction study.  Enzymes responsible for inactivation of these compds. once they enter systemic circulation are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWI5LwOkT64rVg90H21EOLACvtfcHk0liF-5pWYfPymA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOhtbc%253D&md5=320e6fbb1cf87ba8c03fc17795f6802f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00308%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DS.%26aulast%3DBourin%26aufirst%3DA.%26aulast%3DAlen%26aufirst%3DJ.%26aulast%3DGeraets%26aufirst%3DJ.%26aulast%3DSchroeders%26aufirst%3DP.%26aulast%3DCastermans%26aufirst%3DK.%26aulast%3DKindt%26aufirst%3DN.%26aulast%3DBoumans%26aufirst%3DN.%26aulast%3DPanitti%26aufirst%3DL.%26aulast%3DFransen%26aufirst%3DS.%26aulast%3DVanormelingen%26aufirst%3DJ.%26aulast%3DStassen%26aufirst%3DJ.%2BM.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DDefert%26aufirst%3DO.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%252C%2520highly%2520active%2520soft%2520ROCK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4309%26epage%3D4324%26doi%3D10.1021%2Facs.jmedchem.5b00308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huth, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cothron, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajduk, P. J.</span></span> <span> </span><span class="NLM_article-title">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">224</span>, <span class="refDoi">Â DOI: 10.1021/ja0455547</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0455547" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=217-224&author=J.+R.+Huthauthor=R.+Mendozaauthor=E.+T.+Olejniczakauthor=R.+W.+Johnsonauthor=D.+A.+Cothronauthor=Y.+Liuauthor=C.+G.+Lernerauthor=J.+Chenauthor=P.+J.+Hajduk&title=ALARM+NMR%3A+a+rapid+and+robust+experimental+method+to+detect+reactive+false+positives+in+biochemical+screens&doi=10.1021%2Fja0455547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span></div><div class="casAuthors">Huth, Jeffrey R.; Mendoza, Renaldo; Olejniczak, Edward T.; Johnson, Robert W.; Cothron, Darlene A.; Liu, Yaya; Lerner, Claude G.; Chen, Jun; Hajduk, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput screening (HTS) of large compd. collections typically results in numerous small mol. hits that must be carefully evaluated to identify valid drug leads.  Although several filtering mechanisms and other tools exist that can assist the chemist in this process, it is often the case that costly synthetic resources are expended in pursuing false positives.  We report here a rapid and reliable NMR-based method for identifying reactive false positives including those that oxidize or alkylate a protein target.  Importantly, the reactive species need not be the parent compd., as both reactive impurities and breakdown products can be detected.  The assay is called ALARM NMR (a La assay to detect reactive mols. by NMR) and is based on monitoring DTT-dependent 13C chem. shift changes of the human La antigen in the presence of a test compd. or mixt.  Extensive validation has been performed to demonstrate the reliability and utility of using ALARM NMR to assess thiol reactivity.  This included comparing ALARM NMR to a glutathione-based fluorescence assay, as well as testing a collection of more than 3500 compds. contg. HTS hits from 23 drug targets.  The data show that current in silico filtering tools fail to identify more than half of the compds. that can act via reactive mechanisms.  Significantly, we show how ALARM NMR data has been crit. in identifying reactive compds. that would otherwise have been prioritized for lead optimization.  In addn., a new filtering tool has been developed on the basis of the ALARM NMR data that can augment current in silico programs for identifying nuisance compds. and improving the process of hit triage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolKou1lGZ8tbVg90H21EOLACvtfcHk0lj0FxwGSt7ocg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF&md5=466332d4bdcddf6bc8a630aacbbb32ef</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fja0455547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0455547%26sid%3Dliteratum%253Aachs%26aulast%3DHuth%26aufirst%3DJ.%2BR.%26aulast%3DMendoza%26aufirst%3DR.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DJohnson%26aufirst%3DR.%2BW.%26aulast%3DCothron%26aufirst%3DD.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLerner%26aufirst%3DC.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DALARM%2520NMR%253A%2520a%2520rapid%2520and%2520robust%2520experimental%2520method%2520to%2520detect%2520reactive%2520false%2520positives%2520in%2520biochemical%2520screens%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D217%26epage%3D224%26doi%3D10.1021%2Fja0455547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and drug-like compounds: the rule-of-five revolution</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">337</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&author=C.+A.+Lipinski&title=Lead-+and+drug-like+compounds%3A+the+rule-of-five+revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0lj0FxwGSt7ocg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520drug-like%2520compounds%253A%2520the%2520rule-of-five%2520revolution%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D341%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>â <span class="NLM_lpage">6756</span>, <span class="refDoi">Â DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhYp9UQFDYBlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4872</span>â <span class="NLM_lpage">4875</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0lhYp9UQFDYBlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span>AbbVie
Compound Toolbox, <a href="https://www.openinnovation.abbvie.com/web/compound-toolbox" class="extLink">https://www.openinnovation.abbvie.com/web/compound-toolbox</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AbbVie%0ACompound+Toolbox%2C+https%3A%2F%2Fwww.openinnovation.abbvie.com%2Fweb%2Fcompound-toolbox."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatenhorst, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roser, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saal, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TÃ¶nges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingor, P.</span></span> <span> </span><span class="NLM_article-title">ROCK inhibition in models of neurodegeneration and its potential for clinical translation</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">21</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2018.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.pharmthera.2018.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=29621594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFWqt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2018&pages=1-21&author=J.+C.+Kochauthor=L.+Tatenhorstauthor=A.+E.+Roserauthor=K.+A.+Saalauthor=L.+T%C3%B6ngesauthor=P.+Lingor&title=ROCK+inhibition+in+models+of+neurodegeneration+and+its+potential+for+clinical+translation&doi=10.1016%2Fj.pharmthera.2018.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ROCK inhibition in models of neurodegeneration and its potential for clinical translation</span></div><div class="casAuthors">Koch, Jan Christoph; Tatenhorst, Lars; Roser, Anna-Elisa; Saal, Kim-Ann; Toenges, Lars; Lingor, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative disorders like Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis are affecting a rapidly increasing population worldwide.  While common pathomechanisms such as protein aggregation, axonal degeneration, dysfunction of protein clearing and an altered immune response have been characterized, no disease-modifying therapies have been developed so far.  Interestingly, a significant involvement of the Rho kinase (ROCK) signaling pathway has been described in all of these mechanisms making it a promising target for new therapeutic approaches.In this article, we first review current knowledge of the involvement of ROCK in neurodegenerative disorders and the utility of its inhibition as a disease-modifying therapy in different neurodegenerative disorders.  After a detailed description of the biochem. characteristics of ROCK and its mol. interactors, differences of ROCK-expression under physiol. and pathol. conditions are compared.  Next, different pharmacol. and mol.-genetic strategies to inhibit ROCK-function are discussed, focusing on pharmacol. ROCK-inhibitors.  The role of the ROCK-pathway in cellular processes that are central in neurodegenerative disorders pathol. like axonal degeneration, autophagy, synaptic and glial function is explained in detail.  Finally, all available data on ROCK-inhibition in different animal models of neurodegenerative disorders is reviewed and first approaches for translation into human patients are discussed.Taken together, there is now extensive evidence from preclin. studies in several neurodegenerative disorders that characterize ROCK as a promising drug target for further translational research in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg_1c2sOs7RLVg90H21EOLACvtfcHk0li-28FeW4TWyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFWqt7c%253D&md5=6f6b694b27280ad3947c3a734633ba09</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DJ.%2BC.%26aulast%3DTatenhorst%26aufirst%3DL.%26aulast%3DRoser%26aufirst%3DA.%2BE.%26aulast%3DSaal%26aufirst%3DK.%2BA.%26aulast%3DT%25C3%25B6nges%26aufirst%3DL.%26aulast%3DLingor%26aufirst%3DP.%26atitle%3DROCK%2520inhibition%2520in%2520models%2520of%2520neurodegeneration%2520and%2520its%2520potential%2520for%2520clinical%2520translation%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D189%26spage%3D1%26epage%3D21%26doi%3D10.1016%2Fj.pharmthera.2018.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lingor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teusch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤hr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">189</span>, <span class="refDoi">Â DOI: 10.1111/j.1471-4159.2007.04756.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1111%2Fj.1471-4159.2007.04756.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17608642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qu7bJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2007&pages=181-189&author=P.+Lingorauthor=N.+Teuschauthor=K.+Schwarzauthor=R.+Muellerauthor=H.+Mackauthor=M.+B%C3%A4hrauthor=B.+K.+Mueller&title=Inhibition+of+Rho+kinase+%28ROCK%29+increases+neurite+outgrowth+on+chondroitin+sulphate+proteoglycan+in+vitro+and+axonal+regeneration+in+the+adult+optic+nerve+in+vivo&doi=10.1111%2Fj.1471-4159.2007.04756.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo</span></div><div class="casAuthors">Lingor, Paul; Teusch, Nicole; Schwarz, Katrin; Mueller, Reinhold; Mack, Helmut; Baehr, Mathias; Mueller, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Inhibitory mols. derived from CNS myelin and glial scar tissue are major causes for insufficient functional regeneration in the mammalian CNS.  A multitude of these mols. signal through the Rho/Rho kinase (ROCK) pathway.  We evaluated three inhibitors of ROCK, Y-27632, Fasudil (HA-1077), and Dimethylfasudil (H-1152), in models of neurite outgrowth in vitro.  We show, that all three ROCK inhibitors partially restore neurite outgrowth of Ntera-2 neurons on the inhibitory chondroitin sulfate proteoglycan substrate.  In the rat optic nerve crush model Y-27632 dose-dependently increased regeneration of retinal ganglion cell axons in vivo.  Application of Dimethylfasudil showed a trend towards increased axonal regeneration in an intermediate concn.  We demonstrate that inhibition of ROCK can be an effective therapeutic approach to increase regeneration of CNS neurons.  The selection of a suitable inhibitor with a broad therapeutic window, however, is crucial in order to minimize unwanted side effects and to avoid deleterious effects on nerve fiber growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopIfA6qAjEj7Vg90H21EOLACvtfcHk0li-28FeW4TWyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qu7bJ&md5=1cd9c9135e936e471df9512111b97c9f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2007.04756.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2007.04756.x%26sid%3Dliteratum%253Aachs%26aulast%3DLingor%26aufirst%3DP.%26aulast%3DTeusch%26aufirst%3DN.%26aulast%3DSchwarz%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DR.%26aulast%3DMack%26aufirst%3DH.%26aulast%3DB%25C3%25A4hr%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DB.%2BK.%26atitle%3DInhibition%2520of%2520Rho%2520kinase%2520%2528ROCK%2529%2520increases%2520neurite%2520outgrowth%2520on%2520chondroitin%2520sulphate%2520proteoglycan%2520in%2520vitro%2520and%2520axonal%2520regeneration%2520in%2520the%2520adult%2520optic%2520nerve%2520in%2520vivo%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D103%26spage%3D181%26epage%3D189%26doi%3D10.1111%2Fj.1471-4159.2007.04756.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="note"><p class="first last">Additional studies to identify positive controls for the optic nerve crush model are ongoing and will be published separately at a future date.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zilun  Hu</span>, <span class="hlFld-ContribAuthor ">Cailan  Wang</span>, <span class="hlFld-ContribAuthor ">Peter W.  Glunz</span>, <span class="hlFld-ContribAuthor ">Julia  Li</span>, <span class="hlFld-ContribAuthor ">Nathan L.  Cheadle</span>, <span class="hlFld-ContribAuthor ">Alice Y.  Chen</span>, <span class="hlFld-ContribAuthor ">Xue-Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Joseph E.  Myers</span>, <span class="hlFld-ContribAuthor ">Victor R.  Guarino</span>, <span class="hlFld-ContribAuthor ">Anne  Rose</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Doree  Sitkoff</span>, <span class="hlFld-ContribAuthor ">David S.  Taylor</span>, <span class="hlFld-ContribAuthor ">Songmei  Xu</span>, <span class="hlFld-ContribAuthor ">Chunhong  Yan</span>, <span class="hlFld-ContribAuthor ">Hongwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lisa  Zhang</span>, <span class="hlFld-ContribAuthor ">James  Hennan</span>, <span class="hlFld-ContribAuthor ">Leonard P.  Adam</span>, <span class="hlFld-ContribAuthor ">Ruth R.  Wexler</span>, <span class="hlFld-ContribAuthor ">Mimi L.  Quan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (21)
                                     , 127495. <a href="https://doi.org/10.1016/j.bmcl.2020.127495" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127495</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127495%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bphenylpyrazole%252Bamide%252BROCK%252Binhibitor%252Bas%252Ba%252Btool%252Bmolecule%252Bfor%252Bin%252Bvivo%252Bstudies%26aulast%3DHu%26aufirst%3DZilun%26date%3D2020%26volume%3D30%26issue%3D21%26spage%3D127495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laijun  Song</span>, <span class="hlFld-ContribAuthor ">Chunyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Wenxin  Zheng</span>, <span class="hlFld-ContribAuthor ">Dan  Lu</span>, <span class="hlFld-ContribAuthor ">Hong  Jiao</span>, <span class="hlFld-ContribAuthor ">Rongbing  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhonglei  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Computational systematic selectivity of the Fasalog inhibitors between ROCK-I and ROCK-II kinase isoforms in Alzheimerâs disease. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2020,</strong> <em>87 </em>, 107314. <a href="https://doi.org/10.1016/j.compbiolchem.2020.107314" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2020.107314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2020.107314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2020.107314%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DComputational%252Bsystematic%252Bselectivity%252Bof%252Bthe%252BFasalog%252Binhibitors%252Bbetween%252BROCK-I%252Band%252BROCK-II%252Bkinase%252Bisoforms%252Bin%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DSong%26aufirst%3DLaijun%26date%3D2020%26volume%3D87%26spage%3D107314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. Alison  Rinderspacher</span>. </span><span class="cited-content_cbyCitation_article-title">Six-Membered Ring Systems: Diazines and Benzo Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 465-504. <a href="https://doi.org/10.1016/B978-0-12-819962-6.00013-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-819962-6.00013-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819962-6.00013-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819962-6.00013-0%26sid%3Dliteratum%253Aachs%26atitle%3DSix-Membered%252BRing%252BSystems%25253A%252BDiazines%252Band%252BBenzo%252BDerivatives%26aulast%3DRinderspacher%26aufirst%3DK.%2BAlison%26date%3D2020%26spage%3D465%26epage%3D504%26pub%3DElsevier%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seketoulie  Keretsu</span>, <span class="hlFld-ContribAuthor ">Swapnil P.  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Seung  Joo Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-019-48949-w" title="DOI URL">https://doi.org/10.1038/s41598-019-48949-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-019-48949-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-019-48949-w%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DComputational%252Bstudy%252Bof%252Bparoxetine-like%252Binhibitors%252Breveals%252Bnew%252Bmolecular%252Binsight%252Bto%252Binhibit%252BGRK2%252Bwith%252Bselectivity%252Bover%252BROCK1%26aulast%3DKeretsu%26aufirst%3DSeketoulie%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neetu  Dayal</span>, <span class="hlFld-ContribAuthor ">Clinton G.  Mikek</span>, <span class="hlFld-ContribAuthor ">Delmis  Hernandez</span>, <span class="hlFld-ContribAuthor ">George A.  Naclerio</span>, <span class="hlFld-ContribAuthor ">Elizabeth Fei  Yin Chu</span>, <span class="hlFld-ContribAuthor ">Brandon A.  Carter-Cooper</span>, <span class="hlFld-ContribAuthor ">Rena G.  Lapidus</span>, <span class="hlFld-ContribAuthor ">Herman O.  Sintim</span>. </span><span class="cited-content_cbyCitation_article-title">Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f]quinoline boronic acid ROCK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 449-456. <a href="https://doi.org/10.1016/j.ejmech.2019.06.089" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.089%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotently%252Binhibiting%252Bcancer%252Bcell%252Bmigration%252Bwith%252Bnovel%252B3H-pyrazolo%25255B4%25252C3-f%25255Dquinoline%252Bboronic%252Bacid%252BROCK%252Binhibitors%26aulast%3DDayal%26aufirst%3DNeetu%26date%3D2019%26volume%3D180%26spage%3D449%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Montaruli</span>, <span class="hlFld-ContribAuthor ">Domenico  Alberga</span>, <span class="hlFld-ContribAuthor ">Fulvio  Ciriaco</span>, <span class="hlFld-ContribAuthor ">Daniela  Trisciuzzi</span>, <span class="hlFld-ContribAuthor ">Anna Rita  Tondo</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search â . </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2233. <a href="https://doi.org/10.3390/molecules24122233" title="DOI URL">https://doi.org/10.3390/molecules24122233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAccelerating%252BDrug%252BDiscovery%252Bby%252BEarly%252BProtein%252BDrug%252BTarget%252BPrediction%252BBased%252Bon%252Ba%252BMulti-Fingerprint%252BSimilarity%252BSearch%252B%2525E2%252580%2525A0%26aulast%3DMontaruli%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of HTS hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Scheme for HTC Library Follow up on Compound <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) PS-DCC, DIEA, DMA, microwave, 100 Â°C, 10 min.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structures of compound <b>12</b> in (a) PKA (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9L">6E9L</a>), (b) Rock1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9W">6E9W</a>), and (c) Rock2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ED6">6ED6</a>). All structures were obtained by cocrystallization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route towards (Benzyloxy)benzene Analogues <b>16</b>â<b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME, DIPEA, 80 Â°C, 72 h; (ii) (<i>R</i>)- or (<i>S</i>)-1-(3-methoxyphenyl)ethan-1-amine, EDAC, HOBt, 0 Â°C to RT, O/N.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route towards (Benzyloxy)benzene Analogues <b>26</b>â<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd<sub>2</sub>(dba)<sub>3</sub>, sodium 2-methylpropan-2-olate, <sup>t</sup>BuXPhos, dioxane, N<sub>2</sub>, 80 Â°C, O/N.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route towards Key Intermediates for Compounds <b>36</b>â<b>44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDAC, HOBt, 0 Â°C to RT, O/N, 61%; (ii) Na<sub>2</sub>CO<sub>3</sub>, DMSO, 110 Â°C, 34%; (iii) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 Â°C, 75%; (iv) chiral separation; (v) TFA, DCM, 61%.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route towards Compounds <b>46</b>â<b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>4</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME, DIPEA, 80 Â°C, 72 h; (ii) EDAC, HOBt, 0 Â°C to RT, O/N; (iii) <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine, diamine, DMSO, 110 Â°C, O/N.</p></p></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of compound <b>47</b> in the active site of PKA (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E99">6E99</a>). Structure was obtained by cocrystallization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Radar plot of calculated physicochemical properties and (b) predicted reduced risk of toxicity, for compounds <b>1</b>, <b>5</b>, <b>6</b>, <b>16</b>, <b>44</b>, and <b>58</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthetic Route towards Compounds <b>54</b>â<b>58</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EDAC, HOBt, 0 Â°C to RT, O/N; (ii) <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine, diamine, DMSO 110 Â°C, O/N; (iii) CH<sub>3</sub>CO<sub>2</sub>K, 4,4,4â²,4â²,5,5,5â²,5â²-octamethyl-2,2â²-bi(1,3,2-dioxaborolane), 4-chloropyrimidine hydrochloride, PdCl<sub>2</sub>(dppf)-DCM, Cs<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, 65 Â°C, 3 h; (iv) TFA.</p></p></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/medium/jm-2018-01098z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Protection of the retinal nerve fiber layer with compound <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b01098/20181226/images/large/jm-2018-01098z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01098&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i130">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakafuku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span> <span> </span><span class="NLM_article-title">Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2208</span>â <span class="NLM_lpage">2216</span>, <span class="refDoi">Â DOI: 10.1002/j.1460-2075.1996.tb00574.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1002%2Fj.1460-2075.1996.tb00574.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=2208-2216&author=T.+Matsuiauthor=M.+Amanoauthor=T.+Yamamotoauthor=K.+Chiharaauthor=M.+Nakafukuauthor=M.+Itoauthor=T.+Nakanoauthor=K.+Okawaauthor=A.+Iwamatsuauthor=K.+Kaibuchi&title=Rho-associated+kinase%2C+a+novel+serine%2Fthreonine+kinase%2C+as+a+putative+target+for+small+GTP+binding+protein+Rho&doi=10.1002%2Fj.1460-2075.1996.tb00574.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1996.tb00574.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1996.tb00574.x%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DChihara%26aufirst%3DK.%26aulast%3DNakafuku%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DOkawa%26aufirst%3DK.%26aulast%3DIwamatsu%26aufirst%3DA.%26aulast%3DKaibuchi%26aufirst%3DK.%26atitle%3DRho-associated%2520kinase%252C%2520a%2520novel%2520serine%252Fthreonine%2520kinase%252C%2520as%2520a%2520putative%2520target%2520for%2520small%2520GTP%2520binding%2520protein%2520Rho%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D2208%26epage%3D2216%26doi%3D10.1002%2Fj.1460-2075.1996.tb00574.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narumiya, S.</span></span> <span> </span><span class="NLM_article-title">ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">193</span>, <span class="refDoi">Â DOI: 10.1016/0014-5793(96)00811-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2F0014-5793%2896%2900811-3" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=1996&pages=189-193&author=O.+Nakagawaauthor=K.+Fujisawaauthor=T.+Ishizakiauthor=Y.+Saitoauthor=K.+Nakaoauthor=S.+Narumiya&title=ROCK-I+and+ROCK-II%2C+two+isoforms+of+Rho-associated+coiled-coil+forming+protein+serine%2Fthreonine+kinase+in+mice&doi=10.1016%2F0014-5793%2896%2900811-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2896%2900811-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252896%252900811-3%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DO.%26aulast%3DFujisawa%26aufirst%3DK.%26aulast%3DIshizaki%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DNakao%26aufirst%3DK.%26aulast%3DNarumiya%26aufirst%3DS.%26atitle%3DROCK-I%2520and%2520ROCK-II%252C%2520two%2520isoforms%2520of%2520Rho-associated%2520coiled-coil%2520forming%2520protein%2520serine%252Fthreonine%2520kinase%2520in%2520mice%26jtitle%3DFEBS%2520Lett.%26date%3D1996%26volume%3D392%26spage%3D189%26epage%3D193%26doi%3D10.1016%2F0014-5793%2896%2900811-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manser, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span> <span> </span><span class="NLM_article-title">The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5313</span>â <span class="NLM_lpage">5127</span>, <span class="refDoi">Â DOI: 10.1128/MCB.16.10.5313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1128%2FMCB.16.10.5313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=8816443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADyaK28XlvFamt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=5313-5127&author=T.+Leungauthor=X.+Q.+Chenauthor=E.+Manserauthor=L.+Lim&title=The+p160+RhoA-binding+kinase+ROK+alpha+is+a+member+of+a+kinase+family+and+is+involved+in+the+reorganization+of+the+cytoskeleton&doi=10.1128%2FMCB.16.10.5313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The p160 RhoA-binding kinase ROKÎ± is a member of a kinase family and is involved in the reorganization of the cytoskeleton</span></div><div class="casAuthors">Leung, Thomas; Chen, Xiang-Qun; Manser, Edward; Lim, Louis</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5313-5327</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The GTPase RhoA has been implicated in various cellular activity, including the formation of stress fiber,s motility, and cytokinesis.  We recently reported on a p150 serine/threonine kinase (termed ROKÎ±) binding RhoA only in its active GTP-bound state and on its cDNA; introduction of RhoA into HeLa cells resulted in translocation of the cytoplasmic kinase to plasma membranes, consistent with ROKÎ± being a target for RhoA (T. Leung, E. Manser, L. Tan, and L. Lim, J. Biol. Chem. 256:29051-29054, 1995).  Reanal. of the cDNA revealed that ROKÎ± contains an addnl. N-terminal region.  We also isolated another cDNA which encoded a protein (ROKÎ²) with 90% identity of ROKÎ± in the kinase domain.  Both ROKÎ± and ROKÎ², which has a mol. mass of 160 kDa, contained a highly conserved cysteine/histidine-rich domain located within a putative pleckstrin homol. domain.  The kinases bound Rho, RhoB, and RhoC but not Rac1 and Cdc42.  The Rho-binding domain comprises about 30 amino acids.  Mutations within this domain caused partial or complete loss of Rho binding.  The morphol. effects of ROKÎ± were investigated by microinjecting HeLa cells with DNA constructs encoding various forms of ROKÎ±.  Full-length ROKÎ± promoted formation of stress fibers and focal adhesion complexes, consistent with its being an effector of RhoA.  ROKÎ± truncated at the C terminus promoted this formation and also extensive condensation of actin microfilaments and nuclear disruption.  The proteins exhibited protein kinase activity which was required for stress fiber formation; the kinase-dead ROKÎ±K112A and N-terminally truncated mutants showed no such promotion.  The latter mutant instead induced disassembly of stress fibers and focal adhesion complexes, accompanied by cell spreading.  These effects were mediated by the C-terminal region contg. Rho-binding, cysteine/histidine-rich, and pleckstrin homol. domains.  Thus, the multidomained ROKÎ± appears to be involved in reorganization of the cytoskeleton, with the N and C termini acting as pos. and neg. regulators, resp., of the kinase domain whose activity is crucial for formation of stress fibers and focal adhesion complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojaok4XDTUh7Vg90H21EOLACvtfcHk0ljXAGQH-6jtyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvFamt7g%253D&md5=ff30cf0f5819581e9d74001197154a25</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FMCB.16.10.5313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.16.10.5313%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%2BQ.%26aulast%3DManser%26aufirst%3DE.%26aulast%3DLim%26aufirst%3DL.%26atitle%3DThe%2520p160%2520RhoA-binding%2520kinase%2520ROK%2520alpha%2520is%2520a%2520member%2520of%2520a%2520kinase%2520family%2520and%2520is%2520involved%2520in%2520the%2520reorganization%2520of%2520the%2520cytoskeleton%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D5313%26epage%3D5127%26doi%3D10.1128%2FMCB.16.10.5313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manser, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, L.</span></span> <span> </span><span class="NLM_article-title">A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">29051</span>â <span class="NLM_lpage">29054</span>, <span class="refDoi">Â DOI: 10.1074/jbc.270.49.29051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1074%2Fjbc.270.49.29051" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=29051-29054&author=T.+Leungauthor=E.+Manserauthor=L.+Tanauthor=L.+Lim&title=A+novel+serine%2Fthreonine+kinase+binding+the+Ras-related+RhoA+GTPase+which+translocates+the+kinase+to+peripheral+membranes&doi=10.1074%2Fjbc.270.49.29051"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.49.29051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.49.29051%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DT.%26aulast%3DManser%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DLim%26aufirst%3DL.%26atitle%3DA%2520novel%2520serine%252Fthreonine%2520kinase%2520binding%2520the%2520Ras-related%2520RhoA%2520GTPase%2520which%2520translocates%2520the%2520kinase%2520to%2520peripheral%2520membranes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D29051%26epage%3D29054%26doi%3D10.1074%2Fjbc.270.49.29051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakafuku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamatsu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span> <span> </span><span class="NLM_article-title">Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">248</span>, <span class="refDoi">Â DOI: 10.1126/science.273.5272.245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1126%2Fscience.273.5272.245" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=245-248&author=K.+Kimuraauthor=M.+Itoauthor=M.+Amanoauthor=K.+Chiharaauthor=Y.+Fukataauthor=M.+Nakafukuauthor=B.+Yamamoriauthor=J.+Fengauthor=T.+Nakanoauthor=K.+Okawaauthor=A.+Iwamatsuauthor=K.+Kaibuchi&title=Regulation+of+myosin+phosphatase+by+Rho+and+Rho-associated+kinase+%28Rho-kinase%29&doi=10.1126%2Fscience.273.5272.245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.245%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DChihara%26aufirst%3DK.%26aulast%3DFukata%26aufirst%3DY.%26aulast%3DNakafuku%26aufirst%3DM.%26aulast%3DYamamori%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DOkawa%26aufirst%3DK.%26aulast%3DIwamatsu%26aufirst%3DA.%26aulast%3DKaibuchi%26aufirst%3DK.%26atitle%3DRegulation%2520of%2520myosin%2520phosphatase%2520by%2520Rho%2520and%2520Rho-associated%2520kinase%2520%2528Rho-kinase%2529%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D245%26epage%3D248%26doi%3D10.1126%2Fscience.273.5272.245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span> <span> </span><span class="NLM_article-title">Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">670</span>â <span class="NLM_lpage">676</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M007074200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1074%2Fjbc.M007074200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=670-676&author=T.+Sumiauthor=K.+Matsumotoauthor=T.+Nakamura&title=Specific+activation+of+LIM+kinase+2+via+phosphorylation+of+threonine+505+by+ROCK%2C+a+Rho-dependent+protein+kinase&doi=10.1074%2Fjbc.M007074200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M007074200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M007074200%26sid%3Dliteratum%253Aachs%26aulast%3DSumi%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DT.%26atitle%3DSpecific%2520activation%2520of%2520LIM%2520kinase%25202%2520via%2520phosphorylation%2520of%2520threonine%2520505%2520by%2520ROCK%252C%2520a%2520Rho-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D670%26epage%3D676%26doi%3D10.1074%2Fjbc.M007074200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">361</span>, <span class="refDoi">Â DOI: 10.1083/jcb.145.2.347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1083%2Fjcb.145.2.347" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1999&pages=347-361&author=Y.+Fukataauthor=N.+Oshiroauthor=N.+Kinoshitaauthor=Y.+Kawanoauthor=Y.+Matsuokaauthor=V.+Bennettauthor=Y.+Matsuuraauthor=K.+Kaibuchi&title=Phosphorylation+of+adducin+by+Rho-kinase+plays+a+crucial+role+in+cell+motility&doi=10.1083%2Fjcb.145.2.347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1083%2Fjcb.145.2.347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.145.2.347%26sid%3Dliteratum%253Aachs%26aulast%3DFukata%26aufirst%3DY.%26aulast%3DOshiro%26aufirst%3DN.%26aulast%3DKinoshita%26aufirst%3DN.%26aulast%3DKawano%26aufirst%3DY.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DBennett%26aufirst%3DV.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DKaibuchi%26aufirst%3DK.%26atitle%3DPhosphorylation%2520of%2520adducin%2520by%2520Rho-kinase%2520plays%2520a%2520crucial%2520role%2520in%2520cell%2520motility%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1999%26volume%3D145%26spage%3D347%26epage%3D361%26doi%3D10.1083%2Fjcb.145.2.347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickers, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, T. C.</span></span> <span> </span><span class="NLM_article-title">Rho kinase activates ezrin-radixin-moesin (ERM) proteins and mediates their function in cortical neuron growth, morphology and motility in vitro</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">34</span>â <span class="NLM_lpage">46</span>, <span class="refDoi">Â DOI: 10.1002/jnr.21102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1002%2Fjnr.21102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17075902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVyhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2007&pages=34-46&author=M.+A.+Haasauthor=J.+C.+Vickersauthor=T.+C.+Dickson&title=Rho+kinase+activates+ezrin-radixin-moesin+%28ERM%29+proteins+and+mediates+their+function+in+cortical+neuron+growth%2C+morphology+and+motility+in+vitro&doi=10.1002%2Fjnr.21102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase activates ezrin-radixin-moesin (ERM) proteins and mediates their function in cortical neuron growth, morphology and motility in vitro</span></div><div class="casAuthors">Haas, Matilda A.; Vickers, James C.; Dickson, Tracey C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-46</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ezrin-radixin-moesin (ERM) family of proteins contribute to cytoskeletal processes underlying many vital cellular functions.  Their previously elucidated roles in non-neuronal cells are an indication of their potential importance in CNS neurons.  The specific mechanisms of their activation are unknown, but are likely to depend on factors such as the cell type and biol. context.  For ERM proteins to become active they must be phosphorylated at a specific C-terminal threonine residue.  In non-neuronal cells, several kinases, including the Rho GTPase family member Rho kinase, have been identified as capable of phosphorylating the C-terminal threonine.  In these expts. we have investigated specifically the potential role of Rho kinase mediated ERM activation in cortical neurons, utilizing a new pharmacol. inhibitor of Rho kinase and quant. anal. of aspects of neuronal functions potentially mediated by ERM proteins.  Rho kinase inhibition significantly suppressed aspects of neuronal development including neurite initiation and outgrowth, as well as growth cone morphol., with a concomitant loss of phosphorylated ERM immunolabeling in areas assocd. with neuronal growth.  The ability of the Rho kinase inhibitor to decrease the amt. of pERM protein was shown by immunoblotting.  Post-injury responses were neg. affected by Rho kinase inhibition, namely by a significant decrease in the no. of regenerative neurites.  We investigated a novel role for ERM proteins in neuron migration using a post-injury motility assay, where Rho kinase inhibition resulted in significant and drastic redn. in neuron motility and phosphorylated ERM immunolabeling.  Thus, Rho kinase is an important activator of ERMs in mediating specific neuronal functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt00xr3lqJjLVg90H21EOLACvtfcHk0li3xoVUP5ZohA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVyhuw%253D%253D&md5=9fe29b0df3c0cf9b85228eed08279ddc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fjnr.21102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.21102%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DM.%2BA.%26aulast%3DVickers%26aufirst%3DJ.%2BC.%26aulast%3DDickson%26aufirst%3DT.%2BC.%26atitle%3DRho%2520kinase%2520activates%2520ezrin-radixin-moesin%2520%2528ERM%2529%2520proteins%2520and%2520mediates%2520their%2520function%2520in%2520cortical%2520neuron%2520growth%252C%2520morphology%2520and%2520motility%2520in%2520vitro%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2007%26volume%3D85%26spage%3D34%26epage%3D46%26doi%3D10.1002%2Fjnr.21102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noma, K.</span></span> <span> </span><span class="NLM_article-title">Rho kinase (ROCK) inhibitors</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">24</span>, <span class="refDoi">Â DOI: 10.1097/FJC.0b013e318070d1bd</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1097%2FFJC.0b013e318070d1bd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17666911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFGju7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=17-24&author=J.+K.+Liaoauthor=M.+Setoauthor=K.+Noma&title=Rho+kinase+%28ROCK%29+inhibitors&doi=10.1097%2FFJC.0b013e318070d1bd"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase (ROCK) inhibitors</span></div><div class="casAuthors">Liao, James K.; Seto, Minoru; Noma, Kensuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-24</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The Rho kinase (ROCK) isoforms, ROCK1 and ROCK2, were initially discovered as downstream targets of the small GTP-binding protein Rho.  Because ROCKs mediate various important cellular functions such as cell shape, motility, secretion, proliferation, and gene expression, it is likely that this pathway will intersect with other signaling pathways known to contribute to cardiovascular disease.  Indeed, ROCKs have already been implicated in the regulation of vascular tone, proliferation, inflammation, and oxidative stress.  However, it is not entirely clear how ROCKs are regulated, what some of their downstream targets are, and whether ROCK1 and ROCK2 mediate different cellular functions.  Clin., inhibition of ROCK pathway is believed to contribute to some of the cardiovascular benefits of statin therapy that are independent of lipid lowering (ie, pleiotropic effects).  To what extent ROCK activity is inhibited in patients on statin therapy is not known, but it may have important clin. implications.  Indeed, several pharmaceutical companies are already actively engaged in the development of ROCK inhibitors as the next generation of therapeutic agents for cardiovascular disease because evidence from animal studies suggests the potential involvement of ROCK in hypertension and atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqni4R9YzHCArVg90H21EOLACvtfcHk0li3xoVUP5ZohA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFGju7o%253D&md5=2eb3df6bf289cd09427daae4ec16e707</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1097%2FFJC.0b013e318070d1bd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFJC.0b013e318070d1bd%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BK.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DNoma%26aufirst%3DK.%26atitle%3DRho%2520kinase%2520%2528ROCK%2529%2520inhibitors%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2007%26volume%3D50%26spage%3D17%26epage%3D24%26doi%3D10.1097%2FFJC.0b013e318070d1bd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohmura, E.</span></span> <span> </span><span class="NLM_article-title">Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride</span>. <i>Neurosurgery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">214</span>â <span class="NLM_lpage">223</span>, <span class="refDoi">Â DOI: 10.1227/01.NEU.0000147975.24556.BC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1227%2F01.NEU.0000147975.24556.BC" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2005&pages=214-223&author=K.+Tanakaauthor=H.+Minamiauthor=M.+Kotaauthor=K.+Kuwamuraauthor=E.+Kohmura&title=Treatment+of+cerebral+vasospasm+with+intra-arterial+fasudil+hydrochloride&doi=10.1227%2F01.NEU.0000147975.24556.BC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1227%2F01.NEU.0000147975.24556.BC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1227%252F01.NEU.0000147975.24556.BC%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DH.%26aulast%3DKota%26aufirst%3DM.%26aulast%3DKuwamura%26aufirst%3DK.%26aulast%3DKohmura%26aufirst%3DE.%26atitle%3DTreatment%2520of%2520cerebral%2520vasospasm%2520with%2520intra-arterial%2520fasudil%2520hydrochloride%26jtitle%3DNeurosurgery%26date%3D2005%26volume%3D56%26spage%3D214%26epage%3D223%26doi%3D10.1227%2F01.NEU.0000147975.24556.BC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokushige, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanihara, H.</span></span> <span> </span><span class="NLM_article-title">Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">964</span>â <span class="NLM_lpage">970</span>, <span class="refDoi">Â DOI: 10.3109/02713683.2011.599106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.3109%2F02713683.2011.599106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=21950703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Ggsb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=964-970&author=H.+Tokushigeauthor=M.+Wakiauthor=Y.+Takayamaauthor=H.+Tanihara&title=Effects+of+Y-39983%2C+a+selective+Rho-associated+protein+kinase+inhibitor%2C+on+blood+flow+in+optic+nerve+head+in+rabbits+and+axonal+regeneration+of+retinal+ganglion+cells+in+rats&doi=10.3109%2F02713683.2011.599106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Y-39983, a Selective Rho-Associated Protein Kinase Inhibitor, on Blood Flow in Optic Nerve Head in Rabbits and Axonal Regeneration of Retinal Ganglion Cells in Rats</span></div><div class="casAuthors">Tokushige, Hideki; Waki, Mitsunori; Takayama, Yoshiko; Tanihara, Hidenobu</div><div class="citationInfo"><span class="NLM_cas:title">Current Eye Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">964-970</span>CODEN:
                <span class="NLM_cas:coden">CEYRDM</span>;
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">To investigate the effects of Y-39983, a selective Rho-assocd. coiled coil-forming protein kinase inhibitor, on blood flow in the optic nerve head (ONH) in rabbits and axonal regeneration of retinal ganglion cells (RGCs) in rats.  Blood flow in ONH was measured by the laser speckle method after topical administration of 0.05% Y-39983 soln. or its vehicle in rabbit eyes.  To investigate the effects of Y-39983 on axonal regeneration of RGCs, RGCs purified from rat eyes were cultured with or without 10 Î¼M Y-39983 and morphol. obsd. by phase-contrast microscopy.  Moreover, the effects of intravitreal administration of Y-39983 were evaluated using an in vivo model of axotomized RGCs in peripheral nerve-grafted rats.  Topical administration of 0.05% Y-39983 soln. significantly increased blood flow in ONH compared with the vehicle group in rabbits.  Maximum increase in blood flow in the 0.05% Y-39983 group was 122.84 Â± 5.98% (Mean Â± S.E.) at 90 min after administration compared with before administration.  Neurites in rat RGCs treated with 10 Î¼M Y-39983 were extended compared with those without Y-39983 treatment of RGCs in vitro.  Y-39983 dose-dependently increased the no. of RGCs with regenerating axons in vivo.  The nos. of RGCs with regenerating axons in 10 and 100 Î¼M Y-39983-treated rats were 99.3 Â± 10.5 and 169.5 Â± 43.3 cells/mm2 (Mean Â± S.D.), resp., and significantly increased compared with those in saline-treated rats (43.3 Â± 6.0 cells/mm2).  Y-39983 may be a candidate drug not only for lowering of IOP but also for increasing of blood flow in ONH in the treatment of glaucoma.  Moreover, Y-39983 may have therapeutic potential for axonal regeneration of RGCs in the treatment of diseases with degenerating axons of RGCs including glaucoma, although improvements of formulation or route of administration are needed in order to reach an effective concn. in retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOzPXxK8ZBM7Vg90H21EOLACvtfcHk0li3xoVUP5ZohA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Ggsb%252FE&md5=05042fb5ee8f28ddf604a0fbeede3ab9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3109%2F02713683.2011.599106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02713683.2011.599106%26sid%3Dliteratum%253Aachs%26aulast%3DTokushige%26aufirst%3DH.%26aulast%3DWaki%26aufirst%3DM.%26aulast%3DTakayama%26aufirst%3DY.%26aulast%3DTanihara%26aufirst%3DH.%26atitle%3DEffects%2520of%2520Y-39983%252C%2520a%2520selective%2520Rho-associated%2520protein%2520kinase%2520inhibitor%252C%2520on%2520blood%2520flow%2520in%2520optic%2520nerve%2520head%2520in%2520rabbits%2520and%2520axonal%2520regeneration%2520of%2520retinal%2520ganglion%2520cells%2520in%2520rats%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D2011%26volume%3D36%26spage%3D964%26epage%3D970%26doi%3D10.3109%2F02713683.2011.599106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teusch, T.</span></span> <span> </span><span class="NLM_article-title">Rho kinase, a promising drug target for neurological disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">387</span>â <span class="NLM_lpage">398</span>, <span class="refDoi">Â DOI: 10.1038/nrd1719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1038%2Fnrd1719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15864268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1OktLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=387-398&author=B.+K.+Muellerauthor=H.+Mackauthor=T.+Teusch&title=Rho+kinase%2C+a+promising+drug+target+for+neurological+disorders&doi=10.1038%2Fnrd1719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase, a promising drug target for neurological disorders</span></div><div class="casAuthors">Mueller, Bernhard K.; Mack, Helmut; Teusch, Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">387-398</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rho kinases (ROCKs), the first Rho effectors to be described, are serine/threonine kinases that are important in fundamental processes of cell migration, cell proliferation and cell survival.  Abnormal activation of the Rho/ROCK pathway has been obsd. in various disorders of the central nervous system.  Injury to the adult vertebrate brain and spinal cord activates ROCKs, thereby inhibiting neurite growth and sprouting.  Inhibition of ROCKs results in accelerated regeneration and enhanced functional recovery after spinal-cord injury in mammals, and inhibition of the Rho/ROCK pathway has also proved to be efficacious in animal models of stroke, inflammatory and demyelinating diseases, Alzheimer's disease and neuropathic pain.  ROCK inhibitors therefore have potential for preventing neurodegeneration and stimulating neuroregeneration in various neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3XJk9e8s-qLVg90H21EOLACvtfcHk0ljJ31ORdXnp0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1OktLw%253D&md5=605b180f2f817091aadfc143df6d0205</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1719%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DB.%2BK.%26aulast%3DMack%26aufirst%3DH.%26aulast%3DTeusch%26aufirst%3DT.%26atitle%3DRho%2520kinase%252C%2520a%2520promising%2520drug%2520target%2520for%2520neurological%2520disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D387%26epage%3D398%26doi%3D10.1038%2Fnrd1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, A.</span></span> <span> </span><span class="NLM_article-title">Rho kinase and hypertension</span>. <i>Biochim. Biophys. Acta, Mol. Basis Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1802</i></span>,  <span class="NLM_fpage">1276</span>â <span class="NLM_lpage">1284</span>, <span class="refDoi">Â DOI: 10.1016/j.bbadis.2010.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bbadis.2010.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=20460153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKkt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1802&publication_year=2010&pages=1276-1284&author=A.+Wirth&title=Rho+kinase+and+hypertension&doi=10.1016%2Fj.bbadis.2010.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rho kinase and hypertension</span></div><div class="casAuthors">Wirth, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1802</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1276-1284</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Arterial hypertension is a multifactorial disease that is characterized by increased peripheral vascular resistance often accompanied by smooth muscle cell hypertrophy and proliferation.  Rho kinases (ROCKs) are the most extensively studied effectors of the small G-protein RhoA and abnormalities in RhoA/ROCK signaling were obsd. in various cardiovascular disease including hypertension.  The RhoA/ROCK-pathway is a key player in different smooth muscle cell functions including contractility, proliferation and migration.  Furthermore, there is extensive crosstalk between RhoA/ROCK- and NO-signaling.  Therefore, not only ROCK inhibitors but also NO-donators or pleiotropic agents like statins exert their beneficial effects on the cardiovascular system at least in part via Rho/Rho-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptzXz8fiHcHLVg90H21EOLACvtfcHk0ljJ31ORdXnp0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKkt7rN&md5=311f8b1d2dd850738baf997e9fd7198c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2010.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2010.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DA.%26atitle%3DRho%2520kinase%2520and%2520hypertension%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2010%26volume%3D1802%26spage%3D1276%26epage%3D1284%26doi%3D10.1016%2Fj.bbadis.2010.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Quy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh-Xuan, A. T.</span></span> <span> </span><span class="NLM_article-title">Role of Rho-kinase and its inhibitors in pulmonary hypertension</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">352</span>â <span class="NLM_lpage">364</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2012.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.pharmthera.2012.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=23261521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2qtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2013&pages=352-364&author=S.+Duong-Quyauthor=Y.+Beiauthor=Z.+Liuauthor=A.+T.+Dinh-Xuan&title=Role+of+Rho-kinase+and+its+inhibitors+in+pulmonary+hypertension&doi=10.1016%2Fj.pharmthera.2012.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Rho-kinase and its inhibitors in pulmonary hypertension</span></div><div class="casAuthors">Duong-Quy, Sy; Bei, Yihua; Liu, Zhongmin; Dinh-Xuan, Anh Tuan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">352-364</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Pulmonary hypertension (PH) is an incurable disease with a dreadful survival rate.  The disease is characterized by sustained vasoconstriction, progressive vascular remodeling, and irreversible right heart dysfunction.  While hypoxic pulmonary vasoconstriction (HPV) is known to be the main pathophysiol. factor causing the rise in pulmonary arterial pressure, biol. mechanisms leading to HPV and vascular remodeling are multiple and complex and, as yet, incompletely understood.  It is thought that mol. interactions and cross talks are involved in the pathogenesis of PH, perturbing the physiol. balance between substances controlling vascular tone, cell growth and apoptosis.  This balance is achieved by subtle interactions between factors acting as both vasodilators and inhibitors of cell growth like nitric oxide, prostacyclin, vasoactive intestinal peptide and mols. with potent vasoconstrictor and cell growth activities like endothelin-1.  Recent in vivo studies showed that the Rho GTPase/RhoA pathway and its downstream effectors, the Rho-kinases (ROCK-1 and ROCK-2), had an important role in PH, due to its lasting effects on vasoconstriction and pulmonary cell proliferation leading to vascular remodeling.  Beneficial effects obtained in vivo with Rho-kinase inhibitors (e.g.Y-27632 and fasudil) in exptl. PH will hopefully lead to future clin. trials with new compds. selectively targeting this pathway, which is now proven to be detrimental when over-activated in both exptl. animals and human patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO29d7VxfcKbVg90H21EOLACvtfcHk0ljJ31ORdXnp0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2qtA%253D%253D&md5=124b129eb40fd189081eb60c0ba17747</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2012.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2012.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Quy%26aufirst%3DS.%26aulast%3DBei%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDinh-Xuan%26aufirst%3DA.%2BT.%26atitle%3DRole%2520of%2520Rho-kinase%2520and%2520its%2520inhibitors%2520in%2520pulmonary%2520hypertension%26jtitle%3DPharmacol.%2520Ther.%26date%3D2013%26volume%3D137%26spage%3D352%26epage%3D364%26doi%3D10.1016%2Fj.pharmthera.2012.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, O.</span></span> <span> </span><span class="NLM_article-title">Rho kinase (ROCK) inhibitors and their therapeutic potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2269</span>â <span class="NLM_lpage">2300</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00683</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00683" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2269-2300&author=Y.+Fengauthor=P.+V.+LoGrassoauthor=O.+Defertauthor=O.+Li&title=Rho+kinase+%28ROCK%29+inhibitors+and+their+therapeutic+potential&doi=10.1021%2Facs.jmedchem.5b00683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential</span></div><div class="casAuthors">Feng, Yangbo; LoGrasso, Philip V.; Defert, Olivier; Li, Rongshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2269-2300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinases (ROCKs) belong to the serine-threonine family, the inhibition of which affects the function of many downstream substrates.  As such, ROCK inhibitors have potential therapeutic applicability in a wide variety of pathol. conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidney failure, neuronal degeneration, and osteoporosis.  To date, two ROCK inhibitors have been approved for clin. use in Japan (fasudil and ripasudil) and one in China (fasudil).  In 1995 fasudil was approved for the treatment of cerebral vasospasm, and more recently, ripasudil was approved for the treatment of glaucoma in 2014.  In this Perspective, we present a comprehensive review of the physiol. and biol. functions for ROCK, the properties and development of over 170 ROCK inhibitors as well as their therapeutic potential, the current status, and future considerations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXh2BorYftcbVg90H21EOLACvtfcHk0ljb8foUO0TScA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Oqtb%252FJ&md5=99b0e10dca303023b1bf382fcb255771</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00683%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DDefert%26aufirst%3DO.%26aulast%3DLi%26aufirst%3DO.%26atitle%3DRho%2520kinase%2520%2528ROCK%2529%2520inhibitors%2520and%2520their%2520therapeutic%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2269%26epage%3D2300%26doi%3D10.1021%2Facs.jmedchem.5b00683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frackowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2355</span>â <span class="NLM_lpage">2360</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2006.12.043" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2355-2360&author=Y.+Fengauthor=M.+D.+Cameronauthor=B.+Frackowiakauthor=E.+Griffinauthor=L.+Linauthor=C.+Ruizauthor=T.+Schr%C3%B6terauthor=P.+LoGrasso&title=Structure-activity+relationships%2C+and+drug+metabolism+and+pharmacokinetic+properties+for+indazole+piperazine+and+indazole+piperidine+inhibitors+of+ROCK-II&doi=10.1016%2Fj.bmcl.2006.12.043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DFrackowiak%26aufirst%3DB.%26aulast%3DGriffin%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DLoGrasso%26aufirst%3DP.%26atitle%3DStructure-activity%2520relationships%252C%2520and%2520drug%2520metabolism%2520and%2520pharmacokinetic%2520properties%2520for%2520indazole%2520piperazine%2520and%2520indazole%2520piperidine%2520inhibitors%2520of%2520ROCK-II%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2355%26epage%3D2360%26doi%3D10.1016%2Fj.bmcl.2006.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaitanopoulos, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehon, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semus, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fries, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span> <span> </span><span class="NLM_article-title">Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1021/jm0609014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0609014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlansbnF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6-9&author=K.+B.+Goodmanauthor=H.+Cuiauthor=S.+E.+Dowdellauthor=D.+E.+Gaitanopoulosauthor=R.+L.+Ivyauthor=C.+A.+Sehonauthor=R.+A.+Stavengerauthor=G.+Z.+Wangauthor=A.+Q.+Vietauthor=W.+Xuauthor=G.+Yeauthor=S.+F.+Semusauthor=C.+Evansauthor=H.+E.+Friesauthor=L.+J.+Jolivetteauthor=R.+B.+Kirkpatrickauthor=E.+Dulauthor=S.+S.+Khandekarauthor=T.+Yiauthor=D.+K.+Jungauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=D.+J.+Behmauthor=R.+Bentleyauthor=C.+P.+Doeauthor=E.+Huauthor=D.+Lee&title=Development+of+dihydropyridone+indazole+amides+as+selective+Rho-kinase+inhibitors&doi=10.1021%2Fjm0609014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors</span></div><div class="casAuthors">Goodman, Krista B.; Cui, Haifeng; Dowdell, Sarah E.; Gaitanopoulos, Dimitri E.; Ivy, Robert L.; Sehon, Clark A.; Stavenger, Robert A.; Wang, Gren Z.; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Semus, Simon F.; Evans, Christopher; Fries, Harvey E.; Jolivette, Larry J.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Bentley, Ross; Doe, Christopher P.; Hu, Erding; Lee, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinase (ROCK1) mediates vascular smooth muscle contraction and is a potential target for the treatment of hypertension and related disorders.  Indazole amide 3 was identified as a potent and selective ROCK1 inhibitor but possessed poor oral bioavailability.  Optimization of this lead resulted in the discovery of a series of dihydropyridones, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead.  Indazole substitution played a crit. role in decreasing clearance and improving oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgOGlkSgS6prVg90H21EOLACvtfcHk0ljb8foUO0TScA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlansbnF&md5=4a2b2f5636a4631f95e521ec98068e0e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm0609014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0609014%26sid%3Dliteratum%253Aachs%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DDowdell%26aufirst%3DS.%2BE.%26aulast%3DGaitanopoulos%26aufirst%3DD.%2BE.%26aulast%3DIvy%26aufirst%3DR.%2BL.%26aulast%3DSehon%26aufirst%3DC.%2BA.%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DG.%2BZ.%26aulast%3DViet%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DSemus%26aufirst%3DS.%2BF.%26aulast%3DEvans%26aufirst%3DC.%26aulast%3DFries%26aufirst%3DH.%2BE.%26aulast%3DJolivette%26aufirst%3DL.%2BJ.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DKhandekar%26aufirst%3DS.%2BS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DDoe%26aufirst%3DC.%2BP.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520dihydropyridone%2520indazole%2520amides%2520as%2520selective%2520Rho-kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6%26epage%3D9%26doi%3D10.1021%2Fjm0609014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwakubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Rho kinase inhibitors (II)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">350</span>â <span class="NLM_lpage">364</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2006.09.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmc.2006.09.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=350-364&author=M.+Iwakuboauthor=A.+Takamiauthor=Y.+Okadaauthor=T.+Kawataauthor=Y.+Tagamiauthor=H.+Ohashiauthor=M.+Satoauthor=T.+Sugiyamaauthor=K.+Fukushimaauthor=H.+Iijima&title=Design+and+synthesis+of+Rho+kinase+inhibitors+%28II%29&doi=10.1016%2Fj.bmc.2006.09.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.09.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.09.052%26sid%3Dliteratum%253Aachs%26aulast%3DIwakubo%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DTagami%26aufirst%3DY.%26aulast%3DOhashi%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DT.%26aulast%3DFukushima%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Rho%2520kinase%2520inhibitors%2520%2528II%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D350%26epage%3D364%26doi%3D10.1016%2Fj.bmc.2006.09.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaitanopoulos, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semus, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">5</span>, <span class="refDoi">Â DOI: 10.1021/jm060873p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060873p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2-5&author=R.+A.+Stavengerauthor=H.+Cuiauthor=S.+E.+Dowdellauthor=R.+G.+Franzauthor=D.+E.+Gaitanopoulosauthor=K.+B.+Goodmanauthor=M.+A.+Hilfikerauthor=R.+L.+Ivyauthor=J.+D.+Leberauthor=J.+P.+Marinoauthor=H.+Ohauthor=A.+Q.+Vietauthor=W.+Xuauthor=G.+Yeauthor=D.+Zhangauthor=Y.+Zhaoauthor=L.+J.+Jolivetteauthor=M.+S.+Headauthor=S.+F.+Semusauthor=P.+A.+Elkinsauthor=R.+B.+Kirkpatrickauthor=E.+Dulauthor=S.+S.+Khandekarauthor=T.+Yiauthor=D.+K.+Jungauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=D.+J.+Behmauthor=C.+P.+Doeauthor=R.+Bentleyauthor=Z.+X.+Chenauthor=E.+Huauthor=D.+Lee&title=Discovery+of+aminofurazan-azabenzimidazoles+as+inhibitors+of+Rho-kinase+with+high+kinase+selectivity+and+antihypertensive+activity&doi=10.1021%2Fjm060873p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity</span></div><div class="casAuthors">Stavenger, Robert A.; Cui, Haifeng; Dowdell, Sarah E.; Franz, Robert G.; Gaitanopoulos, Dimitri E.; Goodman, Krista B.; Hilfiker, Mark A.; Ivy, Robert L.; Leber, Jack D.; Marino, Joseph P., Jr.; Oh, Hye-Ja; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Zhang, Daohua; Zhao, Yongdong; Jolivette, Larry J.; Head, Martha S.; Semus, Simon F.; Elkins, Patricia A.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Doe, Christopher P.; Bentley, Ross; Chen, Zunxuan X.; Hu, Erding; Lee, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented.  Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases.  Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzfD1mp8bYv7Vg90H21EOLACvtfcHk0lhye0I4SzKz-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlansbnE&md5=055d95d44fc906aba4e0bdbf0bc1aac9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm060873p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060873p%26sid%3Dliteratum%253Aachs%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DDowdell%26aufirst%3DS.%2BE.%26aulast%3DFranz%26aufirst%3DR.%2BG.%26aulast%3DGaitanopoulos%26aufirst%3DD.%2BE.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DHilfiker%26aufirst%3DM.%2BA.%26aulast%3DIvy%26aufirst%3DR.%2BL.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DOh%26aufirst%3DH.%26aulast%3DViet%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJolivette%26aufirst%3DL.%2BJ.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DSemus%26aufirst%3DS.%2BF.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DKirkpatrick%26aufirst%3DR.%2BB.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DKhandekar%26aufirst%3DS.%2BS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DJung%26aufirst%3DD.%2BK.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DDoe%26aufirst%3DC.%2BP.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DHu%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520aminofurazan-azabenzimidazoles%2520as%2520inhibitors%2520of%2520Rho-kinase%2520with%2520high%2520kinase%2520selectivity%2520and%2520antihypertensive%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Fjm060873p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uehata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narumiya, S.</span></span> <span> </span><span class="NLM_article-title">Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">990</span>â <span class="NLM_lpage">994</span>, <span class="refDoi">Â DOI: 10.1038/40187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1038%2F40187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=9353125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADyaK2sXntVarsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=990-994&author=M.+Uehataauthor=T.+Ishizakiauthor=H.+Satohauthor=T.+Onoauthor=T.+Kawaharaauthor=T.+Morishitaauthor=H.+Tamakawaauthor=K.+Yamagamiauthor=J.+Inuiauthor=M.+Maekawaauthor=S.+Narumiya&title=Calcium+sensitization+of+smooth+muscle+mediated+by+a+Rho-associated+protein+kinase+in+hypertension&doi=10.1038%2F40187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension</span></div><div class="casAuthors">Uehata, Masayoshi; Ishizaki, Toshimasa; Satoh, Miroyuki; Ono, Takashi; Kawahara, Toshio; Morishita, Tamami; Tamakawa, Hiroki; Yamagami, Keiji; Inui, Jun; Maekawa, Midori; Narumiya, Shuh</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6654</span>),
    <span class="NLM_cas:pages">990-994</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Abnormal smooth-muscle contractility may be a major cause of disease states such as hypertension, and a smooth-muscle relaxant that modulates this process would be useful therapeutically.  Smooth-muscle contraction is regulated by the cytosolic Ca2+ concn. and by the Ca2+ sensitivity of myofilaments: the former activates myosin light-chain kinase and the latter is achieved partly by inhibition of myosin phosphatase.  The small GTPase Rho and its target, Rho-assocd. kinase, participate in this latter mechanism in vitro, but their participation has not been demonstrated in intact muscles.  Here the authors show that a pyridine deriv., Y-27632, selectively inhibits smooth-muscle contraction by inhibiting Ca2+ sensitization.  The authors identified the Y-27632 target as a Rho-assocd. protein kinase, p160ROCK.  Y-27632 consistently suppresses Rho-induced, p160ROCK-mediated formation of stress fibers in cultured cells and dramatically corrects hypertension in several hypertensive rat models.  The authors' findings indicate that p160ROCK-mediated Ca2+ sensitization is involved in the pathophysiol. of hypertension and suggest that compds. that inhibit this process might be useful therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2FDG7oWwZ6bVg90H21EOLACvtfcHk0lhye0I4SzKz-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVarsbY%253D&md5=9a5664b84a72d3486df1433579364943</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F40187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F40187%26sid%3Dliteratum%253Aachs%26aulast%3DUehata%26aufirst%3DM.%26aulast%3DIshizaki%26aufirst%3DT.%26aulast%3DSatoh%26aufirst%3DH.%26aulast%3DOno%26aufirst%3DT.%26aulast%3DKawahara%26aufirst%3DT.%26aulast%3DMorishita%26aufirst%3DT.%26aulast%3DTamakawa%26aufirst%3DH.%26aulast%3DYamagami%26aufirst%3DK.%26aulast%3DInui%26aufirst%3DJ.%26aulast%3DMaekawa%26aufirst%3DM.%26aulast%3DNarumiya%26aufirst%3DS.%26atitle%3DCalcium%2520sensitization%2520of%2520smooth%2520muscle%2520mediated%2520by%2520a%2520Rho-associated%2520protein%2520kinase%2520in%2520hypertension%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D990%26epage%3D994%26doi%3D10.1038%2F40187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avedissian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thouin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulanger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essagian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerracher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubell, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 4-(1-aminoalkyl)-<i>N</i>-(4-pyridyl)cyclohexanecarboxamides as Rho kinase inhibitors and neurite outgrowth promoters</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4931</span>â <span class="NLM_lpage">4934</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2004.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2004.07.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=4931-4934&author=K.+Gingrasauthor=H.+Avedissianauthor=E.+Thouinauthor=V.+Boulangerauthor=C.+Essagianauthor=L.+McKerracherauthor=W.+D.+Lubell&title=Synthesis+and+evaluation+of+4-%281-aminoalkyl%29-N-%284-pyridyl%29cyclohexanecarboxamides+as+Rho+kinase+inhibitors+and+neurite+outgrowth+promoters&doi=10.1016%2Fj.bmcl.2004.07.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DGingras%26aufirst%3DK.%26aulast%3DAvedissian%26aufirst%3DH.%26aulast%3DThouin%26aufirst%3DE.%26aulast%3DBoulanger%26aufirst%3DV.%26aulast%3DEssagian%26aufirst%3DC.%26aulast%3DMcKerracher%26aufirst%3DL.%26aulast%3DLubell%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25204-%25281-aminoalkyl%2529-N-%25284-pyridyl%2529cyclohexanecarboxamides%2520as%2520Rho%2520kinase%2520inhibitors%2520and%2520neurite%2520outgrowth%2520promoters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D4931%26epage%3D4934%26doi%3D10.1016%2Fj.bmcl.2004.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼rer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5727</span>â <span class="NLM_lpage">5737</span>, <span class="refDoi">Â DOI: 10.1021/jm100579r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100579r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWksLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5727-5737&author=X.+Fangauthor=Y.+Yinauthor=Y.+T.+Chenauthor=L.+Yaoauthor=B.+Wangauthor=M.+D.+Cameronauthor=L.+Linauthor=S.+Khanauthor=C.+Ruizauthor=T.+Schr%C3%B6terauthor=W.+Grantauthor=A.+Weiserauthor=J.+Pocasauthor=A.+Pachoriauthor=S.+Sch%C3%BCrerauthor=P.+LoGrassoauthor=Y.+Feng&title=Tetrahydroisoquinoline+derivatives+as+highly+selective+and+potent+Rho+kinase+inhibitors&doi=10.1021%2Fjm100579r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Derivatives As Highly Selective and Potent Rho Kinase Inhibitors</span></div><div class="casAuthors">Fang, Xingang; Yin, Yan; Chen, Yen Ting; Yao, Lei; Wang, Bo; Cameron, Michael D.; Lin, Li; Khan, Susan; Ruiz, Claudia; Schroter, Thomas; Grant, Wayne; Weiser, Amiee; Pocas, Jennifer; Pachori, Alok; Schurer, Stephan; Lo Grasso, Philip; Feng, Yangbo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5727-5737</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rho kinase (ROCK) is a promising drug target for the treatment of many diseases including hypertension, multiple sclerosis, cancer, and glaucoma.  The structure-activity relationships (SAR) around a series of tetrahydroisoquinolines were evaluated utilizing biochem. and cell-based assays to measure ROCK inhibition.  These novel ROCK inhibitors possess high potency, high selectivity, and appropriate pharmacokinetic properties for glaucoma applications.  The lead compd., 35, had subnanomolar potency in enzyme ROCK-II assays as well as excellent cell-based potency (IC50 = 51 nM).  In a kinase panel profiling, 35 had an off-target hit rate of only 1.6% against 442 kinases.  Pharmacol. studies showed that compd. 35 was efficacious in reducing intraocular pressure (IOP) in rats with reasonably long duration of action.  These results suggest that compd. 35 may serve as a promising agent for further development in the treatment of glaucoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8rKBfPtO8L7Vg90H21EOLACvtfcHk0ljanE0GWjCMjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWksLo%253D&md5=2278d64dd3ac09f0e5d8406f7e21eca9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm100579r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100579r%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DGrant%26aufirst%3DW.%26aulast%3DWeiser%26aufirst%3DA.%26aulast%3DPocas%26aufirst%3DJ.%26aulast%3DPachori%26aufirst%3DA.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%26aulast%3DLoGrasso%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26atitle%3DTetrahydroisoquinoline%2520derivatives%2520as%2520highly%2520selective%2520and%2520potent%2520Rho%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5727%26epage%3D5737%26doi%3D10.1021%2Fjm100579r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiratsuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totsuka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, H.</span></span> <span> </span><span class="NLM_article-title">Development of specific Rho-kinase inhibitors and their clinical application</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1754</i></span>,  <span class="NLM_fpage">245</span>â <span class="NLM_lpage">252</span>, <span class="refDoi">Â DOI: 10.1016/j.bbapap.2005.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bbapap.2005.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=16213195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlags7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=245-252&author=M.+Tamuraauthor=H.+Nakaoauthor=H.+Yoshizakiauthor=M.+Shiratsuchiauthor=H.+Shigyoauthor=H.+Yamadaauthor=T.+Ozawaauthor=J.+Totsukaauthor=H.+Hidaka&title=Development+of+specific+Rho-kinase+inhibitors+and+their+clinical+application&doi=10.1016%2Fj.bbapap.2005.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of specific Rho-kinase inhibitors and their clinical application</span></div><div class="casAuthors">Tamura, Masahiro; Nakao, Hiroshi; Yoshizaki, Hideo; Shiratsuchi, Masami; Shigyo, Hiromichi; Yamada, Hajime; Ozawa, Takatoshi; Totsuka, Junko; Hidaka, Hiroyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1754</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">245-252</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hexahydro-1-(isoquinoline-5-sulfonyl)-1H-1,4-diazepine, HA-1077, is a known selective inhibitor of Rho-kinase.  Although its IC50 value against Rho-kinase is more than 10 times lower than those for kinases such as PKA, PKB, PKC, PKG, MLCK, CaMKII and others, the mol. still retains relative potent inhibition activities against these kinases.  In order to produce highly specific Rho-kinase inhibitors, several HA-1077 analogs were synthesized and their kinase inhibition properties evaluated.  (S)-Hexahydro-1-(4-ethenylisoquinoline-5-sulfonyl)-2-methyl-1H-1,4-diazepine was found to be a potent Rho-kinase inhibitor.  The IC50 value against Rho-kinase was 6 nM, while those against other kinases remained at almost the same level as that of HA-1077.  Furthermore, we designed HA-1077 analogs on the basis of the complex structure of PKA and HA-1077.  Amongst these, (S)-hexahydro-4-glycyl-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1H-1,4-diazepine and other glycine derivs. were found to be highly specific Rho-kinase inhibitors.  These Rho-kinase specific inhibitors were applied to rabbit ocular hypertensive models and were shown to reduce intraocular pressure.  These results demonstrate that the new 5-isoquinolinesulfonylamides are not only potent ROCK selective compds., but are also useful compds. for clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc5VQGumuqnbVg90H21EOLACvtfcHk0ljanE0GWjCMjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlags7bK&md5=467ca0607a8aa691fbe0b1b3bb340405</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2005.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2005.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DTamura%26aufirst%3DM.%26aulast%3DNakao%26aufirst%3DH.%26aulast%3DYoshizaki%26aufirst%3DH.%26aulast%3DShiratsuchi%26aufirst%3DM.%26aulast%3DShigyo%26aufirst%3DH.%26aulast%3DYamada%26aufirst%3DH.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DTotsuka%26aufirst%3DJ.%26aulast%3DHidaka%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520specific%2520Rho-kinase%2520inhibitors%2520and%2520their%2520clinical%2520application%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1754%26spage%3D245%26epage%3D252%26doi%3D10.1016%2Fj.bbapap.2005.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of Rho kinase inhibitors (I)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2115</span>â <span class="NLM_lpage">2137</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2004.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmc.2004.02.025" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2115-2137&author=A.+Takamiauthor=M.+Iwakuboauthor=Y.+Okadaauthor=T.+Kawataauthor=H.+Odaiauthor=N.+Takahashiauthor=K.+Shindoauthor=K.+Kimuraauthor=Y.+Tagamiauthor=M.+Miyakeauthor=K.+Fukushimaauthor=M.+Inagakiauthor=M.+Amanoauthor=K.+Kaibuchiauthor=H.+Iijima&title=Design+and+synthesis+of+Rho+kinase+inhibitors+%28I%29&doi=10.1016%2Fj.bmc.2004.02.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DTakami%26aufirst%3DA.%26aulast%3DIwakubo%26aufirst%3DM.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DOdai%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DShindo%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DTagami%26aufirst%3DY.%26aulast%3DMiyake%26aufirst%3DM.%26aulast%3DFukushima%26aufirst%3DK.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DKaibuchi%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520Rho%2520kinase%2520inhibitors%2520%2528I%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2115%26epage%3D2137%26doi%3D10.1016%2Fj.bmc.2004.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwakubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaibuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iijima, H.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of rho kinase inhibitors (III)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1022</span>â <span class="NLM_lpage">1033</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2006.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmc.2006.10.028" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=1022-1033&author=M.+Iwakuboauthor=A.+Takamiauthor=Y.+Okadaauthor=T.+Kawataauthor=Y.+Tagamiauthor=M.+Satoauthor=T.+Sugiyamaauthor=K.+Fukushimaauthor=S.+Tayaauthor=M.+Amanoauthor=K.+Kaibuchiauthor=H.+Iijima&title=Design+and+synthesis+of+rho+kinase+inhibitors+%28III%29&doi=10.1016%2Fj.bmc.2006.10.028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DIwakubo%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DA.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DKawata%26aufirst%3DT.%26aulast%3DTagami%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DT.%26aulast%3DFukushima%26aufirst%3DK.%26aulast%3DTaya%26aufirst%3DS.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DKaibuchi%26aufirst%3DK.%26aulast%3DIijima%26aufirst%3DH.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520rho%2520kinase%2520inhibitors%2520%2528III%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D1022%26epage%3D1033%26doi%3D10.1016%2Fj.bmc.2006.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokuyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochizuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, A.</span></span> <span> </span><span class="NLM_article-title">Effects of Y-27632, a Rho/Rho kinase inhibitor, on leukotriene D(4)- and histamine-induced airflow obstruction and airway microvascular leakage in guinea pigs in vivo</span>. <i>Pharmacology</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">195</span>, <span class="refDoi">Â DOI: 10.1159/000056170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1159%2F000056170" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2002&pages=189-195&author=K.+Tokuyamaauthor=H.+Nishimuraauthor=K.+Iizukaauthor=M.+Katoauthor=H.+Arakawaauthor=R.+Sagaauthor=H.+Mochizukiauthor=A.+Morikawa&title=Effects+of+Y-27632%2C+a+Rho%2FRho+kinase+inhibitor%2C+on+leukotriene+D%284%29-+and+histamine-induced+airflow+obstruction+and+airway+microvascular+leakage+in+guinea+pigs+in+vivo&doi=10.1159%2F000056170"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1159%2F000056170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000056170%26sid%3Dliteratum%253Aachs%26aulast%3DTokuyama%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DIizuka%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DH.%26aulast%3DSaga%26aufirst%3DR.%26aulast%3DMochizuki%26aufirst%3DH.%26aulast%3DMorikawa%26aufirst%3DA.%26atitle%3DEffects%2520of%2520Y-27632%252C%2520a%2520Rho%252FRho%2520kinase%2520inhibitor%252C%2520on%2520leukotriene%2520D%25284%2529-%2520and%2520histamine-induced%2520airflow%2520obstruction%2520and%2520airway%2520microvascular%2520leakage%2520in%2520guinea%2520pigs%2520in%2520vivo%26jtitle%3DPharmacology%26date%3D2002%26volume%3D64%26spage%3D189%26epage%3D195%26doi%3D10.1159%2F000056170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldie, R. G.</span></span> <span> </span><span class="NLM_article-title">A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">67</span>â <span class="NLM_lpage">74</span>, <span class="refDoi">Â DOI: 10.1016/j.pupt.2004.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.pupt.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15607129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOntbnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=67-74&author=P.+J.+Henryauthor=T.+S.+Mannauthor=R.+G.+Goldie&title=A+Rho+kinase+inhibitor%2C+Y-27632+inhibits+pulmonary+eosinophilia%2C+bronchoconstriction+and+airways+hyperresponsiveness+in+allergic+mice&doi=10.1016%2Fj.pupt.2004.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Rho kinase inhibitor, Y-27632 inhibits pulmonary eosinophilia, bronchoconstriction and airways hyperresponsiveness in allergic mice</span></div><div class="casAuthors">Henry, Peter J.; Mann, Tracy S.; Goldie, Roy G.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Asthma is a complex inflammatory disorder involving obstruction, constriction, edema, remodelling and hyperresponsiveness of the airways.  These effects are induced by a raft of mediators, many of which exert their actions by stimulating specific G-protein-coupled receptors linked to a signal transduction pathway involving the monomeric GTPase; rho, and a downstream effector; rho kinase.  The aim of this study was to det. whether administration of a selective inhibitor of rho kinase, Y-27632, attenuates airway inflammation, bronchoconstriction and hyperresponsiveness in a murine model of acute allergic inflammation.  Intranasal administration of Y-27632 caused a dose-dependent inhibition in the no. of eosinophils recovered from bronchoalveolar lavage fluid of ovalbumin-sensitized and challenged (allergic) mice.  These inhibitory effects of intranasal Y-27632 on pulmonary eosinophilia were accompanied by a significant inhibition of the development of airways hyperresponsiveness in allergic mice.  In addnl. studies, intranasal Y-27632 inhibited methacholine-induced increases in airways resistance in a time-dependent manner.  In conclusion, these findings indicate that activation of rho kinase contributes to bronchoconstriction and eosinophil trafficking in murine models of acute allergic airway inflammation and to the development of airway hyperresponsiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaprMOYMJNI7Vg90H21EOLACvtfcHk0lixZPNTMvKkWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOntbnJ&md5=0ba740a88658e8d4e389914e12134ad1</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DP.%2BJ.%26aulast%3DMann%26aufirst%3DT.%2BS.%26aulast%3DGoldie%26aufirst%3DR.%2BG.%26atitle%3DA%2520Rho%2520kinase%2520inhibitor%252C%2520Y-27632%2520inhibits%2520pulmonary%2520eosinophilia%252C%2520bronchoconstriction%2520and%2520airways%2520hyperresponsiveness%2520in%2520allergic%2520mice%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D18%26spage%3D67%26epage%3D74%26doi%3D10.1016%2Fj.pupt.2004.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafferty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grygielko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivette, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, E.</span></span> <span> </span><span class="NLM_article-title">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1124/jpet.106.110635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1124%2Fjpet.106.110635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17018693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=89-98&author=C.+Doeauthor=R.+Bentleyauthor=D.+J.+Behmauthor=R.+Laffertyauthor=R.+Stavengerauthor=D.+Jungauthor=M.+Bamfordauthor=T.+Panchalauthor=E.+Grygielkoauthor=L.+L.+Wrightauthor=G.+K.+Smithauthor=Z.+Chenauthor=C.+Webbauthor=S.+Khandekarauthor=T.+Yiauthor=R.+Kirkpatrickauthor=E.+Dulauthor=L.+Jolivetteauthor=J.+P.+Marinoauthor=R.+Willetteauthor=D.+Leeauthor=E.+Hu&title=Novel+Rho+kinase+inhibitors+with+anti-inflammatory+and+vasodilatory+activities&doi=10.1124%2Fjpet.106.110635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities</span></div><div class="casAuthors">Doe, Chris; Bentley, Ross; Behm, David J.; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L.; Smith, Gary K.; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivette, Larry; Marino, Joseph P., Jr.; Willette, Robert; Lee, Dennis; Hu, Erding</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis.  We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension.  In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compds. that potently inhibit ROCK enzymic activity.  GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, resp.  GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases.  In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-Î±.  Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, resp.  Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent redn. of systemic blood pressure in spontaneously hypertensive rats.  At doses of 1, 3, and 30 mg/kg, both compds. induced a redn. in blood pressure of approx. 10, 20, and 50 mm Hg.  In addn., administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats.  SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOuPjuVLTrwrVg90H21EOLACvtfcHk0lixZPNTMvKkWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFeqsw%253D%253D&md5=ab8ba12bca20241815721e2cc9273774</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.110635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.110635%26sid%3Dliteratum%253Aachs%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DBentley%26aufirst%3DR.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DLafferty%26aufirst%3DR.%26aulast%3DStavenger%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DD.%26aulast%3DBamford%26aufirst%3DM.%26aulast%3DPanchal%26aufirst%3DT.%26aulast%3DGrygielko%26aufirst%3DE.%26aulast%3DWright%26aufirst%3DL.%2BL.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWebb%26aufirst%3DC.%26aulast%3DKhandekar%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DKirkpatrick%26aufirst%3DR.%26aulast%3DDul%26aufirst%3DE.%26aulast%3DJolivette%26aufirst%3DL.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DWillette%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DE.%26atitle%3DNovel%2520Rho%2520kinase%2520inhibitors%2520with%2520anti-inflammatory%2520and%2520vasodilatory%2520activities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D89%26epage%3D98%26doi%3D10.1124%2Fjpet.106.110635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkinson, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinker, A. C.</span></span> <span> </span><span class="NLM_article-title">Components of successful lead generation</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">421</span>â <span class="NLM_lpage">439</span>, <span class="refDoi">Â DOI: 10.2174/1568026053828411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.2174%2F1568026053828411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15892684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFGhtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=421-439&author=A.+M.+Davisauthor=D.+J.+Keelingauthor=J.+Steeleauthor=N.+P.+Tomkinsonauthor=A.+C.+Tinker&title=Components+of+successful+lead+generation&doi=10.2174%2F1568026053828411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Components of successful lead generation</span></div><div class="casAuthors">Davis, Andrew M.; Keeling, David J.; Steele, John; Tomkinson, Nicholas P.; Tinker, Alan C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">421-439</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review aims to give an overview of current good practice in the prosecution of Lead Generation.  It will assess experiences across the field as judged from the contents of the limited no. of peer-review disclosures to date.  It will also rely heavily on the experiences of the authors from many campaigns within this organization.  Its focus will be on the assembly of an appropriate compd. collection for application in High Throughput Screening (HTS), the prosecution of HTS, the profiling of HTS output and, lastly the Hit-to-Lead optimization of selected HTS output.  Excluded from the scope are detailed aspects of library design [1], parallel synthesis [2], virtual library applications [3], virtual screening [4] and fragment screening [5] approaches, all of which have been the subject of recent reviews.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5UYz5NF4m7Vg90H21EOLACvtfcHk0lhpyqGN75B18g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFGhtL4%253D&md5=ef29c85464f4ecbc63787210fda1b778</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1568026053828411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026053828411%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DKeeling%26aufirst%3DD.%2BJ.%26aulast%3DSteele%26aufirst%3DJ.%26aulast%3DTomkinson%26aufirst%3DN.%2BP.%26aulast%3DTinker%26aufirst%3DA.%2BC.%26atitle%3DComponents%2520of%2520successful%2520lead%2520generation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D421%26epage%3D439%26doi%3D10.2174%2F1568026053828411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency indices as guideposts for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>â <span class="NLM_lpage">469</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(05)03386-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+efficiency+indices+as+guideposts+for+drug+discovery&doi=10.1016%2FS1359-6446%2805%2903386-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2eZ99DzV9moVAbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520efficiency%2520indices%2520as%2520guideposts%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469%26doi%3D10.1016%2FS1359-6446%2805%2903386-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A lipophilic efficiency (LipE) analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4406</span>â <span class="NLM_lpage">4409</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+lipophilic+efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lhpyqGN75B18g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajduk, P. J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based drug design: how big is too big?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6972</span>â <span class="NLM_lpage">6976</span>, <span class="refDoi">Â DOI: 10.1021/jm060511h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060511h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6972-6976&author=P.+J.+Hajduk&title=Fragment-based+drug+design%3A+how+big+is+too+big%3F&doi=10.1021%2Fjm060511h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Design: How Big Is Too Big?</span></div><div class="casAuthors">Hajduk, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6972-6976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Much has been discussed about the proper physicochem. properties (e.g., mol. wt., hydrophobicity, etc.) that should be considered when utilizing fragment leads in drug design.  However, little has been reported as to what emphasis, if any, should be placed on the potency of the resulting fragment leads.  In this report, a retrospective anal. of 18 highly optimized inhibitors is described in which the compds. were systematically deconstructed until the minimal binding elements could be identified.  An anal. of the potency changes that were obsd. as the leads were reduced in size indicate that a nearly linear relationship exists between mol. wt. and binding affinity over the entire range of sizes and potencies represented in the dataset.  On the basis of these observations, prediction maps can be constructed that enable crit. and quant. assessments of the process of lead identification and optimization.  These data place well-defined limits on the ideal size and potency of fragment leads that are being considered for use in fragment-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfCz9NMtBgNrVg90H21EOLACvtfcHk0lgV4ItufcxuyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFOmtLbJ&md5=b27d4ca6446a033b82e0ea223da5e6de</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm060511h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060511h%26sid%3Dliteratum%253Aachs%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DFragment-based%2520drug%2520design%253A%2520how%2520big%2520is%2520too%2520big%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6972%26epage%3D6976%26doi%3D10.1021%2Fjm060511h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span>Maybridge
Chemical Company, <a href="http://www.maybridge.com/" class="extLink">http://www.maybridge.com/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maybridge%0AChemical+Company%2C+http%3A%2F%2Fwww.maybridge.com%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span>Ryan
Scientific, <a href="https://www.ryansci.com" class="extLink">https://www.ryansci.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Ryan%0AScientific%2C+https%3A%2F%2Fwww.ryansci.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mack, H.</span>; <span class="NLM_string-name">Teusch, N.</span>; <span class="NLM_string-name">Mueller, B. K.</span>; <span class="NLM_string-name">Hornberger, W.</span>; <span class="NLM_string-name">Jarvis, M. F.</span>; <span class="NLM_string-name">Sauer, D.</span>; <span class="NLM_string-name">Swann, S.</span>; <span class="NLM_string-name">Bonafoux, D.</span>; <span class="NLM_string-name">Keddy, R.</span>; <span class="NLM_string-name">Hobson, A. D.</span>; <span class="NLM_string-name">Vasudevan, A.</span></span> <span> </span><span class="NLM_article-title">4-(4-Pyridinyl)-benzamides and their Use as Rock Activity Modulators</span>. US Patent <span class="NLM_patent">US 8445686 B2</span>, May 21, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Mack&author=N.+Teusch&author=B.+K.+Mueller&author=W.+Hornberger&author=M.+F.+Jarvis&author=D.+Sauer&author=S.+Swann&author=D.+Bonafoux&author=R.+Keddy&author=A.+D.+Hobson&author=A.+Vasudevan&title=4-%284-Pyridinyl%29-benzamides+and+their+Use+as+Rock+Activity+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMack%26aufirst%3DH.%26atitle%3D4-%25284-Pyridinyl%2529-benzamides%2520and%2520their%2520Use%2520as%2520Rock%2520Activity%2520Modulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¼rer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span> <span> </span><span class="NLM_article-title">Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6686</span>â <span class="NLM_lpage">6690</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.09.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2009.09.115" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6686-6690&author=Y.+Yinauthor=L.+Linauthor=C.+Ruizauthor=M.+D.+Cameronauthor=J.+Pocasauthor=W.+Grantauthor=T.+Schr%C3%B6terauthor=W.+Chenauthor=D.+Duckettauthor=S.+Sch%C3%BCrerauthor=P.+LoGrassoauthor=Y.+Feng&title=Benzothiazoles+as+Rho-associated+kinase+%28ROCK-II%29+inhibitors&doi=10.1016%2Fj.bmcl.2009.09.115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.115%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DPocas%26aufirst%3DJ.%26aulast%3DGrant%26aufirst%3DW.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DDuckett%26aufirst%3DD.%26aulast%3DSch%25C3%25BCrer%26aufirst%3DS.%26aulast%3DLoGrasso%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26atitle%3DBenzothiazoles%2520as%2520Rho-associated%2520kinase%2520%2528ROCK-II%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6686%26epage%3D6690%26doi%3D10.1016%2Fj.bmcl.2009.09.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sessions, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frackowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶ter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoGrasso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, T. D.</span></span> <span> </span><span class="NLM_article-title">The development of benzimidazoles as selective rho kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1939</span>â <span class="NLM_lpage">1943</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2010.01.124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2010.01.124" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1939-1943&author=E.+H.+Sessionsauthor=M.+Smolinskiauthor=B.+Wangauthor=B.+Frackowiakauthor=S.+Chowdhuryauthor=Y.+Yinauthor=Y.+T.+Chenauthor=C.+Ruizauthor=L.+Linauthor=J.+Pocasauthor=T.+Schr%C3%B6terauthor=M.+D.+Cameronauthor=P.+LoGrassoauthor=Y.+Fengauthor=T.+D.+Bannister&title=The+development+of+benzimidazoles+as+selective+rho+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.01.124"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.124%26sid%3Dliteratum%253Aachs%26aulast%3DSessions%26aufirst%3DE.%2BH.%26aulast%3DSmolinski%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFrackowiak%26aufirst%3DB.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DRuiz%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DPocas%26aufirst%3DJ.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26aulast%3DLoGrasso%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBannister%26aufirst%3DT.%2BD.%26atitle%3DThe%2520development%2520of%2520benzimidazoles%2520as%2520selective%2520rho%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1939%26epage%3D1943%26doi%3D10.1016%2Fj.bmcl.2010.01.124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsinman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GonzÃ¡lez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FernÃ¡ndez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrigues, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, V.</span></span> <span> </span><span class="NLM_article-title">PAMPA-a drug absorption in vitro model: 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">429</span>â <span class="NLM_lpage">441</span>, <span class="refDoi">Â DOI: 10.1016/j.ejps.2003.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.ejps.2003.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=14998573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslWntb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=429-441&author=M.+Bermejoauthor=A.+Avdeefauthor=A.+Ruizauthor=R.+Naldaauthor=J.+A.+Ruellauthor=O.+Tsinmanauthor=I.+Gonz%C3%A1lezauthor=C.+Fern%C3%A1ndezauthor=G.+S%C3%A1nchezauthor=T.+M.+Garriguesauthor=V.+Merino&title=PAMPA-a+drug+absorption+in+vitro+model%3A+7.+Comparing+rat+in+situ%2C+Caco-2%2C+and+PAMPA+permeability+of+fluoroquinolones&doi=10.1016%2Fj.ejps.2003.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">PAMPA-a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones</span></div><div class="casAuthors">Bermejo, Marival; Avdeef, Alex; Ruiz, Ana; Nalda, Ricardo; Ruell, Jeffrey A.; Tsinman, Oksana; Gonzalez, Isabel; Fernandez, Carlos; Sanchez, Gloria; Garrigues, Teresa M.; Merino, Virginia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-441</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parallel artificial membrane permeability assay (PAMPA) was used to measure the effective permeability, Pe, as a function of pH from 4 to 10, of 17 fluoroquinolones, including three congeneric series with systematically varied alkyl chain length at the 4'N-position of the piperazine residue.  The permeability values spanned over three orders of magnitude.  The intrinsic permeability, Po, and the membrane permeability, Pm, were detd. from the pH dependence of the effective permeability.  The pKa values were detd. potentiometrically.  The PAMPA method employed stirring, adjusted such that the unstirred water layer (UWL) thickness matched the 30-100 Î¼m range estd. to be in the human small intestine.  The intrinsic permeability coeffs. (10-6 cm/s), representing the permeability of the uncharged form of the drug, are for 4'N-R-norfloxacin: 0.7 (R=H), 49 (Me), 132 (n-Pr), 365 (n-Bu); 4'N-R-ciprofloxacin: 2.7 (H), 37 (Me), 137 (n-Pr), 302 (n-Bu); 4'N-R-3'-methylciprofloxacin: 3.8 (H), 20 (Me), 51 (Et), 160 (n-Pr), 418 (n-Bu).  Increasing the alkyl chain length in the congeneric series resulted in increased permeability, averaging about 0.34 log units per methylene group, except that of the first (H-to-Me), which was about 1.2 log units.  These results were compared to Caco-2 and rat in situ permeability measurements.  The in situ closed loop technique used for obtaining permeability values in rat showed a water layer thickness effect quite consistent with in vivo expectations.  The rat-PAMPA correlation (r2=0.87) was better than that of rat-Caco-2 (r2=0.63).  Caco-2-PAMPA correlation indicated r2=0.66.  The latter correlation improved significantly (r2=0.82) when the Caco-2 data were cor. for the UWL effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FSWu8uWj6bVg90H21EOLACvtfcHk0ljqNAlPk8hprg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslWntb8%253D&md5=ec6df386f69a99de284e53dfdccbd352</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2003.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2003.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DBermejo%26aufirst%3DM.%26aulast%3DAvdeef%26aufirst%3DA.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DNalda%26aufirst%3DR.%26aulast%3DRuell%26aufirst%3DJ.%2BA.%26aulast%3DTsinman%26aufirst%3DO.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DI.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DG.%26aulast%3DGarrigues%26aufirst%3DT.%2BM.%26aulast%3DMerino%26aufirst%3DV.%26atitle%3DPAMPA-a%2520drug%2520absorption%2520in%2520vitro%2520model%253A%25207.%2520Comparing%2520rat%2520in%2520situ%252C%2520Caco-2%252C%2520and%2520PAMPA%2520permeability%2520of%2520fluoroquinolones%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D21%26spage%3D429%26epage%3D441%26doi%3D10.1016%2Fj.ejps.2003.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sevrioukova, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span> <span> </span><span class="NLM_article-title">Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3733</span>â <span class="NLM_lpage">3741</span>, <span class="refDoi">Â DOI: 10.1021/jm400288z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400288z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVylsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3733-3741&author=I.+F.+Sevrioukovaauthor=T.+L.+Poulos&title=Pyridine-substituted+desoxyritonavir+is+a+more+potent+inhibitor+of+cytochrome+P450+3A4+than+ritonavir&doi=10.1021%2Fjm400288z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridine-Substituted Desoxyritonavir Is a More Potent Inhibitor of Cytochrome P450 3A4 than Ritonavir</span></div><div class="casAuthors">Sevrioukova, Irina F.; Poulos, Thomas L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3733-3741</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilization of the cytochrome P 450 3A4 (CYP3A4) inhibitor ritonavir as a pharmacoenhancer for anti-HIV drugs revolutionized the treatment of HIV infection.  However, owing to ritonavir-related complications, there is a need for development of new CYP3A4 inhibitors with improved pharmacochem. properties, which requires a full understanding of the CYP3A4 inactivation mechanisms and the unraveling of possible inhibitor binding modes.  We investigated the mechanism of CYP3A4 interaction with three desoxyritonavir analogs, contg. the heme-ligating imidazole, oxazole, or pyridine group instead of the thiazole moiety (compds. 1, 2, and 3, resp.).  Our data show that compd. 3 is superior to ritonavir in terms of binding affinity and inhibitory potency owing to greater flexibility and the ability to adopt a conformation that minimizes steric clashing and optimizes protein-ligand interactions.  Addnl., Ser119 was identified as a key residue assisting binding of ritonavir-like inhibitors, which emphasizes the importance of polar interactions in the CYP3A4-ligand assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx1sbUve3zPLVg90H21EOLACvtfcHk0ljqNAlPk8hprg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVylsrc%253D&md5=77a94516a246e5823502f4c89cadc5c0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm400288z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400288z%26sid%3Dliteratum%253Aachs%26aulast%3DSevrioukova%26aufirst%3DI.%2BF.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26atitle%3DPyridine-substituted%2520desoxyritonavir%2520is%2520a%2520more%2520potent%2520inhibitor%2520of%2520cytochrome%2520P450%25203A4%2520than%2520ritonavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3733%26epage%3D3741%26doi%3D10.1021%2Fjm400288z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taslimi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, J.</span></span> <span> </span><span class="NLM_article-title">The structure of dimeric ROCK1 reveals the mechanism for ligand selectivity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">260</span>â <span class="NLM_lpage">268</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M508847200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1074%2Fjbc.M508847200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=260-268&author=M.+Jacobsauthor=K.+Hayakawaauthor=L.+Swensonauthor=S.+Bellonauthor=M.+Flemingauthor=P.+Taslimiauthor=J.+Doran&title=The+structure+of+dimeric+ROCK1+reveals+the+mechanism+for+ligand+selectivity&doi=10.1074%2Fjbc.M508847200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508847200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508847200%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DBellon%26aufirst%3DS.%26aulast%3DFleming%26aufirst%3DM.%26aulast%3DTaslimi%26aufirst%3DP.%26aulast%3DDoran%26aufirst%3DJ.%26atitle%3DThe%2520structure%2520of%2520dimeric%2520ROCK1%2520reveals%2520the%2520mechanism%2520for%2520ligand%2520selectivity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D260%26epage%3D268%26doi%3D10.1074%2Fjbc.M508847200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudevan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simler, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namovic, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguirre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassar, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faltynek, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce-Rustay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobson, A. D.</span></span> <span> </span><span class="NLM_article-title">Design of aminobenzothiazole inhibitors of Rho Kinases 1 and 2 utilizing PKA as a structure surrogate</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">613</span>â <span class="NLM_lpage">621</span>, <span class="refDoi">Â DOI: 10.1002/cbic.201700547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1002%2Fcbic.201700547" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=613-621&author=R.+A.+Judgeauthor=A.+Vasudevanauthor=V.+E.+Scottauthor=G.+H.+Simlerauthor=S.+D.+Prattauthor=M.+T.+Namovicauthor=C.+B.+Putmanauthor=A.+Aguirreauthor=V.+S.+Stollauthor=M.+Mamoauthor=S.+I.+Swannauthor=S.+C.+Cassarauthor=C.+R.+Faltynekauthor=K.+L.+Kageauthor=J.+M.+Boyce-Rustayauthor=A.+D.+Hobson&title=Design+of+aminobenzothiazole+inhibitors+of+Rho+Kinases+1+and+2+utilizing+PKA+as+a+structure+surrogate&doi=10.1002%2Fcbic.201700547"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201700547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201700547%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DR.%2BA.%26aulast%3DVasudevan%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DV.%2BE.%26aulast%3DSimler%26aufirst%3DG.%2BH.%26aulast%3DPratt%26aufirst%3DS.%2BD.%26aulast%3DNamovic%26aufirst%3DM.%2BT.%26aulast%3DPutman%26aufirst%3DC.%2BB.%26aulast%3DAguirre%26aufirst%3DA.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DSwann%26aufirst%3DS.%2BI.%26aulast%3DCassar%26aufirst%3DS.%2BC.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DKage%26aufirst%3DK.%2BL.%26aulast%3DBoyce-Rustay%26aufirst%3DJ.%2BM.%26aulast%3DHobson%26aufirst%3DA.%2BD.%26atitle%3DDesign%2520of%2520aminobenzothiazole%2520inhibitors%2520of%2520Rho%2520Kinases%25201%2520and%25202%2520utilizing%2520PKA%2520as%2520a%2520structure%2520surrogate%26jtitle%3DChemBioChem%26date%3D2018%26volume%3D19%26spage%3D613%26epage%3D621%26doi%3D10.1002%2Fcbic.201700547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtucio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnagin, K.</span></span> <span> </span><span class="NLM_article-title">Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">615</span>â <span class="NLM_lpage">625</span>, <span class="refDoi">Â DOI: 10.1124/jpet.113.207662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1124%2Fjpet.113.207662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=24049062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=615-625&author=T.+Akamaauthor=C.+Dongauthor=C.+Virtucioauthor=D.+Sullivanauthor=Y.+Zhouauthor=Y.+K.+Zhangauthor=F.+Rockauthor=Y.+Freundauthor=L.+Liuauthor=W.+Buauthor=A.+Wuauthor=X.+Q.+Fanauthor=K.+Jarnagin&title=Linking+phenotype+to+kinase%3A+identification+of+a+novel+benzoxaborole+hinge-binding+motif+for+kinase+inhibition+and+development+of+high-potency+rho+kinase+inhibitors&doi=10.1124%2Fjpet.113.207662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors</span></div><div class="casAuthors">Akama, Tsutomu; Dong, Chen; Virtucio, Charlotte; Sullivan, David; Zhou, Yasheen; Zhang, Yong-Kang; Rock, Fernando; Freund, Yvonne; Liu, Liang; Bu, Wei; Wu, Anne; Fan, Xiao-Qing; Jarnagin, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">615-625</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Benzoxaboroles are a novel class of drug-like compds. that have been rich sources of novel inhibitors for various enzymes and of new drugs.  While examg. benzoxaborole activity in phenotypic screens, our attention was attracted by the (aminomethylphenoxy)benzoxaborole family, which potently inhibited Toll-like receptor-stimulated cytokine secretion from leukocytes.  After considering their structure-activity relationships and the central role of kinases in leukocyte biol., we performed a kinome-wide screen to investigate the members of the (aminomethylphenoxy)benzoxaborole family.  This technique identified Rho-activated kinase (ROCK) as a target.  We showed competitive behavior, with respect to ATP, and then detd. the ROCK2-drug cocrystal structure.  The drug occupies the ATP site in which the oxaborole moiety provides hydrogen bond donors and acceptors to the hinge, and the aminomethyl group interacts with the magnesium/ATP-interacting aspartic acid common to protein kinases.  The series exhibits excellent selectivity against most of the kinome, with greater than 15-fold selectivity against the next best member of the AGC protein kinase subfamily.  Medicinal chem. efforts with structure-based design resulted in a compd. with a Ki of 170 nM.  Cellular studies revealed strong enzyme inhibition rank correlation with suppression of intracellular phosphorylation of a ROCK substrate.  The biochem. potencies of these compds. also translated to functional activity, causing smooth muscle relaxation in rat aorta and guinea pig trachea.  The series exhibited oral availability and one member reduced rat blood pressure, consistent with ROCK's role in smooth muscle contraction.  Thus, the benzoxaborole moiety represents a novel hinge-binding kinase scaffold that may have potential for therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqksYEBV0FP2bVg90H21EOLACvtfcHk0lh3_AzbAaveWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVyiu7jI&md5=75a9f55dcbaee29e4703aabb16f2276b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207662%26sid%3Dliteratum%253Aachs%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DVirtucio%26aufirst%3DC.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DRock%26aufirst%3DF.%26aulast%3DFreund%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DX.%2BQ.%26aulast%3DJarnagin%26aufirst%3DK.%26atitle%3DLinking%2520phenotype%2520to%2520kinase%253A%2520identification%2520of%2520a%2520novel%2520benzoxaborole%2520hinge-binding%2520motif%2520for%2520kinase%2520inhibition%2520and%2520development%2520of%2520high-potency%2520rho%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D615%26epage%3D625%26doi%3D10.1124%2Fjpet.113.207662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castermans, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindt, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panitti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanormelingen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stassen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leysen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defert, O.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4309</span>â <span class="NLM_lpage">4324</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOhtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4309-4324&author=S.+Bolandauthor=A.+Bourinauthor=J.+Alenauthor=J.+Geraetsauthor=P.+Schroedersauthor=K.+Castermansauthor=N.+Kindtauthor=N.+Boumansauthor=L.+Panittiauthor=S.+Fransenauthor=J.+Vanormelingenauthor=J.+M.+Stassenauthor=D.+Leysenauthor=O.+Defert&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel%2C+highly+active+soft+ROCK+inhibitors&doi=10.1021%2Facs.jmedchem.5b00308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Novel, Highly Active Soft ROCK Inhibitors</span></div><div class="casAuthors">Boland, Sandro; Bourin, Arnaud; Alen, Jo; Geraets, Jacques; Schroeders, Pieter; Castermans, Karolien; Kindt, Nele; Boumans, Nicki; Panitti, Laura; Fransen, Silke; Vanormelingen, Jessica; Stassen, Jean Marie; Leysen, Dirk; Defert, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4309-4324</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ROCK1 and ROCK2 play important roles in numerous cellular functions, including smooth muscle cell contraction, cell proliferation, adhesion, and migration.  Consequently, ROCK inhibitors are of interest for treating multiple indications including cardiovascular diseases, inflammatory and autoimmune diseases, lung diseases, and eye diseases.  However, systemic inhibition of ROCK is expected to result in significant side effects.  Strategies allowing reduced systemic exposure are therefore of interest.  In a continuing effort toward identification of ROCK inhibitors, we here report the design, synthesis, and evaluation of novel soft ROCK inhibitors displaying an ester function allowing their rapid inactivation in the systemic circulation.  Those compds., e.g. I, display subnanomolar activity against ROCK and strong differences of functional activity between parent compds. and expected metabolites.  The binding mode of a representative compd. was detd. exptl. in a single-crystal X-ray diffraction study.  Enzymes responsible for inactivation of these compds. once they enter systemic circulation are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWI5LwOkT64rVg90H21EOLACvtfcHk0lh3_AzbAaveWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOhtbc%253D&md5=320e6fbb1cf87ba8c03fc17795f6802f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00308%26sid%3Dliteratum%253Aachs%26aulast%3DBoland%26aufirst%3DS.%26aulast%3DBourin%26aufirst%3DA.%26aulast%3DAlen%26aufirst%3DJ.%26aulast%3DGeraets%26aufirst%3DJ.%26aulast%3DSchroeders%26aufirst%3DP.%26aulast%3DCastermans%26aufirst%3DK.%26aulast%3DKindt%26aufirst%3DN.%26aulast%3DBoumans%26aufirst%3DN.%26aulast%3DPanitti%26aufirst%3DL.%26aulast%3DFransen%26aufirst%3DS.%26aulast%3DVanormelingen%26aufirst%3DJ.%26aulast%3DStassen%26aufirst%3DJ.%2BM.%26aulast%3DLeysen%26aufirst%3DD.%26aulast%3DDefert%26aufirst%3DO.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%252C%2520highly%2520active%2520soft%2520ROCK%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4309%26epage%3D4324%26doi%3D10.1021%2Facs.jmedchem.5b00308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huth, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cothron, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajduk, P. J.</span></span> <span> </span><span class="NLM_article-title">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">217</span>â <span class="NLM_lpage">224</span>, <span class="refDoi">Â DOI: 10.1021/ja0455547</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0455547" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=217-224&author=J.+R.+Huthauthor=R.+Mendozaauthor=E.+T.+Olejniczakauthor=R.+W.+Johnsonauthor=D.+A.+Cothronauthor=Y.+Liuauthor=C.+G.+Lernerauthor=J.+Chenauthor=P.+J.+Hajduk&title=ALARM+NMR%3A+a+rapid+and+robust+experimental+method+to+detect+reactive+false+positives+in+biochemical+screens&doi=10.1021%2Fja0455547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens</span></div><div class="casAuthors">Huth, Jeffrey R.; Mendoza, Renaldo; Olejniczak, Edward T.; Johnson, Robert W.; Cothron, Darlene A.; Liu, Yaya; Lerner, Claude G.; Chen, Jun; Hajduk, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">217-224</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High-throughput screening (HTS) of large compd. collections typically results in numerous small mol. hits that must be carefully evaluated to identify valid drug leads.  Although several filtering mechanisms and other tools exist that can assist the chemist in this process, it is often the case that costly synthetic resources are expended in pursuing false positives.  We report here a rapid and reliable NMR-based method for identifying reactive false positives including those that oxidize or alkylate a protein target.  Importantly, the reactive species need not be the parent compd., as both reactive impurities and breakdown products can be detected.  The assay is called ALARM NMR (a La assay to detect reactive mols. by NMR) and is based on monitoring DTT-dependent 13C chem. shift changes of the human La antigen in the presence of a test compd. or mixt.  Extensive validation has been performed to demonstrate the reliability and utility of using ALARM NMR to assess thiol reactivity.  This included comparing ALARM NMR to a glutathione-based fluorescence assay, as well as testing a collection of more than 3500 compds. contg. HTS hits from 23 drug targets.  The data show that current in silico filtering tools fail to identify more than half of the compds. that can act via reactive mechanisms.  Significantly, we show how ALARM NMR data has been crit. in identifying reactive compds. that would otherwise have been prioritized for lead optimization.  In addn., a new filtering tool has been developed on the basis of the ALARM NMR data that can augment current in silico programs for identifying nuisance compds. and improving the process of hit triage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolKou1lGZ8tbVg90H21EOLACvtfcHk0lh3_AzbAaveWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVCrurrF&md5=466332d4bdcddf6bc8a630aacbbb32ef</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fja0455547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0455547%26sid%3Dliteratum%253Aachs%26aulast%3DHuth%26aufirst%3DJ.%2BR.%26aulast%3DMendoza%26aufirst%3DR.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DJohnson%26aufirst%3DR.%2BW.%26aulast%3DCothron%26aufirst%3DD.%2BA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLerner%26aufirst%3DC.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26atitle%3DALARM%2520NMR%253A%2520a%2520rapid%2520and%2520robust%2520experimental%2520method%2520to%2520detect%2520reactive%2520false%2520positives%2520in%2520biochemical%2520screens%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D217%26epage%3D224%26doi%3D10.1021%2Fja0455547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and drug-like compounds: the rule-of-five revolution</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">337</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&author=C.+A.+Lipinski&title=Lead-+and+drug-like+compounds%3A+the+rule-of-five+revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0liEd32avVawLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520drug-like%2520compounds%253A%2520the%2520rule-of-five%2520revolution%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D341%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>â <span class="NLM_lpage">6756</span>, <span class="refDoi">Â DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liEd32avVawLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical drug properties associated with in vivo toxicological outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4872</span>â <span class="NLM_lpage">4875</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+DeCrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+drug+properties+associated+with+in+vivo+toxicological+outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0liEd32avVawLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520drug%2520properties%2520associated%2520with%2520in%2520vivo%2520toxicological%2520outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span>AbbVie
Compound Toolbox, <a href="https://www.openinnovation.abbvie.com/web/compound-toolbox" class="extLink">https://www.openinnovation.abbvie.com/web/compound-toolbox</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AbbVie%0ACompound+Toolbox%2C+https%3A%2F%2Fwww.openinnovation.abbvie.com%2Fweb%2Fcompound-toolbox."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatenhorst, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roser, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saal, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TÃ¶nges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingor, P.</span></span> <span> </span><span class="NLM_article-title">ROCK inhibition in models of neurodegeneration and its potential for clinical translation</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">21</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2018.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1016%2Fj.pharmthera.2018.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=29621594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFWqt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2018&pages=1-21&author=J.+C.+Kochauthor=L.+Tatenhorstauthor=A.+E.+Roserauthor=K.+A.+Saalauthor=L.+T%C3%B6ngesauthor=P.+Lingor&title=ROCK+inhibition+in+models+of+neurodegeneration+and+its+potential+for+clinical+translation&doi=10.1016%2Fj.pharmthera.2018.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ROCK inhibition in models of neurodegeneration and its potential for clinical translation</span></div><div class="casAuthors">Koch, Jan Christoph; Tatenhorst, Lars; Roser, Anna-Elisa; Saal, Kim-Ann; Toenges, Lars; Lingor, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative disorders like Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis are affecting a rapidly increasing population worldwide.  While common pathomechanisms such as protein aggregation, axonal degeneration, dysfunction of protein clearing and an altered immune response have been characterized, no disease-modifying therapies have been developed so far.  Interestingly, a significant involvement of the Rho kinase (ROCK) signaling pathway has been described in all of these mechanisms making it a promising target for new therapeutic approaches.In this article, we first review current knowledge of the involvement of ROCK in neurodegenerative disorders and the utility of its inhibition as a disease-modifying therapy in different neurodegenerative disorders.  After a detailed description of the biochem. characteristics of ROCK and its mol. interactors, differences of ROCK-expression under physiol. and pathol. conditions are compared.  Next, different pharmacol. and mol.-genetic strategies to inhibit ROCK-function are discussed, focusing on pharmacol. ROCK-inhibitors.  The role of the ROCK-pathway in cellular processes that are central in neurodegenerative disorders pathol. like axonal degeneration, autophagy, synaptic and glial function is explained in detail.  Finally, all available data on ROCK-inhibition in different animal models of neurodegenerative disorders is reviewed and first approaches for translation into human patients are discussed.Taken together, there is now extensive evidence from preclin. studies in several neurodegenerative disorders that characterize ROCK as a promising drug target for further translational research in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg_1c2sOs7RLVg90H21EOLACvtfcHk0lhsOavtUot_Fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFWqt7c%253D&md5=6f6b694b27280ad3947c3a734633ba09</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2018.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2018.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DJ.%2BC.%26aulast%3DTatenhorst%26aufirst%3DL.%26aulast%3DRoser%26aufirst%3DA.%2BE.%26aulast%3DSaal%26aufirst%3DK.%2BA.%26aulast%3DT%25C3%25B6nges%26aufirst%3DL.%26aulast%3DLingor%26aufirst%3DP.%26atitle%3DROCK%2520inhibition%2520in%2520models%2520of%2520neurodegeneration%2520and%2520its%2520potential%2520for%2520clinical%2520translation%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D189%26spage%3D1%26epage%3D21%26doi%3D10.1016%2Fj.pharmthera.2018.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lingor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teusch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¤hr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, B. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">189</span>, <span class="refDoi">Â DOI: 10.1111/j.1471-4159.2007.04756.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=10.1111%2Fj.1471-4159.2007.04756.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=17608642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qu7bJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2007&pages=181-189&author=P.+Lingorauthor=N.+Teuschauthor=K.+Schwarzauthor=R.+Muellerauthor=H.+Mackauthor=M.+B%C3%A4hrauthor=B.+K.+Mueller&title=Inhibition+of+Rho+kinase+%28ROCK%29+increases+neurite+outgrowth+on+chondroitin+sulphate+proteoglycan+in+vitro+and+axonal+regeneration+in+the+adult+optic+nerve+in+vivo&doi=10.1111%2Fj.1471-4159.2007.04756.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo</span></div><div class="casAuthors">Lingor, Paul; Teusch, Nicole; Schwarz, Katrin; Mueller, Reinhold; Mack, Helmut; Baehr, Mathias; Mueller, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Inhibitory mols. derived from CNS myelin and glial scar tissue are major causes for insufficient functional regeneration in the mammalian CNS.  A multitude of these mols. signal through the Rho/Rho kinase (ROCK) pathway.  We evaluated three inhibitors of ROCK, Y-27632, Fasudil (HA-1077), and Dimethylfasudil (H-1152), in models of neurite outgrowth in vitro.  We show, that all three ROCK inhibitors partially restore neurite outgrowth of Ntera-2 neurons on the inhibitory chondroitin sulfate proteoglycan substrate.  In the rat optic nerve crush model Y-27632 dose-dependently increased regeneration of retinal ganglion cell axons in vivo.  Application of Dimethylfasudil showed a trend towards increased axonal regeneration in an intermediate concn.  We demonstrate that inhibition of ROCK can be an effective therapeutic approach to increase regeneration of CNS neurons.  The selection of a suitable inhibitor with a broad therapeutic window, however, is crucial in order to minimize unwanted side effects and to avoid deleterious effects on nerve fiber growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopIfA6qAjEj7Vg90H21EOLACvtfcHk0lhsOavtUot_Fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qu7bJ&md5=1cd9c9135e936e471df9512111b97c9f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2007.04756.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2007.04756.x%26sid%3Dliteratum%253Aachs%26aulast%3DLingor%26aufirst%3DP.%26aulast%3DTeusch%26aufirst%3DN.%26aulast%3DSchwarz%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DR.%26aulast%3DMack%26aufirst%3DH.%26aulast%3DB%25C3%25A4hr%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DB.%2BK.%26atitle%3DInhibition%2520of%2520Rho%2520kinase%2520%2528ROCK%2529%2520increases%2520neurite%2520outgrowth%2520on%2520chondroitin%2520sulphate%2520proteoglycan%2520in%2520vitro%2520and%2520axonal%2520regeneration%2520in%2520the%2520adult%2520optic%2520nerve%2520in%2520vivo%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D103%26spage%3D181%26epage%3D189%26doi%3D10.1111%2Fj.1471-4159.2007.04756.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="note"><p class="first last">Additional studies to identify positive controls for the optic nerve crush model are ongoing and will be published separately at a future date.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9L','PDB','6E9L'); return false;">PDB: 6E9L</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9W','PDB','6E9W'); return false;">PDB: 6E9W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ED6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ED6','PDB','6ED6'); return false;">PDB: 6ED6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E99" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E99','PDB','6E99'); return false;">PDB: 6E99</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i121"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01098">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33311"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01098">10.1021/acs.jmedchem.8b01098</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HTRF assay protocol; optic nerve crush model protocol; kinome panel protocol and data; PK protocol and curves for compound <b>16</b>; MYPT1 cell assay protocol; crystallization methods and X-ray crystallography diffraction statistics for compound <b>12</b> in ROCK1, ROCK2, and PKA; X-ray crystallography diffraction statistics for compound <b>47</b> in PKA; <sup>1</sup>H NMR for compounds <b>12</b>, <b>16</b>, <b>43</b>, <b>44</b>, <b>54</b>, and <b>56</b>; <sup>13</sup>C NMR for compounds <b>12</b>, <b>16</b>, <b>43</b>, <b>44</b>, <b>54</b>, and <b>56</b>; <sup>19</sup>F NMR for compounds <b>12</b> and <b>43</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_001.pdf">jm8b01098_si_001.pdf (1.34 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01098/suppl_file/jm8b01098_si_002.csv">jm8b01098_si_002.csv (4.13 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes: <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a, compound <b>12</b>, in active site of PKA, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9L">6E9L</a>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b, compound <b>12</b>, in active site of ROCK1, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E9W">6E9W</a>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c, compound <b>12</b>, in active site of ROCK2, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ED6">6ED6</a>; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>47</b>, in active site of PKA, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6E99">6E99</a>. Structures for ROCK1, ROCK2, and PKA with compound <b>12</b> and PKA with compound <b>47</b> have been deposited in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01098&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-24%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01098%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01098" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679972816fb03cb8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
